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ABSTRACT 
Sonication-Assisted Synthesis of Oligomannosides 
by 
Christabel Tomla Tanifum, Doctor of Philosophy 
Utah State University, 2009 
Major Professor: Dr. Cheng-Wei Tom Chang 
Department: Chemistry and Biochemistry 
Oligomannosides prevalently exist as cell surface antigens. They play important roles 
in diseases such as viral infection and cancer, and they have been shown to be useful as 
candidates for vaccines. HIV, one of the most devastating modern diseases, has a high 
content of mannose sugars on its envelope glycoprotein gp120. Oligomannosides of the 
HIV virus, also called Man9, which are found on the glycoprotein gp120, have been 
shown to play a protective role for the HIV virus, shielding highly conserved protein 
domains of gp120 from proteolytic attacks. Thus gp120 plays an important role in HIV 
infection of cells, being responsible for the attachment and penetration of cells to be 
infected and is thus the target for immunotherapy or vaccine development. The synthesis 
of complex oligomannosides is still very challenging as numerous methods have been 
reported but not all are very reproducible.  
The use of sonication as a new methodology tool for the synthesis of 
oligomannosides was investigated. A convenient sonication-mediated protocol applicable 
iv 
 
to glycosylation was developed. The synthesis of oligomannosides such as Man3, Man6, 
and Man9, was achieved under sonication conditions. The use of less reactive or so-called 
“disarmed” mannopyranosyl donors, such as acyl and thiophenyl donors, was 
investigated and interestingly the results gave good yields. These disarmed donors are 
easy to synthesize but it is difficult to perform glycosylation using traditional methods 
(low yields and longer reaction time). A fast and convenient method for the synthesis of 
this compound will be very beneficial in this field. Also, the investigation of the solid 
phase synthesis of carbohydrates under sonication conditions was conducted and the 
preliminary results were good.  
The research investigated a new methodology for the synthesis of complex 
oligomannosides and oligosaccharides in general and also to improve the glycosylation 
process where necessary by using sonication methodology and thus establishing an 
accessible route for the solid phase synthesis of these compounds.  
 
 (397 pages) 
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CHAPTER I 
GENERAL INTRODUCTION 
Carbohydrates are ubiquitous in nature and have been found to play fundamental 
roles in biological systems encompassing cell proliferation, immune response, cell 
adhesion and cell-cell recognition.1 Carbohydrates are a major source of energy and they 
are prime biological substances, of which tons and tons are produced every year through 
the process of photosynthesis by plants and microorganisms. They constitute the major 
components of shells of insects, crabs and lobsters, and the supporting tissue of plants. 
They are also present as parts of all cell walls, spanning the world of microbes to 
mammals.2 They occur in various forms from simple sugars to polysaccharides or as 
conjugates to other biomolecules such as proteoglycans. Carbohydrates were long 
neglected by drug development researchers due to the underestimation of their biological 
potential, but scientific evolvement has shown that these molecules have significant 
diagnostic and therapeutic potential. There exist a great relationship between 
carbohydrate structure and many biological functions due to their diversity and 
complexity.  
The resurgence of interest in carbohydrate chemistry is due to the fact that 
carbohydrates have been shown to be a major source of drug leads.3 It is now believed 
that carbohydrates may provide the missing clues to the puzzling questions: why are there 
unusual properties of the Human Immunodeficiency Virus (HIV) and why is AIDS so 
difficult to treat. Furthermore, how does bacteria, viruses and toxins evade the immune 
system and initiate infective processes, as well as why are some tumor cells able to 
2 
 
 
migrate from their original cancerous sites. As scientists develop new antibiotics or 
modify natural antibiotics towards bacteria defense, bacteria at the same time developed 
constantly growing resistance against various antibiotics. A classical example of these 
can be seen with the aminoglycosides class of antibiotics.  These compounds, including 
neomycin B, streptomycin, kanamycin B, and pyranmycin (figure 1), are highly potent 
broad spectrum antibiotics, but their effectiveness is now being hampered by the 
emergence of bacterial strains that are resistant to these drugs.4  
 
 
Figure 1: Broad spectrum antibiotic aminoglycosides 
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The functional specialization and diversity of biologically active carbohydrate 
molecules and their role in diseases are now well understood. Different types of unique 
carbohydrate-containing biomolecules are found on all cell surfaces. Many carbohydrates 
are information carriers and recognition molecules due to their unique structural 
diversity. Studies have shown that carbohydrates provide signals for protein targeting and 
serve as binding receptors for toxins, viruses, and hormones.5 They also control vital 
events in fertilization and early development.6 They regulate several critical immune 
system recognition events,7 and target aging cells for destruction.5 Cell-cell interactions 
such as antigen-antibody or virus-host interactions are some examples of the 
aforementioned biochemical functions.  
I.1 Classification 
Carbohydrates occur as monomers (glucose, mannose, fructose), dimers (sucrose, 
lactose), oligomers or polymers (starch, cellulose), or as components of biopolymers 
(RNA, DNA) and other naturally occurring biomolecules. The monomers exist as 
aldoses, which are polyhydroxyaldehydes (figure 2), and ketoses, polyhydroxyketones 
(figure 3). Aldoses and ketoses can be of different chain lengths and are all derived from 
glyceraldehyde and dihydroxyacetone respectively (figure 4). Glyceraldehyde occurs in 
two main enantiomeric forms, which are (+)-D-glyceraldehyde with the (R)-configuration 
and (-)-L-glyceraldehyde with (S)-configuration (figure 4). For monosaccharides with 
more than one chiral center, the D- or L-  notation is derived from the configuration of 
chiral center furthest from the carbonyl. If the configuration is (R)-, it is termed a D-sugar 
and if (S)-, it is an L-sugar. Our main focus will be on the D-sugars as they are the most 
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common in living organisms. Monosaccharides with more than six carbon atoms are 
relatively rare.  
 
 
Figure 2: The acyclic forms of D-aldoses 
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Figure 3: The acyclic form of D-ketoses 
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 Figure 4: Structure of ketose and aldoses 
Monosaccharides can be found in open chain and in ring forms. They exist 
preferably as cyclic hemiacetals and hemiketals, which arise from the intramolecular 
nucleophilic attack of a hydroxyl-oxygen atom at the carbonyl atom (scheme 1). 
Depending on which hydroxyl group reacts, five or six membered rings are formed which 
are called furanoses and pyranoses respectively. The ensuing hemiacetal hydroxyl group 
from the reaction could either be in axial position, in which case the product is referred to 
as the α-anomer or in equatorial position, in which case it is referred to as the β-anomer.  
For the graphic representation of monosaccharide structures, several different 
descriptions are used such as Fisher projection, zigzag projection, Mills projection, 
Haworth projection, and the chair conformation. Fisher and zigzag projections are only 
used for acyclic structures. Cyclic sugars are represented by the Mills projection, 
especially when they are part of other larger structures which are non-carbohydrate rings 
(as example we have macrolides). The 6-membered ring of monosaccharides is not planar 
but adopts a regular chair conformation. Thus the cyclic forms of carbohydrates are most 
accurately drawn as chairs. This representation also facilitates the distinction between the 
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axial and equatorial positions, a difference which is very important in carbohydrate 
chemistry. 
The monosaccharides are the simplest monomer building blocks. Condensation of 
two of these monomers by a reaction termed glycosylation (scheme 2) yields a 
disaccharide such as maltose and cellobiose.  The remaining free hydroxyl groups can be 
further glycosylated to higher linear or branched oligosaccharides and polysaccharides. 
Disaccharide units are often found as component of many polysaccharides compounds. 
Disaccharides, which are the simplest oligosaccharides, can also be easily obtained by the 
hydrolysis of abundant polysaccharides. For example, maltose is obtained from starch 
while sucrose is extracted from sugar cane. 
 
 
Scheme 1: Formation of the two cyclic forms of D-glucose 
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Scheme 2: Glycosylation    
Oligosaccharides and polysaccharides are often found as components of proteins 
and lipids  in all cell walls mediating a variety of events such as inflammation, cell-cell 
recognition, immunological response, metastasis, and fertilization.8 Each cell type 
displays different carbohydrates at its cell surface and these are often used as chemical 
markers. Specific carbohydrates have been identified as markers for certain types of 
tumors9 while others are binding sites for bacterial and viral pathogens.10  
Polysaccharides, also called glycans, differ from each other in the identity of their 
recurring monosaccharide units, in the length of their chains, in the types of bonds linking 
the units, and in the degree of branching. There are two types of polysaccharides (figure 
5): the homopolysaccharides which contain a single type of monomer and can serve as 
storage forms used as fuels (example: starch, glycogen) while others serve as structural 
elements in plant cell walls and animal exoskeletons (example cellulose and chitin).  
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The heteropolysaccharides, on the other hand, provide extracellular support for 
organisms of all kingdoms (example peptidoglycan found on bacteria cell walls). Some 
polysaccharides serve as destination labels for some proteins and as mediators of specific 
cell-cell interactions and interactions between cells and the extracellular matrix. The 
informational carbohydrates covalently joined to a protein or a lipid, form a complex 
called glycoconjugates, which are the biologically active molecules. 
 
 
 
Figure 5: Disaccharide unit of some polysaccharides 
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I.1.1 Carbohydrate drugs 
Many drugs contain carbohydrate moieties as part of their structures. In some 
cases, removal of the sugar moiety eliminates the therapeutic value of the drug. Due to 
the multifunctionality of carbohydrates, it is useful to classify biologically active 
carbohydrates according to their therapeutic activity5 such as anticonvulsant, anti-
inflammatory, anticancer, antidiabetic, antibiotic, and antiviral (figure 6). On the other 
hand, traditional classification would divide the existing drugs or new analogs into the 
following classes of derivatives: mono- and disaccharides, oligosaccharides, and 
polysaccharides.  
As an anticonvulsant agent,11 topiramate is an effective anti-epileptic drug in late-
phase clinical trials. The antidiabetic agent  MDL 73945,12 is an inhibitor of intestinal α-
glucohydrolases and is under the evaluation for treatment of non-insulin dependent 
diabetes mellitus. Acarbose,13 an α-glucosidase inhibitor, is effective in the treatment of 
patients whose non-insulin dependent diabetes mellitus cannot be managed by diet alone. 
The antitumor agent, 3-deoxy-3-fluoro-phosphatidyl inositol, for example, inhibits cancer 
cell growth by inhibiting the signaling pathways, and mediates the effect of activated 
oncogenes.14 Cell surface carbohydrates are known to change upon malignant 
transformation,15 and are more responsible for the differences in surface properties 
between metastatic and nonmestatic cells.16 The antibiotic agents Everninomycins17 are 
active against a variety of strains of Staphylococcus, Streptococcus, Bacillus and 
Mycobacteria. The antiviral agent 4-guanidino-NEU5Ac2en18 inhibits the replication of 
both influenza A and B viruses in cell culture and is effective in animal models when 
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administered intranasally. The anti-inflammatory agent sialyl Lewis X, is a blood group 
antigen.19 Sialyl Lewis is a tetrasaccharide of glycolipids, which is displayed on the 
surface of white blood cells and is responsible for the repair of injured tissues.  
  
   
     
     
Figure 6: Some carbohydrates with biological potential  
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I.1.2 Glycoconjugates 
 As mentioned above, oligosaccharides and polysaccharides are often found 
attached to proteins and lipids (figure 7). This produces a large number of 
glycoconjugates, called glycoproteins, proteoglycans, glycolipids, and GPI anchors, 
respectively.20 Proteoglycans are macromolecules of the cell surface or extracellular 
matrix in which one or more polysaccharide chains, also called glycosaminoglycan 
chains, are joined covalently to a membrane protein. They have a polyanionic character 
and consist mainly of repeating disaccharide subunits, which are often O-sulfated. They 
are major components of connective tissue, such as cartilage. Glycolipids are membrane 
lipids in which the hydrophilic head groups have oligosaccharides which act as specific 
sites for recognition by carbohydrate-binding proteins.  
  
 
Figure 7: Glycoproteins and glycolipids21  
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Glycoproteins are carbohydrate conjugates in which the carbohydrate moieties are 
smaller and more structurally diverse than the glycosaminoglycans of proteoglycans. 
Glycoproteins are more rich in information than glycosaminoglycans. There are three 
important type of linkages by which carbohydrates are covalently bound to proteins 
(figure 8). The first type of glycoprotein linkage is the O-glycans which usually contain 
an N-acetylgalactosamine attached through a glycosidic bond to the O-terminus of either 
threonine or serine. The second form of O-linked glycan consists of a galactose or a 
glucosyl-galactose disaccharide linked to the hydroxyl group of hydroxylysine. O-linked 
glycoproteins assemble their oligosaccharides on the polypeptide chain.  
The second type of glycoprotein linkage is the N-linked glycans, which involve a 
glycosidic bond between N-acetylglucosamine and the N-terminus of an asparagine 
residue.22 The third type of linkage, involves attachment through ethanolamine 
phosphate, which occurs in glycosylphosphatidylinositols called GPI anchors. In contrast 
with the O-linked glycoprotiens, N-linked glycoproteins assemble their oligosaccharide 
portions on a lipid linked intermediate, dolichol phosphate.  
Glycophorin A (figure 9), for example, is a glycoprotein that spans the plasma 
membrane ("Lipid bilayer") of human red blood cells.23  As shown on the figure, fifteen 
carbohydrate chains are O-linked to serine and threonine and one carbohydrate chain is 
linked to the asparagine (at position 26). Glycophorin A is the most important attachment 
site by which the parasite Plasmodium falciparum invades human red blood cells. 
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Figure 8: The different types of glycoprotein linkages 
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Figure 9: Structure of glycophorin A24 
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Most glycoproteins share a peptide-linked pentasaccharide fragment called the 
core region which consist of Man-(α1,6)[Man-(α1,3)]Man-(β1,4)-GlcNAc-(β1,4)-
GlcNAc (figure 10), with the terminal GlcNAc N-glycosidically linked to an asparagine 
residue of the peptide chain.25 Attached to this uniform core region, are oligosaccharide 
chains with different saccharides leading to branched or unbranched structures. Based on 
this finding, N-glycans have been classified into three types: The high mannose-type, the 
complex-type, and the hybrid-type. 
The simplest N-glycans are high mannose-type oligosaccharides (also called 
oligomannosides) which contain only α-mannosyl residues bound to the branching N-
glycoprotein core. In complex type, the α-mannose residues forming the bisecting core 
are elongated with N-acetylglucosamine residues and N-acetyllactosamine (Galβ1-
4GlcNAc) disaccharide moieties.  
 
 
   Figure 10: Structure of Man-(α1,6)[Man-(α1,3)]Man-(β1,4)-GlcNAc-(β1,4)-GlcNAc 
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Oligomannosides are ubiquitous in nature and have been found to be involved in 
important biological functions. This explains why many scientists are interested in their 
synthesis (more detailed discussion on this later). The oligosaccharide portions of 
glycoproteins are rich in information. They form highly specific sites for recognition and 
high-affinity binding by other proteins. They function as molecular addresses and by 
interaction with specific receptors, they can orchestrate a variety of biological functions 
in intercellular communication, such as cell proliferation, cell-cell adhesion, and cell 
migration. Molecules which can decode the information stored in carbohydrates are 
called lectins. These are proteins, which are specialized for the specific recognition of 
carbohydrate ligands resulting in the formation of non-covalent carbohydrate-protein 
(lectin) complexes. 
I.2 Lectins 
Lectins, non-enzymatic sugar-binding proteins, play an important role in 
biological recognition phenomena involving cells and proteins.26 They possess unique 
structural features which provide them the ability to discriminate among a gamut of 
complex carbohydrate structures found on the surface of cells, invading microorganisms, 
in intracellular matrices, as well as those attached to soluble glycoproteins. Although first 
discovered in plants and microorganisms, lectins are now known to be widely distributed 
in animals as well.27 The discussion in this section will be focused on animal lectins.   
Lectins have the ability to selectively bind with free sugars as well as sugar 
residues of polysaccharides, glycoproteins, and glycolipids. Surfactant protein D (SP-D) 
for example shows monosaccharide specificity in the order maltose>glucose>mannose.28 
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Lectins bind monosaccharides rather weakly, but employ the same strategies for 
enhanced affinity and specificity in binding more complex oligomers.29  X-ray 
crystallography studies reveal that relatively low affinity binding sites for 
monosaccharides are formed at shallow indentations on protein surfaces, while selectivity 
is achieved by a combination of hydrogen bonding to the sugar hydroxyl groups and van 
der Waals packing. This often includes packing of a hydrophobic sugar face against 
aromatic amino acid side chains. Higher selectivity is achieved through additional direct 
and water-mediated contact between oligosaccharides and the protein surface. The higher 
affinity for oligomers results from clustering of simple binding sites in oligomers of the 
lectin, while the geometry of such oligomers helps to establish the selectivity.30   
Several animal lectins can selectively bind to the surface of intruding bacterial 
and viral pathogens and initiate steps towards their neutralization. Others mediate 
adhesion between animal cells, sorting of newly synthesized glycoproteins in the 
endoplasmic recticulum, and endocytosis of selected subsets of circulating 
glycoproteins.30 
Animal lectins are classified based on the nature of their carbohydrate ligands, the 
biological activity, subcellular localization, and divalent cation dependence.27 The 
carbohydrate-binding section of lectins, known as the carbohydrate-recognition domain 
(CRD) are generally conserved within each subclass of lectins. CRDs within a major 
class may be further subdivided based on properties different from structural similarities. 
Animal lectins consist of three groups, (i) the S-type lectins, (ii) the C-type lectins, and 
(iii) the P-type lectins. S-type lectins do not require any divalent ions for their activity, 
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but require reducing agents (thiols) for full activity. They are intra- and extracellular, and 
specifically bind β-galactosides.27  Among the P-type lectins, the most prominent 
example is the mannose-6-phosphate receptor, which serves as targeting of glycosylated 
lysosomal enzymes to their subcellular compartments.  
On the other hand, lectins with CRDs which require calcium ions for their activity 
for example, are designated C-type lectins. They are also extracellular and bind a variety 
of sugars. C-type lectins are comprised of endocytic lectins, collectins, and selectins (L-, 
E-, P-selectin).  
One of the most prominent representatives of the C-type lectin is the mannose-
binding protein (MBP) expressed on macrophages; these are important cells of the 
immune system which engulf and destroy infectious organisms after receptor binding. 
This type of defense not depending on antibodies is called innate immunity. Another 
group is the mannose-binding proteins which are soluble lectins present in mammalian 
serum and liver. They bind to oligomannosides on infectious microorganisms, causing 
activation of compliment without antibody participation, and subsequent lysis of the 
pathogens. 
Mannose-binding lectin is a calcium-dependent serum protein that plays a role in 
the innate immune response by binding to carbohydrates on the surface of a wide range 
of pathogens (viruses, bacteria, fungi, protozoa), where it can activate the complement 
system or act directly as an opsonin.31 The complement system is a set of plasma proteins 
that work together to attack extracelluar pathogens. While the most important role of the 
complement system is to opsonize pathogens (by making them more liable to destruction 
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by phagocytes), it also recruits inflammatory cells and kills pathogens directly through 
membrane attack complexes. Once MBP recognizes a pathogen, its lectin domain will 
bind to mannose, or other carbohydrate sugar residues on the pathogen surface, and 
activate complement via the MB-lectin pathway. Many lectins occur as oligomers such as 
MBP which occurs as a trimer (figure 11).  
Different lectins specific for the same oligosaccharide may recognize different 
regions on its surface. Due to the flexibility of oligosaccharides (freedom of rotation 
around the glycosidic bonds), the selection of a specific three-dimensional 
oligosaccharide structure from the array of existing structures is one of the most 
important features of lectin-sugar interactions which awaits elucidation. 
 
   
         Figure 11: Representation of mannose-binding protein32 (MBP trimer) 
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Man9, which is the oligomannoside found on the gp120 glycoprotein envelope of the 
human immunodeficiency virus (HIV), is one of the most important oligosaccharides that 
have attracted many researchers due to their role in the HIV infection.  
I.3 Oligomannosides and their role with HIV 
Oligomannosides are oligosaccharides that consist of only mannose as the 
monomer. Mannose is absorbed eight times slower than glucose. When digested, 
mannose goes directly from the upper gastrointestinal (GI) tract to the blood stream 
instead of being converted into glycogen, or stored in the liver. Of the eight essential 
sugars for optimal health in humans, mannose is the most important. It is involved in 
more cell actions than any other essential sugars and deficiencies in mannose can lead to 
a whole host of physical problems.  
Mannose is essential in communication between cells and also in the inhibition of 
tumor growth and spread and the prevention of parasitic, bacterial, viral, and fungal 
infections. It is necessary for the production of cytokines which fight infections and 
diseases. It has been found to also ease inflammation from rheumatoid arthritis, lower 
blood sugar and triglyceride levels in diabetics, and also help in urinary tract infections.  
Figure 12 below shows the bacterium Escherichia coli adhering to the cells lining 
the bladder and urinary tract through the fimbria on their cell walls.33 The fimbria 
contains glycoproteins that bind to the first molecule of sugar that it encounters, which is 
mannose in this case. Mannose is found on the surfaces of these cells and act as receptors, 
inviting the fimbria of E. coli to attach and allowing them to bind tightly to the tissue. 
When mannose is ingested, it goes directly to the urinary system and binds competitively 
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to the bacterial lectins, occupying sites that would normally bind host cell mannose 
receptors, which prevents attachment; without attachment, infection is prevented. 
Oligomannosides are important in cell–cell communication involved in both 
normal functions and diseases and as receptors on cell surface; they are an important part 
of disease processes such as cancer and inflammation. They are found in nature as 
essential substructures of many bioactive glycoconjugates such as N-glycans, fungal cell 
wall mannans,34 and glycosylphosphatidylinositol molecules (GPI anchors).35 They also 
occur as high affinity ligands for mannose 6-phosphate receptors.36   
  
            
 
 
Figure 12: Escherichia coli adhering to human intestinal cells33 
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HIV, one of the most devastating modern diseases, has a high content of mannose 
sugars on its envelope. HIV infection occurs via virus-cell and cell-cell fusions mediated 
by the two envelope glycoproteins, gp120 and gp4137-39 (figure 13). In fact gp120 plays 
an important role in the HIV infection of cells, being responsible for the attachment and 
penetration of cells to be infected. For this reason, it is a target for immunotherapy or 
vaccine development. Gp120 binds to CD4 and chemokine receptors, triggering a series 
of events that lead to the insertion of the fusion peptide of gp41 into the target membrane 
and subsequent membrane fusion.40 This leads to a conformational change of gp41 
causing it to snap shut into a six helix coiled-coil bundle. The surface of gp120 is 
characterized by an abundance of high mannose N-linked glycosylation sites.  
 
 
Figure 13: Structure of HIV viron41 
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Post-translational glycosylation of gp120 covers conserved portions of the protein with 
host generated carbohydrates that constitute almost half of the molecular mass of gp120 
and limit recognition by the immune system, thereby allowing HIV to evade detection 
and destruction.  
Few antibodies have been isolated which successfully bind to the 
immunologically silent region of gp120 which is the heavily glycosylated exposed face. 
The carbohydrates moieties found on the envelope glycoprotein gp120 of the HIV virus, 
are promising targets for immunogen design as demonstrated by a potent neutralizing 
human monoclonal antibody 2G12. 2G12 (an antibody that binds to a portion of the silent 
region of gp120) is capable of neutralizing a broad range of HIV strains.42 A successful 
vaccine approach would seek to elicit a focused immune response of 2G12-like 
antibodies by exposing the immune system to an effective-scanning mimic of the 2G12 
epitope. The dense carbohydrate coat on the HIV-1 envelope provides a strong defense 
for the virus to evade humoral immune recognition. However, this strong shield is not 
completely seamless. HIV-1 surface carbohydrates have proven to be targets for 
developing anti-HIV strategy (as example there is cyanovirin-N and some lectins specific 
for oligomannose structures which have demonstrated anti-HIV activities in in-vitro 
assays).43 
Besides this relationship between oligomannoses and HIV, branched 
oligomannoses are also integral structural components of asparagine-linked glycans (N-
glycan), one of the major types of postsynthetic protein modifications.1 N-glycans are 
involved in many fundamental biological processes such as cell differentiation, viral 
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infection, nascent protein processing and tumor migration.44 The neutralizing antibody 
2G1245 and the anti-HIV protein cyanovirin-N specifically target high mannose sugars on 
the surface of gp12046,47 (figure 14). Cyanovirin is a cyanobacterial protein isolated from 
Nostoc ellipsosprum,48 that inhibits HIV-1 fusion at nanomolar concentrations through 
tight binding to the high mannose type oligosaccharides (Man9 and Man8) of gp120. 
Another cyanobacterial protein, MVL isolated from a laboratory culture of 
Microcystis viridis NIES-102,50 has been shown to inhibit HIV-1 envelope-mediated cell 
fusion at nanomolar concentrations by binding to high-mannose N-linked carbohydrates, 
Man9 (figure 15), on the surface of the envelope glycoprotein gp120.51 Cyanovirin and 
MVL are unusual in that they bind oligosaccharides with very high affinity in the absence 
of multivalent interactions. Cyanovirin-N specifically recognizes the disaccharide 
Manα(1-2)Manα (in blue) located at the terminal branches of mammalian high mannose 
oligosaccharides.45,47,52 In contrast, MVL is specific to its target which is the Manα(1-
6)Manβ(1-4)GlcNAcβ(1-4)GlcNAc tetrasaccharide core (in red) found in N-linked 
oligomannosides.51  
The existence of broadly neutralizing antibody 2G12, and the characterization of 
its epitope as a novel oligosaccharide cluster on HIV-1 gp120, raises a possibility of 
developing a carbohydrate-based vaccine against HIV-AIDS. However, carbohydrate 
antigens have not been adequately exploited for HIV-1 vaccine design, despite their 
abundance on HIV-1 surface.53 The exploration of various HIV-1 glycopeptides as new 
and unique epitopes, may open a new avenue for vaccine development. Efficient 
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syntheses of branched oligomannoses can therefore provide much needed materials to 
facilitate their biological studies. 
 
 
Figure 14: Carbohydrates in cell-cell recognition49 (CV-N blocks the gp120-CD4 fusion) 
 
 
Figure 15: Structure of Man9GlcNAc2 
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I.4 Synthetic Methods 
Currently, the synthesis of oligosaccharides is being pursued by researchers from 
different areas.54-57 Carbohydrate synthesis is achieved through a process called 
glycosylation protocol. This implies the activation of a suitable glycosyl donor equipped 
with a leaving group at the anomeric center and the efficient and stereoselective coupling 
to a glycosyl acceptor, which is promoted by a suitable activator. Several synthetic 
methods for activating various glycosyl donors have been developed.53,58,59 Sophisticated 
methods, such as one-pot programmable glycosylation,60,61 chemoenzymatic synthesis,62 
solid-phase oligosaccharide synthesis,63,64 and iterative glycosylation,65 have been 
developed with the aim of alleviating the challenges faced in oligosaccharides synthesis. 
However, the diverse and complicated methods found in the literature57,63,66 do not 
always make it easy for researchers to select the best approach to synthesize the desired 
oligosaccharides. This is due to the fact that different carbohydrate (glycosyl donors or 
acceptors), manifest moderate to drastic reactivity depending on the reaction conditions. 
And sometimes, optimization of the reaction conditions for each carbohydrate moiety is 
very problematic. Moreover, few of these methods are reproducible or yield enough 
material to use for biological studies. 
There are still two types of glycosylation where the efficiency is not always 
satisfactory. The first type is the case where large glycosyl donors are used in a reaction 
and the second type is when glycosylation is carried out at multiple sites simultaneaously. 
For example, solid-phase oligosaccharide synthesis often requires excess glycosyl donors 
(5 – 10 equiv.) to achieve the desired outcome. Also very complex to expensive reagents 
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have been used to achieve glycosylation and these are seldom used in the synthesis of 
oligosaccharides. 
As mentioned above, one of the key factors in oligosaccharide synthesis is the 
reactivity and the stability of the leaving group (glycosyl donor) and the conditions used 
to activate one over the other. Glycosyl donors (figure 16), such as glycosyl halides,67 
glycosyl trichloroacetimidate,68 thioglycosyl donors,69 O-acyl donor,70 n-pentenyl 
glycoside,71 glycosyl sulfoxide,72 have all been developed and used in carbohydrate 
synthesis, but not all have been efficient in the synthesis of oligosaccharides. 
 
 
Figure 16: The different glycosyl donors 
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In this regard, the development of new synthetic methodologies, which can 
provide adequate protocols with cheaper starting materials are much needed. In an 
attempt to further contribute to the synthetic methods that are currently in use, our 
attention was focused on the synthesis of oligomannosides under sonication 
methodology. Sonication,73-77 also called sonochemistry, has long been employed as the 
energy source for enhancing the rate of chemical reactions. It has been employed in many 
traditional chemical reactions as it provides the needed energy to overcome the different 
reactivity among various carbohydrate derivatives. It may enable the development of 
general protocols for facilitating the synthesis of complex carbohydrates. 
Our research group has been able to synthesize carbohydrate compounds with the 
use of sonication for various glycosylations.78 Sonication has proven to be time efficient 
and the yields obtained have been very encouraging. The use of sonication for sterically 
hindered compounds has also proven to be successful in our laboratory. Our emphasis 
will be on the study of glycosylations using mannose-based donors, such as 
phenylthiomannosides and mannosyl acetate donors. These donors are known for their 
relatively low reactivity as compared to the other glycosyl donors, such as glycosyl 
trichloroacetimidate and glycosyl halide. Glycosylation reactions carried out under 
sonication conditions have been accomplished in a matter of minutes and the yields have 
been very good. This methodology was then applied into the synthesis of complex 
oligomannoside Man9,79,80 which has been shown to have immense therapeutic 
applications.81 Although the synthesis of Man9 has been accomplished, the lengthened 
30 
 
 
synthetic steps and the reaction time are not very encouraging if one intends to repeat it’s 
synthetic schemes.  
The aim of this research was to investigate the use of sonication as a new 
methodology tool for the synthesis of complex oligomannosides such as Man9. Before the 
synthesis of Man9 could be attempted, simpler molecules had to be synthesized using 
sonication before attemting the synthesis of more complex carbohydrates. 
Stereoselectivity in glycosylation using mannose sugar very often favors the α-anomer 
and the synthesis of β-mannosides is often very problematic. Experiments were carried 
out under the same condition with different solvents to attempt to yield a better 
stereoselectivity. This was then followed by the synthesis of monosaccharides using a 
single acceptor: 6-azidohexanol. This choice was based on the fact that, the azide group 
could be reduced to an amine group which will then facilitate the attachment of the sugar 
to a carrier protein to enable some biological testing. The synthesis of disaccharides and 
trisaccharides was then achieved, followed by the synthesis of more complex 
oligomannosides Man6 and Man9. Solid phase synthesis under sonication was also 
investigated as it could be a means of shortening the synthetic steps involved in solution 
phase synthesis, which often require multiple purification steps. 
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CHAPTER II 
SOLUTION PHASE SYNTHESIS OF OLIGOMANNOSIDES 
Oligomannosides possess a variety of important biological implications and 
applications such as regulating immune response,82 mediating cellular interactions,83 
utilized as tumor-associated antigens,81 involved in fungal infection,84 viral85 and 
bacterial86 pathogens. As a result, the synthesis of structurally diverse natural and non-
natural oligomannosides as potential therapeutic agents has been pursued by various 
researchers.87 Some strategies for the conventional step-wise solution phase synthesis of 
oligosaccharides have been developed. These involve selective protection, followed by 
glycosylation and deprotection sequences which are time consuming and require 
chromatographic purification of all intermediates. In addition, while these work well for 
glucose and galactose sugars, they do not work well for mannose. So the search for new 
and expedient methods for oligosaccharide synthesis is imperative. Indeed, several 
research groups across the globe are currently pursuing research in this area. 
To contribute to this effort, sonication was investigated as a new method for the 
expedient synthesis of oligomannosides. As stated earlier, sonication has been employed 
to enhance the rate of many traditional chemical reactions73-77 including carbohydrate 
chemistry.88 However, only a few examples of glycosylation reactions employing 
glycosyl donors such as unprotected donors,89 glycosyl halides,90 and glycosyl sulfones91 
have been reported. In this investigation, efforts were directed towards the development 
of general protocols of glycosylation using mannose-based donors including 
phenylthiomannosides and mannose acetate. These two donors are relatively stable and 
32 
 
can be prepared in large quantities. Their reactivity is low compared to glycosyl 
trichloroacetimidate and glycosyl halide, especially in the presence of acyl protecting 
groups.  
II.1 Sonication or Sonochemistry 
The study of ultrasonic chemical effect is a research area that is expanding 
rapidly. The most recent applications of sonochemistry are in the synthesis and 
modification of both organic and inorganic chemistry.92 In 1927, two researchers Alfred 
Lee Loomis and Robert Williams were the first to report the effect of ultrasonic waves in 
liquid media.93 Sonochemistry was rejuvenated in the 80s when inexpensive reliable 
instruments with high intensity ultrasound, were made available. Ultrasound wave often 
produces very high temperatures (5000 K) and pressures, and increases chemical 
reactivity by up to a million fold.94 In the laboratory, ultrasound is applied using an 
ultrasonic bath or probe known as sonicator. It has many applications which include 
degassing liquids, deactivating biological materials, cleaning instruments or extracting 
microfossils from rocks.94   
In chemistry, energy is one of the most important things that chemical reactions 
need in order to occur. Energy derived from ultrasound differs greatly from that 
generated from traditional sources (such as heat, light, ionization) in the duration, the 
pressure and the energy per molecule.95 Ultrasonic waves have a unique means of driving 
chemical reactions under extreme conditions.96 Unlike sonochemical reactions, traditional 
reactions involve a direct interaction between the molecular species and its surrounding 
such as bond breaking. The mechanism of sonochemistry is dependent upon two major 
factors which are: the intensification of mass-transfer processes and acoustic cavitation.97 
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Cavitation is defined as the formation of bubbles, followed by the growth and then the 
implosive collapse of these bubbles. This yields an enormous rise of local temperatures 
and pressures.  
The role of cavitation is that it concentrates the diffuse energy of sound. When 
cavitation causes bubble collapse, this generates intense localized hot spots, high 
pressures and very short life times. These extreme conditions can cause chemical bond to 
rupture. It should be noted that cavitation in a homogenous liquid system is quite 
different from that of a liquid solid system. Cavities grow rapidly and reach sizes where 
they can efficiently absorb energy generated by the sound field and when overgrown, 
they can no longer absorb the sound energy and implode.95  
The chemical enhancement of reactions by ultrasound has beneficial applications 
in mixed phase synthesis, material chemistry, and in biomedical uses. In chemical 
kinetics for example, it has been observed that ultrasound can greatly enhance chemical 
reactivity in a number of systems, effectively acting as catalyst by exciting the atomic 
and molecular modes of the system.98 When gas compresses, heat is generated in 
irradiated liquid, compression of cavities increases collapse of bubble. This generates a 
short-lived localized hot spot which is the source of homogeneous sonochemistry. 
In this chapter, we present our findings on the influence of sonication on the 
synthesis of oligomannosides. The results obtained show that glycosylation reactions 
carried out under sonication proceed much faster and with better yields than those carried 
out under traditional conditions. There is also some evidence that with the right solvent 
choice, sonication also leads to superior selectivity between α and β anomers.  Also, 
glycosylation carried out on secondary alcohols only afforded α anomers. Some concepts 
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in the stereoselectivity of glycosylation are first discussed followed by the first part of 
this research which covers the synthesis of glycosyl donors and acceptors (acetyl and 
thiophenyl-based), which are the starting materials for glycosylation reactions. This is 
then followed by the exploration of solvent effects on stereoselectivity and yields, and 
glycoslation test runs using some of the donors with 6-azidohexanol as the acceptor. 
These provided some knowledge on the stereoselectivity of mannose-based compounds 
and the desired solvents in which to run the glycosylation reactions after which, the 
synthesis of dimannosides, trimannosides, and more complex oligomannosides including 
Man9 was achieved. 
Glycosylation which is the condensation of two molecules, one being a glycone 
moiety (donor) and the other an aglycon often occurs at the anomeric center. 
Glycosylation is a key step in the synthesis of oligosaccharides in general. 
Oligomannoside synthesis is achieve through glycosylation methodology necessitating 
the activation of a donor with a leaving group at the anomeric center and the 
stereoselective coupling to an acceptor, promoted by a good activator to lead to the 
desired compound. The stereochemical outcome of glycosylation could depend on 
whether or not the substituent at C-2 is participating in the mechanism of the reaction. 
II.2 General concepts on stereoselectivity in glycosylation reactions 
II.2.1 Neighboring group participation 
During a glycosylation reaction, there is the formation of an oxocarbenium 
intermediate which is formed. The participation of the substituent at C-2 (such as ester 
groups), would lead to the formation of an acyloxonium intermediate which can react 
with a nucleophile in the opposite direction (or trans-cleavage), yielding the 1,2-trans 
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glycoside (scheme 3). In the case of mannose sugar with the axial orientation at C-2, the 
formation of the acyloxonium is greatly enhanced due to the reverse anomeric effect.2 
Benzoate or pivaloate groups at C-2 are less favored to form the acyloxonium 
intermediate compare to acetate group. Also ether groups at C-2 will not favor any 1,2-
orthoester intermediate. 
II.2.2 Anomeric effect 
 Generally, substituents at the equatorial position of a sugar ring are 
thermodynamically favored over those at the axial position when they adopt their chair 
conformation. For D-pyranoses and compounds with electronegative groups at the 
anomeric center, the α-derivatives at the axial position are often more stable than it has 
been predicted by steric hindrance with neighboring substituents.2  
 
 
Scheme 3: Mechanism depicting the neighboring group effect 
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During the anomeric effect, a lone pair of electrons located in the n-molecular 
orbital of atom Y (or O) overlaps with the antibonding σ*-orbital of the C-X bond 
leading to a favorable delocalization of nonbonding electrons (figure 17). This is only 
possible with an anti-periplanar arrangement of the involved orbitals. Also, the anomeric 
effect is strongly influenced by the nature of the substituent at C-2 as it is proportional to 
the electronegativity of the atom at C-1, and it is greatly enhanced in the case of mannose 
which has an axial C-2-substituent. The nature of the anomeric group is important for 
anomeric effect as it depends on the electronegativity of the substituent bound at this 
center. Solvents also influence the anomeric effect. More polar solvents decrease the 
influence of the anomeric effect on the equilibration of α and β conformers in solution.2  
  
 
 
Figure 17: Stable and unstable anomers 
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II.2.3 Armed and disarmed concept 
The reactivity of the anomeric center depends on the sugar and mostly on the 
substituents. The reactivities of the different glycosyl donors can also be used to explain 
the stereochemistry of the products. In the late 1970s, Paulsen’s group observed that 
electron withdrawing groups such as acyl groups reduce the reactivity at the anomeric 
center leading to the term “disarmed glycosyl donor,” while electron donating groups 
such as benzyl ethers, enhance the reactivity and are classified as “armed glycosyl 
donors.” Also the reactivity may depend on the nature of substituent at C-2 (scheme 4). 
 
   
Scheme 4: Concept of stereoselective glycosylation 
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II.3 Synthesis of mannose-based monosaccharide derivatives 
The synthesis of donor 599 (scheme 5) started with the acetylation of the 
commercially available α-D-mannose 1, to give a mannose pentaacetate 2. Compound 2 
was then treated with a mixture of hydrobromic and acetic acids to selectively brominate 
the anomeric acetyl group to give 3. Treatment of 3 with silver oxide in anhydrous 
methanol and toluene gave the orthoester 4. Methanolysis of 4 followed by benzylation 
gave the orthoester donor 5 and a byproduct 6 obtained from the workup (1N 
hydrochloric acid solution). It should be noted that during workup, if the reaction mixture 
is not washed with 1N hydrochloric acid, little to no byproduct 6, is obtained. When 5 
was diluted with CH2Cl2, mixed with 1N HCl and stirred for 2 hrs, 6 and 7 were obtained.  
Compound 6 could be transformed into 2 major donors 8100 and 9. First the 
acetylation of compound 6 using triethylamine as the base gave acetyl donor 8. Also, 6 
could be transformed to the more reactive trichloroacetimidate donor 9 using 
trichloroacetonitrile and a catalytic amount of DBU (scheme 6). Though donor 9 is very 
reactive, it also decomposes very fast during glycosylation. So it is not always a very 
good donor to use and reactions with this donor are not always 100% effective.  
The treatment of the orthoester 5 with thiophenol in acidic medium using 
sonication, gave glycosyl donor 1099 and another product 11101 (scheme 7). Under reflux 
conditions, this reaction usually takes 3 to 5 hours to complete, but under sonication 
conditions, the reaction is complete within 10 to 30 minutes depending on the quantity of 
starting material used (1 to 5 g). The yield is also very good compared to traditional 
methods. The formation of 11 is also greatly reduced under sonication. Methanolysis of 
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the acetyl group of each of these compounds, 10 and 11, gave the glycosyl acceptors 
12102 and 13101, respectively. 
 
 
Scheme 5:  Synthesis of D-mannopyranose donor 5  
 
Scheme 6: Synthesis of donors 8 and 9 
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            Scheme 7: Synthesis of D-mannopyranose donor and acceptor 
The synthesis of mannose derivatives (scheme 8) began with the selective 
protection of the primary alcohol in 14 using trityl chloride in basic medium, followed by 
benzylation of the remaining hydroxyl groups to give 15. Deprotection of the primary 
alcohol in 15 using a mild acid gave acceptor 16. Acetylation of 16 gave donor 17,103 
which was treated with NBS to yield 1-OH intermediate that was further treated with 
trichloroacetonitrile and DBU to give trichloroacetimidate donor 18. Again, the hydroxyl 
group at position 6 of compound 14 was selectively activated using tosyl chloride, 
followed by benzylation to give 19. Reduction of 19 using lithium aluminum hydride, 
gave donor 20 which was further treated with NBS to give 21 followed by acetylation to 
give 22. Azido substitution of the tosyl group in 19 gave 23, while treatment of 19 with 
TBAF in acetonitrile under reflux gave 24. Treatment of 24 with NBS gave 25, followed 
by acetylation to give 26. The synthesis of these donors was carried out to enable the 
synthesis of Man9 analogs, upon development of a successful methodology.  
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Scheme 8: Synthesis α-D-mannopyranose derivatives 
As shown in scheme 9, compound 14 was used to generate many other donors. 
The 4- and 6- positions were first selectively protected using benzylidene acetal. This 
gave compound 27, which was subjected to different types of reactions.  First, it was 
benzylated to give donor 28104 and also acetylated to give donor 29. Selective benzylation 
using tetrabutylammonium hydrogen sulfate as the key reagent gave compounds 30 and 
31. Compound 30 was acetylated to give donor 32105 which was further subjected to a 
selective deprotection of the benzylidene group to give 36. Acetylation of 36 gave donor 
37.106 Compound 30 again was treated with benzoyl chloride to give 33. The selective 
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deprotection of the benzylidene group on 33 followed by acetylation gave donor 34. On 
the other hand, selective deprotection of 31 followed by acetylation gave 38. On the other 
hand, direct acetylation of 31 gave donor 35. Treatment of 35 with borane 
tetrahydrofuran complex gave 39 which was then acetylated to give 38. 
 
Scheme 9: Synthesis of phenylthio-α-D-mannopyranose donors 
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For the synthesis of acetyl-α-D-mannose donors (scheme 10), commercially 
available methyl α-D-mannopyranoside 40 was subjected to benzylation to give 
compound 41. Selective acetylation of 41 using concentrated sulfuric acid as catalyst, 
gave 42107 and 43. When a larger amount of acid was used in the same reaction, donors 
42, 44, and 45, respectively, were obtained.  
As shown in scheme 11, the commercially available methyl α-D-
mannopyannoside 40 was also used to generate many other compounds. The 4-,6- 
positions were protected as a benzylidene acetal to give 46 which was then selectively 
benzylated to give two distinct acceptors 47 and 48. Acetylation of 47108 and 48 gave 
compounds 49 and 52, respectively. Also, selective deprotection of the benzylidene group 
of 47 and 48 using borane-tetrahydrofuran complex gave 50 and 51, respectively. 
Acetylation of 50 gave 53, which was then converted to donor 44. Also acetylation of 51 
gave 54.  
  
 
 Scheme 10: Synthesis of acetyl-α-D-mannopyranose donors  
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Scheme 11: Synthesis of methyl-α-D-mannopyranose derivatives 
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II.4 Solvent effect on the stereoselectivity 
The primary goal was to determine the effect of solvents and protecting groups on 
the stereoselectivity of sonication assisted glycosylation. However, despite numerous 
attempts, the solvent effect on the stereochemistry is still unclear. Both 2-O-acyl and 2-
O-alkyl groups favor the formation of α-glycosidic bond via neighboring group 
participation and anomeric effect, respectively. 
Mannose is well known for its stereochemistry, which is predominantly the α-
anomer. Extreme conditions have to be met in order to prepare the β-anomer. Crich 
proposed a general glycosylation mechanism using phenylthiomannosides as donors and 
1-benzenesulfinyl piperidine (BSP) and triflic anhydride as the activating agents for the 
preparation of β-anomers.109 In the proposed mechanism of this reaction, the α-mannosyl 
triflate intermediate is in equilibrium with a β-selective contact ion pair (CIP) and an α-
selective solvent separated ion pair (SSIP) (figure 18). It is likely that sonication provides 
energy which facilitates an SN2-like glycosylation through intermediate A or the contact 
ion pair (CIP) respectively, which will lead to the formation of β-mannosides. 
 
 
Figure 18: Proposed glycosylation mechanism 
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To carry out this study, compound 17 and 6-azidohexanol78 were chosen as the 
donor and acceptor respectively (scheme 12). Compound 17 does not contain any 
participating groups on C-2 or C-3, which have been shown to always favor the α-
anomer. 6-azidohexanol was chosen because after attachment of the sugar, the azide 
group will be reduced to an amine group. The amine group could then be used as an 
attachment point for a carrier protein to facilitate delivery into the body. Among the 
different solvents examined, there was no outstanding preference in the stereoselectivity 
under our sonication-assisted protocol. 
 Despite the difficulty in obtaining the β stereoisomer over α stereoisomer under 
sonication, it is evident that sonication can enhance the efficiency of glycosylation 
(entries 5 – 10, Table 1). The stereoselectivity of the products obtained was confirmed by 
1JCH using HETCOR experiment. The most important carbon that was evaluated was the 
carbon at the anomeric center C-1. 1JCH values ranging from 158 – 165 are attributed to β 
stereoisomers while those that range from 168 – 180 are attributed to α stereoisomers. 
As shown in Table 1, all the different solvents used gave both α- and β-anomers. 
However, traditional glycosylation (-78 oC to RT) which does occur in less polar solvents 
like toluene and ether, gave modest to excellent yields under sonication. A mixture of 
solvents (entry 9) was also used, but the result was the same, as both anomers were 
obtained. Though no selectivity was observed under sonication conditions, the formation 
of the β-anomer in the presence of a non-participating group on C-2 (such as benzyl 
group) was observed, leading us to believe that this reaction undergo a different type of 
mechanism under sonication.  
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Scheme 12: Coupling of 16 with 6-azidohexanol 
Table 1: Effects of solvent on the stereoselectivity 
Entry Solvent Condition Yield (%)a α/β ratio 
1 Toluene No reaction - 
2 Et2Ob No reaction - 
3 CH2Cl2 90% 1/1 
4 CH3CN 
 
-78 oC – RT, 
5 hr to overnight 
98% 3/2 
5 Toluene 80% 2/1 
6 Et2O 40% 1/1 
7 CH2Cl2 92% 3/2 
8 CH3CN 65% 3/2 
9 Toluene/dioxane (1:1) 
 
 
Sonication, rt 
8 min 
90% 1/1 
 
10 
CH2Cl2 NIS, BF3-OEt2 
Sonication, 8 min 
80% 3/1 
a: isolated yield, b : no reaction even after heating (30 – 40 oC) for 5 hr 
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II.5 Synthesis of monosaccharides with 6-azidohexanol 
Several mannose donors including glycosyl acetate, thiophenyl glycosyl and the 
orthoester donor, were examined under sonication. They are known to have low reactivity 
under traditional glycosylation conditions. All the monosaccharides were prepared using 
a single glycosyl acceptor which is the 6-azidohexanol and the time needed to complete 
these reactions was between eight to ten minutes (scheme 13).  
Acetate donor 42 was glycosylated in eight minutes to give 55 with α/β ratio of 
6/1, when using CH2Cl2 as the solvent but when the solvent was changed to CH3CN, only 
α-selectivity was observed. This could be due to the solvent used or simply the fact that 
the other isomer was not isolated during purification but no reasonable explanation can 
account for the observed selectivity at this point. There is a great difference nevertheless 
in the products obtained when using thiophenyl donors compare to acetate donors. 
Methanolysis of 55 gave 56. Sonication using the thioglycosyl donor 37 gave 57 as a 
single α-anomer and treatment with NaOMe in MeOH gave 58. As stated earlier, this 
shows that electron withdrawing groups at C-3 also have an effect on the stereochemistry 
of product. Glycosylation with orthoester donor 5 gave 59 which was further treated with 
NaOMe in MeOH to give 60. The benzylidene protected donor 32 which usually gives 
the β-anomer under extreme traditional conditions, gave α-anomer 61. While the 
benzylidene protected donor 29 also gave 62 with α-selectivity. 28 bearing no 
carboxylated group gave 63 as a mixture of α/β with the ratio 3/2. Thioglycosyl donor 38 
also gave 64 as a single compound. Interestingly, glycosylation between two acceptors 16 
and 6-azidohexanol gave a monosaccharide 56. Formation of a disaccharide could be 
observed in this reaction. Treatment of donor thiophenyl 35 with 6-azidohexanol gave 65. 
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Coupling of acetate donor 45 with the same alcohol gave 66 while thiophenyl donor 33 
yielded 67 and all these reactions gave good yields under sonication.  
As expected, glycosylation with O-2 acetyl participation gave only the α-anomer. 
Glycosylation with mannose bearing an acyl group at C-3 yielded predominantly α-
mannosides. This selectivity has been explained by the neighboring group participation 
via a twist-boat conformation intermediate.110 
 
Scheme 13: Investigation of sonication assisted glycosylation 
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            Scheme 13: Investigation of sonication assisted glycosylation (continued) 
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II.6 Synthesis of disaccharides 
As well as synthesizing monosaccharide donors, it was envisioned envisioned that 
disaccharide donors (scheme 14) could be of great used in the synthesis of Man9, one of 
our target molecules. Acceptor 12 was glycosylated with 1,2-diacetyl donor 8 to give 
thioglycosyl donor 68 with an acetyl group at the 2′ position. It was glycosylated with 
1,6-diacetyl donor 42 as well to give donor 69 with an acetyl group at the 6′ position. 
Disaccharide donor 68 was also transformed to the corresponding acetyl donor, by 
treating with N-bromosuccinimide in acetone to give 70, followed by acetylation to 
obtain the disaccharide acetyl donor 71. Glycosylation of 12 with donor 2 gave donor 72. 
The synthesis of disaccharides gave solely α-anomers when the reactions were 
carried out with a secondary alcohol acceptor. No disaccharide β-anomer was isolated in 
these reactions as compared to reactions carried out with a primary alcohol acceptor. 
The synthesis of some disaccharide compounds was also achieved with great 
success as can be seen in scheme 15. The coupling of 48 with 43 using a Lewis acid gave 
compound 73. The coupling of 13 and thiophenyl donor 74 gave 75. Glycosylation 
between two acceptors, 76111 and 16 gave the disaccharide 77. Interestingly, sonication of 
the disaccharide donor 68 and 71 with 6-azidohexanol using the same conditions both 
gave the product 78. Methanolysis of 78 gave 79. Glycosylation using thiophenyl 
disaccharide donor under traditional conditions has rarely been successful when using 
NIS, TMSOTf.  In order to activate this donor, several other reagents (AgOTf, PhSCl, 
AW 300, Et2O/CH2Cl2) have to be combined together, but most often it is thiotoluene 
that has been used successfully with these reagents. But as shown in our protocol, this 
donor is very reactive and product is obtained in good yield.  
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Scheme 14: Sonication assisted synthesis of disaccharides donors 
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Scheme 15: Sonication assisted synthesis of disaccharides compounds 
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As shown in scheme 16, the synthesis of 84 began from 80 with the selective 
protection of the secondary alcohol at C-3 over C-2 using pivaloyl chloride in basic 
medium to give 81. Treatment of 81 with Bu4NHSO4 and benzyl bromide did not yield 
the desired product. Instead, migration of the pivaloyl group from C-3 to C-2 in 82 was 
observed. Coupling of 82 with donor 10 gave 83. Unfortunately, treatment of 83 with 
copper triflate and borane-tetrahydrofuran complex to selectively open the benzylidene 
ring, gave 84 in low yield. This was a synthetic route aimed towards the synthesis of 
Man9, but was not pursued any further for this reason. 
 
 
Scheme 16: Synthesis of disaccharide compound 84 
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II.7 Synthesis trimannosides 
The synthesis of the trimannosides was designed and accomplished with the goal 
of doing some X-ray crystallography studies of the carbohydrate-protein interaction with 
a protein known as surfactant protein D (SP-D). Studies carried out on this protein with 
different sugars showed that SP-D binds strongest to D-mannose sugar and weakest to 
maltose and galactose under dynamic conditions.112 This protein is a member of the 
collectin family of C-type lectins and binds carbohydrates in a calcium dependent 
manner. Several mannose binding protein (MBP)-carbohydrate complex structures, 
including complexes of MBP with several monosaccharides, have been determined by X-
ray crystallography. It was found that SP-D recognizes carbohydrates by a mechanism 
similar to that of MBP.113 Unfortunately for us, the results from the X-ray crystallography 
study were not completed in time for us to know how the interaction between the 1,6 and 
1,2-linked trimannosides with SP-D occur. 
II.7.1 Synthesis of 1,6-linked trimannoside 
The synthesis of 1,6 linkages was accomplished with similar efficiency as with 
the synthesis for disaccharides using sonication (schemes 17 and 18). As stated earlier, 
1JCH values obtained from HETCOR experiment were used to confirm the formation of 
the desired product. A mixture of both stereoisomer α and β was observed only when a 
glycosylation reaction was carried out between a primary alcohol and a donor. So the 
HETCOR experiment was very useful at this stage. 
As shown in scheme 17, the orthoester 4, was glycosylated with benzyl alcohol to 
give 85. Methanolysis of 85 gave 86. Selective protection of the primary alcohol at C-6 
using trityl chloride, followed by benzylation and deprotection of the trityl group 
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afforded 87114 with a free hydroxyl group on C-6. Compound 87 was coupled with donor 
17 to give 88. Hydrolysis of 88 gave 89, which was subjected to another glycosylation 
with 17 to give 90. Methanolysis of 90 followed by global deprotection gave 92. 
Glycosylation carried out on a primary alcohol with a donor having a nonparticipating 
group at 2 or 3-position, under sonication conditions gave a very small amount of the 
corresponding β-selectivity. Though difficult to separate after glycosylation with the 
protecting groups on, both anomers were easily separable after hydrolysis. 
In scheme 18, α-methyl-D-mannoside 40 was treated with trityl chloride to 
selectively protect the primary alcohol at C-6, followed by benzylation and deprotection 
to give 76. Acceptor 76 was glycosylated with donor 17 to give 93. Treatment of 93 with 
NaOMe in MeOH gave 77 which was subjected to another glycosylation with donor 10 to 
give 94, as a mixture of epimers. When 94 was subjected to methanolysis, the 2 epimers 
were separated to give 95 and epi-95. Global deprotection of 95 using deactivated 
palladium on carbon gave 96. 
II.7.2 Synthesis of 1,2-linked trimannosides 
The synthesis of 101 (scheme 19) began with glycosylation of acceptor 13 with 
donor 10 to give 97.  Methanolysis of 97 gave 98, which was subjected to another 
glycosylation with 10 to give 99. Another methanolysis of 99 followed by global 
deprotection gave 101. The synthesis of another 1,2-trimannoside 108 (scheme 20) began 
with glycosylation of orthoester donor 5 with benzyl alcohol to give 102.115 Methanolysis 
of 102 followed by another glycosylation with donor 10 gave 104. Methanolysis of 104 
gave 105 which was subjected to another glycosylation with donor 17 to give 106. 
General deprotection of 107 afforded 108. 
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Scheme 17: Synthesis of 1,6-linked trimannoside 
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Scheme 18: Synthesis of methyl 1,6-linked trimannoside 
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  Scheme 19: Synthesis of methyl 1,2-linked trimannoside 
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Scheme 20: Synthesis of 1,2-linked trimannoside  
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II.8 Retrosynthetic analysis of complex oligomannoside 
The synthesis of Man9 was designed to follow the retrosynthetic scheme 21 below 
where Man9 could be obtained from Man6 which in turn could be obtained from Man3. 
Man3 will be obtained from glycosylation of fragment A with B followed by 
glycosylation with C. 
 
 
Scheme 21: Retrosynthetic protocol of Man9 
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II.9 Synthesis of Man6 
 With success recorded in synthesizing di- and trimannosides, focus was 
then directed towards the synthesis of the more complex oligosaccharide, Man6116 
considered as the prelude to the synthesis of Man9, which has a potential of being used for 
HIV vaccine development. The synthesis of Man6 (scheme 22) started with the coupling 
of acceptor 47 at C-3 with donor 10 to give disaccharide 109. The 4,6-benzylidene 
protecting group in 109 was then selectively reduced to provide a primary alcohol in 110 
using cupper triflate and boranetetrahydrofuran complex.117 Disaccharide acceptor 110 
was then coupled with donor 37 to give trisaccharide 111. Hydrolysis of the acetyl groups 
in 111 gave acceptor 112 with three free hydroxyl groups. Trisaccharide 112 was again 
glycosylated with donor 10 to give hexammanoside 113, followed by hydrolysis to obtain 
114. The synthesis of methyl-Man6 using sonication conditions was very successful and 
the route was now applicable to a more complex oligomannoside Man9, which is the 
oligosaccharide found on the surface of the gp120 glycoprotein of the HIV virus where it 
plays an important role. 
II.10 Synthesis of Man9 
The synthesis of Man9 (scheme 23) began with glycosylation of pentacetylated 
mannose 2 with 6-azidohexanol to give 115. Methanolysis of 115 using sodium 
methoxide in anhydrous methanol gave 116. Selective protection of 116 using 
benzylidene acetal gave 80. Selective benzylation of 80 using tetrabutylammonium 
hydrogen sulfate gave 117 (benzylated at C-2), and 118 (benzylated C-3). To differentiate 
between the two, both compounds 117 and 118 were acetylated to give 3-O-acetyl and 2-
O-acetyl derivatives. Glycosyl acceptor 117 was then coupled with thioglycosyl donor 10 
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to give disaccharide 119. Selective deprotection of 119 afforded the primary alcohol 120, 
and a diol 121. The disaccharide 120 was then glycosylated with 34 to yield trisaccharide 
122. Methanolysis of 122 gave 123, with three free hydroxyl groups. Trisaccharide 
acceptor 123 was then triglycosylated with 10 to afford hexamannoside 124, which was 
treated with NaOMe in MeOH to yield 125. This was again triglycosylated with 17 to 
afford 126, which was subjected to hydrolysis, to give 127. The conditions for the 
synthesis of Man9 need to be optimized so that analogs could be synthesized. In order to 
let reactions go to completion under sonication conditions, excess donor needed to be 
used especially when dealing with large molecule with more than one hydroxyl group. 
Reactions carried out under these conditions were successful. The yields obtained were 
moderate to excellent, but some of the low yields were sometimes due to little material 
used. Sonication has proven to be reliable towards the synthesis of complex 
carbohydrates and more studies are needed to understand the stereoselectivity under this 
method.  
In summary, the synthesis of oligomannosides was achieved using sonication in a 
relatively short synthetic scheme with good yields. Glycosylation carried out using 
primary alcohol as acceptor, sometimes gave a mixture of α / β products. All 
glycosylation reactions carried out using secondary alcohols as the acceptor exclusively 
gave the α-anomer. Glycosylation reaction that were carried out with electron 
withdrawing groups at C-2 or C-3 gave only α-anomer which is consistent with the 
results obtained by other research group under traditional methods.97 Glycosylation with 
acetyl donors preferentially gave the α-anomer whereas glycosylation with the acetyl 
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group would provide both anomers: α and β. Sonication has proven to be an efficient tool 
that improves the synthesis of oligosaccharides over traditional glycosylation methods. 
 
 
 
 
    
Scheme 22: Synthesis of methyl- Man6 
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Scheme 23: Synthesis of 6-azidohexyl- Man9  
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Scheme 23: Synthesis of 6′-azidohexyl-Man9 (continued) 
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CHAPTER III 
SOLID PHASE APPROACH SYNTHESIS 
Over the past two decades, advances in technology have revolutionized the drug 
discovery process. The emergence of the high-throughput screening (HTS) techniques in 
pharmaceutical research has allowed biologists to design and set up assays (aimed toward 
the identification of active compound) that can rapidly test large numbers of compounds. 
This, therefore, requires high speed chemistry to provide these testing machines with 
compounds. If only traditional organic synthesis was to be used to provide biologist with 
these compounds, then chemists would have been faced with a huge challenge. 
Traditional methods are very time consuming and expensive, and thus incapable of 
feeding the fast paced biological testing procedures. 
A new discipline called combinatorial chemistry, capable of significantly 
increasing the throughput of chemical synthesis in terms of diversity was developed to 
fulfill the HTS needs. Herein, very large numbers of compounds are synthesized by 
condensing small number of reagents together in all combinations defined by a given 
reaction sequence. Combinatorial chemistry can be used for either solution phase or solid 
phase techniques. Solid phase technique was introduced in the 1960s by Merrifield for 
the efficient synthesis of polypeptides118 and has now become a standard technology for 
the preparation of oligopeptides and oligonucleotides, as well as small molecules to a 
lesser extent.  
The most common solid support in solid phase synthesis is hydrophobic 
polystyrene (PS) resin beads. They are spherical microparticles and have different sizes 
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with reaction sites located both on the surface and within the beads. The bead diameter 
lies between 80 – 200 µm on average and the loading capacity which is the number of 
reaction sites is generally between 0.2 – 1.5 mmol/g.119 
Solvation of the resins strongly influences the reactivity of the bead sites. The 
beads absorb solvents but remain insoluble and swell into gels in the course of a reaction. 
Swelling depends heavily of the solvent and on the percentage of cross-linking of the 
polystyrene support. Hydrophobic polystyrene resins swell properly in apolar solvent and 
their swelling is poor in polar protic solvents such as alcohols and water. Therefore, a 
good understanding of the swelling capacity of the resin in different organic solvents is 
the key to optimizing solution phase reactions for synthesis on the resin. For example, 
polystyrene swells to 8 ml/g resin in dichloromethane and hardly swells in methanol. 
Solvent and reagents move within the polymer matrix by diffusion. As most of the 
reaction sites on each resin bead are located inside the sphere, a good solvent for solid 
phase reaction will be one which can render the reaction sites accessible to reagents.  
The use of a solid support to carry out organic chemistry has a profound influence 
on some of the reaction parameters;120 above all there is a strong effect on the rate of the 
reaction. When a reaction takes place under traditional conditions, the reactants can freely 
interact and the reaction will depend on parameters such as temperature, concentration, 
etc. But when a resin-bound reagent is involved, the reaction will depend on the rate of 
diffusion of the reagent in solution into and out of the resin beads. Reaction rates are 
generally slower in solid phase chemistry than in solution phase. It is common to use 
excess reagents, in order to drive reactions to completion in solid phase synthesis 
compared to the solution phase synthesis. 
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Other than the reaction rate difference between solution phase synthesis and solid 
phase synthesis, another major difference is the work-up procedure for the reaction. 
During a solution phase synthesis, when the reaction is complete, it is quenched, then the 
workup to separate and purify the desired products from byproducts and other impurities. 
For a reaction carried out on solid phase, the reaction product remains attached to the 
resin while all the excess reagents and byproducts remain in solution. A typical workup 
will involve simple filtration of the resin followed by repeated washings with fresh 
solvents in which the resin swells well and the reagent and impurities are soluble. 
Combinatorial organic synthesis, originally designed for peptide synthesis, has 
been favored by the availability of efficient and high-repetitive-yield synthetic protocols. 
Peptides are suitable for the construction of libraries due to the fact that a high degree of 
structural diversification can be easily achieved simply by varying the peptide sequence 
length or by introducing different amino acids other than the naturally occurring ones. 
Recent advances in this field have been extended to smaller organic molecules and 
reaction types.121-124  
Several research groups have been involved in the solid phase synthesis of 
carbohydrates.64,125 Major impediments to the growing field of molecular glycobiology is 
the lack of pure, structurally defined carbohydrates and glycoconjugates. These 
biomolecules are often found in low concentrations and in microheterogeneous forms in 
nature, greatly complicating their identification and isolation. The procurement of 
sufficient quantities of defined oligosaccharides required for detailed biophysical and 
biomedical studies therefore relies on efficient synthetic methods.  Although much 
progress has been made in oligosaccharide synthesis,126 the construction of complex 
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carbohydrates remains time consuming. The evolution of solid phase paradigm for the 
construction of oligosaccharide was initiated with Frechet’s synthesis of di- and 
trisaccharides on polymer support in 1971.127 Solid phase oligosaccharide synthesis has 
since seen many advancements. Although this has allowed for the construction of 
complex oligosaccharides, the manipulations remain tedious and time consuming. Also, 
the higher complexity of the sugar scaffold has prevented the development of a reliable 
solid phase procedure for the assembly of carbohydrate building blocks in a region- and 
stereospecific manner. In general, the multiple reactive sites and the stereochemical 
complexity have often hampered oligosaccharide synthesis and have prevented the 
growth of an automated technology for the solid phase synthesis of oligosaccharides.128 
Following our success in the use of sonication in solution phase to synthesized 
oligosaccharides we extended the technique to solid phase synthesis as well. I chose 
polystyrene (PS) sulfonyl chloride resin for this project. They are also identified a catch 
and release resin. Another resin that could also be used will be the highly crossedlinked 
macroporous resin (MP). The PS resins require the use of solvents to swell the resin to 
permit reagents access to the functional groups while functional groups in the MP are 
already fully accessible. I decided to use the catch and release resins which are subset of 
the polymer reagents allowing the catching of a small molecule as an activated polymer 
intermediate, analogous to resin capture. The resin can be washed to remove soluble 
byproducts and then subjected to a second transformation to release the product. In this 
case, polystyrene toluene sulfonyl chloride (PS-TsCl), our resin of choice, is used to 
catch alcohols as polymer-bound tosylates. After workup involving resin washing, the 
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resin-bound tosylate is reacted with amines (in our case sodium azide) to release the 
amine products. 
III.1 Solid phase synthesis of monosaccharides 
The synthesis of monosaccharides was achieved using the less reactive acyl and 
thiophenyl glycosyl donors. It commenced with anchoring 1,6-hexanediol to the 
polystyrene sulfonyl chloride resin using TEA and DMAP in dichloromethane ( scheme 
24). This linker is stable to all the reaction conditions employed during the synthesis, 
prior to cleavage of the molecule from the resin, and can be selectively cleaved without 
compromising any part of the molecule. Once on the resin, the hexanediol with one 
hydroxyl group available is coupled to a donor, followed by cleavage from the resin with 
NaN3 to give the product. 
Several monosaccharides were synthesized using various sugars as donors and 6-
azidohexanol as the acceptor (scheme 25), and both acetyl and thiophenyl donors were 
investigated. Interestingly all acetyl donors gave good results with yields ranging from 60 
to 70%. The synthesis of fucose on the resin resulted in the α-anomer but when the 
reaction was carried out in solution, the β-anomer was obtained. This is quite a difference 
in the stereochemistry of this sugar. No mixture of both anomers was obtained. 
 
 
Scheme 24: Synthesis of resin acceptor 
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Scheme 25: Solid phase synthesis of monosaccharides 
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III.2 Solid phase synthesis of disaccharides 
Preliminary test for disaccharide synthesis using both thiophenyl and acetyl 
donors revealed that moderate to good yields for the later and poor yields for the former. 
For this reason only reaction employing with acetyl donors were further pursued. 
Examples of these are presented in scheme 26 and 27.  
Product analysis was carried out both on the resin (FT-IR on KBR disc) and in 
solution using NMR. Solution analysis required cleavage of the product from the resin 
after each step. This rendered the synthesis a little bit tedious as much resin was lost in 
the process. But this problem was alleviated by the use of FT-IR, which entailed using a 
few resin beads to prepare a KBr disc and recording the IR spectrum to estimate the 
degree of completion of reactions at the level of intermediates. This way, complete 
analysis (NMR) was employed only for the final products.  
III.3 Solid phase synthesis of trisaccharide 
Following the successful preparation of monosaccharides and disaccharidesusing 
a solid support, the study was extended to trisaccharides. To synthesize 1,2-linked 
trisaccharide (scheme 28), donor 8 glycosylated with 6-azidohexyl bound to the resin 
followed by methanolysis of the acetyl group. Disaccharide 69 was then coupled to the 
resin bound sugar to give 136. Linear synthesis of this compound was not very good as 
the second sugar will always be cleaved off from the resin bound mannopyranoside.  
As shown in scheme 29, another trisaccharide was also synthesized by coupling 
compound 45 to the resin. After hydrolysis, the resulting compound was subjected to 
another glycosylation reaction, and when the resin was cleaved off, compound 137 was 
obtained. 
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Scheme 26: Solid phase synthesis of disaccharide 135 
 
 
Scheme 27: Solid phase synthesis of disaccharide 78 
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Scheme 28: Solid phase synthesis of trisaccharide 136 
 
 
Scheme 29: Solid phase synthesis of trisaccharide 137 
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III.4 Conclusions 
The investigation of sonication as a new method for the synthesis of 
oligosaccharides has been achieved. The results obtained show that sonication can be 
used to synthesize carbohydrate compounds in good yields and much faster than the 
traditional methods. Solid phase approach under sonication has also proven to be quite 
successful even though more studies are needed to fully establish its usefulness.  
We have been able to synthesize a variety compounds ranging from 
monosaccharides to oligosaccharides using sonication. Based on the desired 
stereoselectivity, donors with participating or non participating groups can be used to 
obtain target molecules in good yields and in record time. 
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CHAPTER IV 
EXPERIMENTAL SECTION 
Chemical reagents and chromatography solvents were reagent grade and used as 
purchased unless otherwise noted. Dichloromethane was freshly distilled from calcium 
hydride under nitrogen atmosphere. Pyridine and triethylamine were distilled and stored 
over 4Å molecular sieve. Column chromatographic purifications were carried out on 
silica gel 230x450 mesh, Sorbent Tech. Analytical TLC was performed on Sorbent 
Technologies silica gel glass TLC plates. Visualization was accomplished with UV light 
(254 nm) followed by staining with diluted sulfuric acid (5% in methanol) solution and 
heating. 
Proton magnetic resonance spectra were recorded using JEOL 300, JEOL 270 or 
Bruker ARX 400 spectrometers. Chemical shifts were reported as parts per million (ppm) 
downfield from tetramethylsilane in δ unit and coupling constants were given in cycles 
per second (Hz). Signal multiplicities were indicated by s (singlet), d (doublet), t (triplet), 
and q (quartet). 13C NMR spectra were obtained using JEOL 300 at 75 MHz, JEOL 270 
at 68 MHz or Bruker 400 at 100 MHz. Sonication was conducted using Bransonic 
ultrasonic bath (model 5510) at 40 KHz with the power of 185 W. 
General Procedure for glycosylation with thiophenyl donors 
In a vial or flask, the acceptor (1 eq) and the donor (1.2 eq) were dissolved in 
CH2Cl2. NIS (1.2 eq) and TMSOTf (0.15 eq) were added respectively and the container 
was sealed with a septum and paraffin paper to prevent solvent from evaporating. The 
reaction mixture was then put into the sonicator at room temperature and time was 
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adjusted to 10 min. After 10 min, TLC was performed to check if the reaction was 
complete (if not then the reaction was sonicated again for 5 min). When complete, the 
reaction was poured into an Erlenmeyer flask containing NaHCO3(S) and Na2SO3(S), and 
stirred for 30 min. When solution (dark red) turned yellow, it was filtered and washed 
with excess EtOAc, followed by removal of solvent and purification through a 
chromatography column. The product was obtained in a hexane/ethyl acetate gradient 
depending on the polarity. This includes compounds 55, 56, 57, 61, 62, 63, 64, 65, 67, 77, 
78, 83, 88, 90, 93, 94, 97, 99, 104, 106, 109, 111, 113, 119, 123, 125. 
General Procedure for glycosylation with acetyl donors 
The acceptor (0.5g, 1 eq) is dissolved in 2 - 8 mL dichloromethane followed by 
addition of  BF3-OEt2 (1 eq) and the mixture is closed with the septum plus paraffin and 
sonicated. Between 1 to 2 min while under sonication, the pressure in the vial is released 
by inserting a needle through the septum and then the acetyl donor (1.5 eq) already 
dissolved in dichloromethane is added slowly for about 1 min using a syringe.  The 
reaction is then left to continue sonicating for the remainder of the time. When complete, 
the reaction is quenched with NaHCO3(s) and MgSO4.7H2O, after which the solids are 
filtered off, the filtrate is concentrated and purified through silica gel column. This 
includes compounds 55, 68, 69, 73, 78, 115. 
General procedure for deprotection of acyl groups 
 The starting material is dissolved in anhydrous methanol and NaOMe (few drops) 
in anhydrous methanol is added and the mixture is stirred for 1 to 2 hours. When 
complete, the reaction is quenched by adding amberlite IR 120 H+ resin to the mixture, 
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followed by filtration through celite, concentration of the filtrate and purification of the 
residue to afford the product. We have compounds 12, 13, 56, 58, 60, 77, 79, 89, 91, 95, 
epi-95, 98, 100, 103, 105, 107, 112, 114, 124, 126.  
General procedure for acetylation of compounds 
 The starting material is dissolved in dichloromethane followed by addition of 
acetic anhydride (2.5 eq), TEA (3.5 eq) and DMAP (cat amount). The mixture is stirred 
at room temperature for 1 hr after which the reaction is quenched by pouring into a flask 
containing saturated solution of sodium bicarbonate. The mixture is stirred until no 
bubbles are visible then it is diluted with ethyl acetate, washed with water, 1N HCl 
solution, NaHCO3 and brine. The organic phase is dried over Na2SO4 followed by 
filtration, concentration and purification of the resulting residue through silica gel 
column. We  have compounds 8, 17, 22, 29, 32, 37, 38, 49, 52, 53, 54, 71. 
General procedure for selective deprotection of the benzylidene group 
 The starting material and copper triflate (0.15 eq) are dissolved in 
dichloromethane followed by slow addition of borane tetrahydrofuran complex (5 eq). 
The mixture is stirred for 2 hrs after which it is quenched with methanol. After stirring 
for some minutes, it is filtered through celite, concentrated and purified through a silica 
gel column. We have compounds 33, 50, 84, 110, 120, 121. 
3,4,6-tri-O-acetyl-1,2-di-O-orthoester-β-D-mannopyranoside(4).129 Compound 
3 (2 g) was dissolved in toluene (10 mL) and anhydrous methanol (4 mL) was added and 
stirred under nitrogen. Silver oxide (1.5 g) was the added and the reaction mixture was 
stirred vigorously for 1 hr. Upon completion of the reaction by TLC analysis, the reaction 
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mixture was filtered through celite, concentrated. Purification by gradient column 
chromatography (hexane: EtOAc = 60:40 to 50:50) afforded the product as white 
crystals. 1H NMR (CDCl3, 400 MHz) δ 5.50 (d, J = 2.6 Hz, 1H, H-1), 5.40 (t, J = 9.7 Hz, 
1H, H-4′), 5.31 (t, J = 9.7 Hz, 1H, H-4), 5.27 ( J = 2.3 Hz, 1H, H-1′), 5.20 (dd, J = 4.0, 
9.8 Hz, 1H, H-3′), 5.15 ( dd, J = 4.0, 9.8 Hz, 1H, H-3), 4.62 (dd, J = 6.6, 3.9 Hz, 1H, H-
2), 4.39 (dd, J = 4.2, 2.4 Hz, 1H, H-2′), 4.25 (m, 2H, H-6, H-6′), 4.1 (m, 2H, H-6′′, H-
6′′′), 3,70 (m, 2H, H-5, H-5′), 3.51 (s, 3H, OMe), 3.3 (s, 3H, OMe);  2.13 – 2.01 (m, 15H, 
5 CH3), 1.75 (s, 3H, CH3), 1.55 (s, 3H, CH3); 13C NMR (CDCl3, 100 MHz) δ 170.8, 
170.7, 170.6, 170.5, 169.6, 169.5, 125.0, 124.7, 97.6, 95.0, 76.8, 75.7, 71.6, 71.4, 70.9, 
70.8, 65.8, 65.6, 62.5, 62.1, 50.3, 50.1, 24.5, 24.2, 20.9, 20.9, 20.8, 20.7. 
3,4,6-tri-O-benzyl-1,2-di-O-orthoester-β-D-mannopyranoside (5).99 Compound 
3 (4 g) was dissolved anhydrous MeOH (20 mL) and NaOMe/MeOH (0.5 mL) was added 
and the reaction mixture was stirred overnight. The next day when complete, the reaction 
mixture was concentrated and used directly. The resulting residue was dissolved in 
dimethylformamide (DMF) and cooled to 0 oC. NaH (3.5 g) was added and the mixture 
wascool to 0 oC and stirred under nitrogen for 10 min after which BnBr (6 mL) was 
slowly added followed by catalytic amount of TBAI and the reaction mixture was stirred 
over night. When the reaction was complete by TLC analysis, it was slowly quenched 
with methanol and stirred for another 1 hr. The residue was diluted with EtOAc, washed 
with water (x3), followed by 1N solution of HCl, NaHCO3, water and brine then it was 
dried over Na2SO4. Removal of the solvent followed by purification through a silica gel 
column chromatography (hexane:EtOAc = 100 to 70:30) afforded compound 5 as 2 
81 
 
enantiomers 5a and 5b which were separable after column and which crystallized when 
dried over vacuum and compound 6 as oil with a gradient (hexane:EtOAc = 100 to 65: 
35). 5a: 1H NMR (CDCl3, 300 MHz) δ  7.3 – 7.5 ( m, 15H), 5.13 ( d, J = 2.4 Hz, 1H, H-
1), 4.96 (d, J = 10.6 Hz, 1H), 4.85 ( d, J = 12.4 Hz, 1H), 4.80 ( d, J = 12.4 Hz, 1H), 4.68 ( 
d, J = 10.6 Hz, 1H), 4.57 ( s, 2H), 4.14 ( dd, J = 1.7, 4.1 Hz, 1H, H-2), 4.07 ( t, J = 9.3 
Hz, 1H, H-4), 3.8 ( m, 3H), 3.49 ( s, 3H, OMe), 1.55 ( s, 3H, CH3); 13C NMR (CDCl3, 75 
MHz) δ  138.4 ( 2 carbons), 138.1, 128.65 ( 2 carbons) 128.60 ( 2 carbons), 128.4 ( 3 
carbons), 128.2 ( 3 carbons), 128.17 ( 3 carbons), 127.9, 127.6, 127.5 ( 2 carbons), 124.3, 
95.0, 79.4, 76.2, 76.1, 75.4, 75.0, 74.3, 74.1, 74.0, 73.6, 73.4, 72.5, 68.9, 50.3, 24.2;  
5b: 1H NMR (CDCl3, 300 MHz) δ   7.2 – 7.4 ( m, 15H), 5.35 ( d, J = 2.7 Hz, 1H, 
H-2), 4.90 ( d, J = 10.6 Hz, 1H), 4.81 ( d, J = 13.1 Hz, 1H), 4.77 ( d, J = 13.1 Hz, 1H), 
4.62 ( d, J = 12.0 Hz, 1H), 4.61 ( d, J = 10.4 Hz, 1H), 4.55 ( d, J = 12.0 Hz, 1H), 4.40 ( 
dd, J = 2.4, 3.8 Hz, 1H, H-2), 3.94 ( t, J = 9.3 Hz, 1H, H-4), 3.7 ( m, 3H), 3.4 ( m, 1H, H-
5), 3.29 ( s, 3H, OMe), 1.75 ( s, 3H, CH3); 13C NMR (CDCl3, 75 MHz) δ   138.3, ( 2 
carbons), 137.9, 128.6 ( 2 carbons), 128.5 ( 2 carbons), 128.4 ( 2 carbons), 128.2 ( 4 
carbons), 127.9, 127.6 ( 3 carbons), 124.1, 97.6, 79.1, 77.3, 75.4, 74.3, 74.2, 73.5, 72.5, 
49.9, 24.6. 
2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranoside (6).130 Please refer to the 
synthesis of compound 5. 1H NMR (CDCl3, 400 MHz) δ 7.4 - 7.3 (m, 15H), 7.17 (m, 
2H), 5.38 (dd, J = 1.9, 3.3 Hz, 2H), 5.22 (dd, J = 1.7, 3.8 Hz, 2H,) 4.88 (d, J = 10.9 Hz, 
1H), 4.72 (d, J = 11.2 Hz, 1H), 4.62 (d, J = 12.2 Hz, 1H), 4.54 (d, J = 11.2 Hz, 2H) 4.53 
(d, J = 12.1 Hz, 1H), 4.48 (d, J = 10.9 Hz, 1H), 4.1 (m, 1H),  4.0 (m, 1H), 3.8 - 3.6 (m, 
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4H), 2.17 (s, 3H, CH3); 13C NMR (CDCl3, 100 MHz) δ 170.7, 138.5, 138.1, 138.0, 128.6, 
128.5, 128.4, 128.3, 128.3, 128.1, 127.9, 127.8, 92.6, 77.9, 75.3, 74.8, 73.6, 71.9, 71.3, 
69.5, 69.3, 21.4. 
Acetyl 3,4,6-tri-O-benzyl-α-D-mannopyranoside (7). 1H NMR (CDCl3, 400 
MHz) δ 7.4 - 7.2 (m, 13H), 7.2 – 7.1 (m, 2H), 5.68 (d, J = 0.8 Hz, 1H, H-1), 4.87 (d, J = 
10.8 Hz, 1H), 4.75 (d, J =11.6 Hz, 1H), 4.70 (d, J = 11.6 Hz, 1H), 4.66 (d, J = 12.2 Hz, 
1H), 4.55 (d, J = 10.8 Hz, 1H), 4.52 (d, J = 12.2 Hz, 1H), 4.16 (d, J = 2.5 Hz, 1H), 3.97 
(t, J = 9.3 Hz, 1H, H-4), 3.2 (m, 2H), 3.68 (dd, J = 3.1, 9.1 Hz, 1H, H-3), 3.6 (m, 1H, H-
5), 2.58 (s, 1H, OH), 2.18 (s, 3H, CH3); 13C NMR (CDCl3, 75 MHz) δ 169.2, 138.2, 
138.1, 137.6, 128.7, 128.5, 128.4, 128.2, 128.1, 127.9, 127.7, 92.6, 81.5, 76.0, 75.3, 73.6, 
71.9, 68.6, 67.6, 21.1; ESI/APCI Calcd for C29H32O7Na ([M+Na]+) m/z 515.2046; 
measured m/z 515.204. 
Acetyl 2-O-acetyl-3,4,6-tri-benzyl-α-D-mannopyranoside (8).100 1H NMR 
(CDCl3, 400 MHz) δ 7.3 - 7.1 (m, 15 H), 6.16 (d, J = 2.0 Hz, 1H, H-1), 5.38 (dd, J = 
4.72, 2.38 Hz, 1H, H-2), 4.84 (d, J = 10.6 Hz, 1H), 4,76 (d, J = 11.2 Hz, 1H), 4.72 (d, J = 
12.2 Hz, 1H), 4.56 (d, J = 11.2 Hz, 1H), 4.52 (d, J = 10.6 Hz, 1H), 4.50 (d, J = 12.2 Hz, 
1H), 3.8 (m, 2H), 3.8 (m, 2H), 3.65 (dd, J = 10.8, 1.6 Hz, 1H, H-6’), 2.18 (s, 3H), 2.14 (s, 
3H); 13C NMR (CDCl3, 100 MHz) δ 170.3, 168.5 138.4, 137.9, 128.6 (3 carbons), 128.6 
(3 carbons), 128.5 (3 carbons), 128.15 (2 carbons), 128.08 (2 carbons), 128.06, 128.00 (2 
carbons) 127.9, 127.8, 91.5, 77.9, 75.6, 74.1, 73.9, 73.8, 72.2, 68.8, 67.8, 21.2, 21.1.  
Methyl 2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranoside (11).101 1H NMR 
(CDCl3, 400 MHz) δ 7.2 – 7.4 (m, 15 H), 5.39 (dd, J = 3.1, 1.9 Hz, 1H, H-2), 4.84 (d, J = 
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10.8 Hz, 1H), 4.78 (d, J = 1.6 Hz, 1H, H-1), 4,72 (dd, J = 12.1, 4.4 Hz, 1H, H-3), 4.55 (d, 
J = 11.6 Hz, 1H), 4.50 (d, J = 10.8 Hz, 1H), 3.98 (dd, J = 9.2, 3.4 Hz, 1H, H-6), 3.90 (t, J 
= 9.4 Hz, 1H, H-4), 3.82 (m, 1H, H-5), 3.78 (m, 1H, H-6’), 3.38 (s, 3H, OMe), 2.18 (s, 
3H) ; 13C NMR (CDCl3, 100 MHz) δ 170.7, 138.7, 138.5, 138.2, 128.6, 128.5, 128.3, 
128.0, 127.9, 127.9, 127.8, 99.0, 78.4, 75.3, 74.6, 73.7, 71.9, 71.5, 69.2, 68.9, 55.1, 21.3.  
Phenyl 3,4,6-tri-O-benzyl-1-thio-α-D-mannopyranoside (12).102 1H NMR 
(CDCl3, 400 MHz) δ  7.48 (m, 2H), 7.2 – 7.4 (m, 18H), 5.63 (s, 1H, H-1), 4.86 (d, J = 
10.8 Hz, 1H), 4.73 (s, 2H), 4.64 (d, J = 12.0 Hz, 1H), 4.86 (d, J = 10.8 Hz, 1H), 4.73 (s, 
2H), 4.64 (d, J = 12.0 Hz, 1H), 4.55 (d, J = 10.8 Hz, 1H), 4.48 (d, J = 12.0 Hz, 1H), 4.33 
(m, 1H, H-5), 4.27 (s, 1H, H-2), 3.96 (t, J = 9.2 Hz, 1H, H-4), 3.89 (dd, J = 2.9, 9.1 Hz, 
1H, H-3), 3.83 (dd, J = 4.5, 10.8 Hz, 1H, H-6), 3.70 (dd, J = 1.4, 10.8 Hz, 1H, H-6′), 2.71 
(s, 1H, OH); 13C NMR (CDCl3, 100 MHz) δ  138.4, 138.39, 137.8, 134.0, 131.8 (2 
carbons), 129.2 ( 2 carbons), 128.8 ( 2 carbons), 128.6 ( 2 carbons), 128.5 ( 2 carbons) 
128.3, 128.2 ( 2 carbons), 128.1 ( 3 carbons), 128.9 ( 2 carbons), 127.9, 127.7, 127.6, 
87.5, 80.5, 75.4, 74.7, 73.6, 72.4, 72.3, 70.1, 69.0. 
Methyl 3,4,6-tri-O-benzyl-α-D-mannopyranoside (13).101 1H NMR (CDCl3, 
400 MHz) δ 7.3 - 7.2 ( m, 15H ), 7.19 (dd, J = 7.5, 1.9 Hz, 3H), 4.83 (d, J = 11.1 Hz, 1H), 
4.81 ( d, J = 1.4 Hz, 1H, H-1), 4.69 (d, J = 12.2 Hz, 2H), 4.66 ( d, J = 12.5 Hz, 1H), 4.55 
(d, J = 12.5 Hz, 1H), 4.52 (d, J = 11.1 Hz, 1H), 4.03 (d, J = 1.9 Hz, 1H), 3.86 (m, 2H), 
3.74 (m, 3H), 3.38 (s, 3H, OMe). 
Phenyl 2,3,4-tri-O-benzyl-1-thio-α-D-mannopyranoside (16). 1H NMR (CDCl3, 
400 MHz) δ 7.5 - 7.3 (m, 20H), 5.61 (s, 1H, H-1), 5.03 (d, J = 10.9 Hz, 1H), 4.8 - 4.7 (m, 
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5H), 4.2 - 4.1 (m, 2H), 4.08 (broad, 1H), 3.91 (dd, J = 2.9, 8.9 Hz, 1H, H-3), 3.90 (s, 2H) 
2.13 (s, 1H, OH); 13C NMR (CDCl3, 100 MHz) δ 138.6, 138.4, 1381, 134.2, 132.1, 129.4, 
128.7, 128.3, 128.2, 128.1, 128.0, 127.9, 86.3, 80.4, 76.7, 75.6, 75.0, 73.6, 72.6, 72.5, 
62.4; ESI/APCI Calcd for C33H34N3O5SNa ([M+Na]+) m/z 565.2025; measured m/z 
565.2026. 
Phenyl 6-O-acetyl-2,3,4-tri-O-benzyl-1-thio-α-D-mannopyranoside (17).103 1H 
NMR (CDCl3, 400 MHz) δ 7.5 - 7.2 (m, 20H), 5.61 (s, 1H, H-1), 5.00 (d, J = 10, 8 Hz, 
1H), 4.76 (d, J = 12.3 Hz, 1H), 4.7-4.6 (m, 4H), 4.4 (m, 3H), 4.0 (m, 2H), 3.93 (dd, J = 
2.62, 9.1 Hz, 1H, H-3), 2.06 (s, 3H, CH3); 13C NMR (CDCl3, 75 MHz) δ 170.9, 138.2, 
138.1, 137.9, 134.1, 131.8129.1, 128.6, 128.5, 128.2, 127.9, 127.9127.7, 85.6, 80.2, 76.1, 
75.4, 74.7, 72.2 72.0, 71.0, 63.6, 20.9. 
Phenyl 2,3,4-tri-O-benzyl-6-deoxy-1-thio-α-D-mannopyranoside (20). 1H 
NMR (CDCl3, 400 MHz) δ 7.6 - 7.4 (m, 20 H), 5.63 (d, J = 1.41 Hz, 1H, H-1), 5.09 (d, J 
=10.8 Hz, 1H), 4.9 - 4.7 (m 5H), 4.3 (m, 1H, H-5), 4.12 (dd, J = 1.7, 2.9 Hz, 1H, H-2), 
3.98 (dd, J = 3.0, 9.3 Hz, 1H, H-3), 3.83 (t, J = 9.3 Hz, 1H, H-4), 1.48 (d, J = 6.2 Hz. 3H, 
CH3); 13C NMR (CDCl3, 100 MHz) δ 138.9, 138.6, 138.2, 135.0, 131.6, 129.3, 128.7, 
128.3, 128.1, 128.0, 127.6, 86.1, 80.8, 80.4, 76.9, 75.8, 72.5, 72.4, 69.7, 18.3; ESI/APCI 
Calcd for C33H34O4SNa ([M+Na]+) m/z 549.2076; measured m/z 549.2083. 
2,3,4-tri-O-benzyl-6-deoxy-α-D-mannopyranoside (21).131 1H NMR (CDCl3, 
300 MHz) δ 7.3 – 7.4 (m, 15H), 5.16 (s, broad, 1H), 4.96 (d, J = 10.6 Hz, 1H), 4.6 – 4.8 
(m, 6H), 3.9 (m, 2H), 3.8 (m, 1H), 3.6 (m, 1H), 3.4 (m, 1H), 2.91 (d, J = 3.4 Hz, 1H), 
1.33 (d, J = 6.2 Hz, 3H, CH3); 13C NMR (CDCl3, 75 MHz) δ 138.68, 138.65, 138.4, 
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138.3, 138.1, 128.7, 128.6, 128.5, 128.47 (4 carbons), 128.4, 128.2, 128.1 (2 carbons), 
128.07 (2 carbons), 127.98, 127.92, 127.8 (2 carbons), 127.74 (2 carbons), 127.6, 93.4 
(β), 93.0, 83.1, 80.6, 80.0, 79.7, 76.6, 75.5, 75.4, 75.1, 74.9, 72.9 (2 carbons), 72.3, 71.7, 
68.3, 18.2, 18.0. 
Acetyl 2,3,4-tri-O-benzyl-6-deoxy-α-D-mannopyranoside (22).132  1H NMR 
(CDCl3, 300 MHz) δ  7.2 – 7.5 (m, 15H), 6.13 (d, J = 2.1 Hz, 1H, H-1), 5.57 (d, J = 0.7 
Hz, H-1B), 4.98 (d, J = 11.0 Hz, 1H, β), 4.97 (d, J = 10.7 Hz, 1H), 4.89 (s, 1H), 4.79 (d, J 
= 12.4Hz, 1H), 4.75 ( d, J = 12.4Hz, 1H), 4.68 (d, J = 11.0Hz, 1H, β), 4.67 ( d, J = 
10.6Hz, 1H), 4.63 (d, J = 2.4Hz, β), 4.62 (d, J = 11.8 Hz, 1H), 4.57 (d, J = 11.8 Hz, 1H), 
3.94 ( d, J = 2.1 Hz, 1H), 3.7 – 3.9 (m, 3H), 3.6 – 3.8 ( m, 4H), 3.47 (m, 1H), 2.09 ( s, 
CH3 for β), 2.03 ( s, 3H, CH3), 1.39 (d, J = 6.2Hz, CH3 for β), 1.36 (d, J = 6.2 Hz, 3H, 
CH3) ; 13C NMR (CDCl3, 75 MHz) δ  169.2, 138.4, 138.37 ( 2 carbons β), 138.3, 138.1 
(β), 137.9, 128.6, 128.5, 128.2, 128.19, 127.96, 127.90, 127.8, 127.7, 93.1, 91.8, 82,4, 
79.9, 79.8, 79.3, 75.7,  75.6, 74.3, 73.7, 72.9, 72.6, 72.3, 72.2, 70.6, 21.1, 18.2, 18.0.  
Phenyl 6-azido-2,3,4-tri-O-benzyl-1-thio-α-D-mannopyranoside (23). 1H NMR 
(CDCl3, 400 MHz) δ 7.6 - 7.3 (m, 20H), 5.75 (d, J = 1.5 Hz, 1H, H-1), 5.13 (d, J = 11.0 
Hz, 1H), 4.9 - 4.7 (m, 5H), 4.4 (m, 1H, H-5), 4.2 (m, 2H), 4.04 (dd, J = 2.9,  9.2 Hz, 1H, 
H-6), 3.6 (m, 2H); 13C NMR (CDCl3, 100 MHz) δ 138.6, 138.4, 138.2, 134.4, 131.8, 
131.8, 129.5, 128.8, 128.4, 128.4, 128.3, 128.2, 127.9, 86.1, 80.4, 76.5, 75.8, 75.7, 72.9, 
72.4, 72.3, 51.8; ESI/APCI Calcd for C33H33N3O4SNa ([M+Na]+) m/z 590.2089; 
measured m/z 590.2087. 
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Phenyl 2,3,4-tri-O-benzyl-6-fluoro-1-thio-α-D-mannopyranoside (24). 1H 
NMR (CDCl3, 400 MHz) δ 7.5 -7.3 (m, 20H), 5.68 (d, J = 1.2 Hz, 1H, H-1), 5.06 (d, J = 
10,7 Hz, 1H), 4.9 - 4.6 (m, 7H), 4.4 (m, 1H, H-5), 4.17 (t, J = 9.4 Hz, 1H, H-4), 4.10 (dd, 
J = 1.7, 4.4 Hz, 1H, H-2), 3.97 (dd, J = 2.9, 9.2 Hz, 1H, H-3); 13C NMR (CDCl3, 100 
MHz) δ 138.5, 138.3, 138.1, 134.5, 131.6, 129.4, 128.8, 128.7, 128.3, 128.2, 128.1, 
127.8, 86.1, 83.3, 81.6, 80.4, 76.4, 75.6, 74.1, 74.0, 72.6, 72.4; ESI/APCI Calcd for 
C33H33O4FSNa ([M+Na]+) m/z 567.1981; measured m/z 567.1980. 
Phenyl 2,3-di-O-acetyl-4,6-O-benzylidene-1-thio-α-D-mannopyranoside (29). 
1H NMR (CDCl3, 400 MHz) δ 7.3 -7.5 ( m, 10H ), 5.63 (dd, J = 1.3, 3.4 Hz, H-2, 1H,), 
5.61(s, 1H, H-1'), 5.45 (d, J = 0.8 Hz, H-1, 1H,), 5.43 (dd, J =  3.4, 10.5 Hz, H-3, 1H), 4.5 
(m, 1H, H-5), 4.27 (dd, J = 4.9 Hz, 10.4 Hz, H-6, 1H,), 4.15 (t, J = 9.7 Hz, H-4, 1H), 3.89 
(t, J = 10.3 Hz, H-6', 1H),  2.18 (s, 3H, CH3), 2.06 (s, 3H, CH3); 13C NMR (CDCl3, 75 
MHz) δ 169.9, 169.8, 137.1, 132.2 (2 carbons), 129.3 (3 carbons), 128.4 (3 carbons), 
128.2, 126.3 (2 carbons), 102.1, 86.9, 76.3, 71.6, 68.6, 68.5, 65.3, 21.0, 20.9; ESI/APCI 
Calcd for C23H24O7SNa ([M+Na]+) m/z 467.1140; measured m/z 467.1141. 
Phenyl 2-O-benzyl-4,6-benzylidene-1-thio-α-D-mannopyranoside (30).133 1H 
NMR (CDCl3, 400 MHz) δ 7.54 (m, 2H), 7.3 – 7.5 (m, 13H), 5.60 (s, 2H,), 4.77 (d, J = 
11.6 Hz, 1H), 4.66 (d, J = 11.6 Hz, 1H), 4.32 (m, 1H), 4.25 (m, 1H), 4.15(m, 2H), 4.02 (t, 
J = 6.8 Hz, 1H), 3.85 (t, J = 10.1 Hz, 1H) 2.47 (d, J = 7.9 Hz, 1H, OH); 13C NMR 
(CDCl3, 100 MHz) δ 137.4, (2 carbons), 133.8, 132.0 (2 carbons), 129.4 (3 carbons), 
128.9 (2 carbons), 128.5 (2 carbons), 128.4, 128.3 (2 carbons), 127.9, 126.5 (2 carbons), 
102.4, 86.4, 80.2, 79.8, 73.4, 69.2, 68.7, 64.9. 
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Phenyl 3-O-benzyl-4,6-benzylidene-1-thio-α-D-mannopyranoside (31).134 1H 
NMR (CDCl3, 400 MHz) δ 7.2 – 7.5 (m, 15H), 5.64 (s, 1H), 5.61 (s, 1H, H-1), 4.92 (d, J 
= 11.7 Hz, 1H), 4.76 (d, J = 11.7 Hz, 1H), 4.3 (m, 2H), 4.2 (m, 2H), 3.99 (dd, J = 3.1, 9.5 
Hz, 1H), 3.89 (t, J = 10.2 Hz, 1H), 2.87 (s, 1H, OH). 
Phenyl 3-O-acetyl-2-O-benzyl-4,6-benzylidene-1-thio-α-D-mannopyranoside 
(32). 1H NMR (CDCl3, 400 MHz) δ  7.48 (m, 4H), 7.3 – 7.4 (m, 11H), 5.61 (s, 1H), 5.58 
(d, J = 1.3 Hz, 1H, H-1), 5.32 (dd, J = 3.4, 10.4 Hz, 1H, H-3), 4.71 (d, J = 12.0 Hz, 1H), 
4.56 (d, J = 12.0 Hz, 1H), 4.4 (m, 1H, H-5), 4.27 (m, 3H), 3.90 (t, J = 10.2 Hz, 1H, H-4), 
2.06 (s, 3H, CH3); 13C NMR (CDCl3, 100 MHz) δ  170.5, 133.8, 132.0, ( 2 carbons) 
129.4, (2 carbons), 129.3, 128.8, ( 2 carbons), 128.5 (2 carbons), 128.36, 128.31 ( 2 
carbons), 127.9, 126.5 ( 2 carbons), 102.1, 86.6, 77.8, 76.4, 73.3, 70.7, 68.7, 65.5, 21.2; 
ESI/APCI Calcd for C28H28O6SNa ([M+Na]+) m/z 515.1504; measured m/z 515.1517.  
Phenyl-3-O-benzoyl-2-O-benzyl-4,6-benzylidene-1-thio-α-D-mannopyra-
noside (33). 1H NMR (CDCl3, 400 MHz) δ  8.1 (m, 2H), 7.1 – 7.6 (m, 18H) 5.67 (s, 1H, 
H-1′), 5.61 (s, 1H, H-1), 5.59 (dd, J = 3.0, 9.7 Hz, 1H, H-3), 4.70 (d, J = 11.9 Hz, 1H), 
4.57 (d, J = 11.9 Hz, 1H), 4.48 (m, 2H), 4.40 (d, J = 3.0 Hz, 1H),  4.30 (dd, J = 4.2, 10.1 
Hz, 1H, H-2), 3.97 (t, J = 9.7 Hz, 1H, H-4); 13C NMR (CDCl3, 100 MHz) δ  166.0, 137.5, 
137.4, 133.9, 133.4, 132.0 (2 carbons), 130.1, 130.05, 129.4 (2 carbons), 129.2, 128.65 (2 
carbons), 128.61 (3 carbons), 128.4 (2 carbons), 128.2 (2 carbons), 127.9, 126.4 (2 
carbons), 101.9, 86.8, 79.1, 76.6, 73.4, 71.4, 68.8, 65.6; ESI/APCI Calcd for 
C33H30O6SNa ([M+Na]+) m/z 577.1661; measured m/z 577.1667. 
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Phenyl-6-O-acetyl-3-O-benzoyl-2,6-di-O-benzyl-1-thio-α-D-mannopyranoside 
(34). 1H NMR (CDCl3, 400 MHz) δ 8.08 (m, 2H), 7.65 – 7.16 (m, 38H), 5.63 (s, 1H, H-
1), 5.50 (dd, J = 3.2, 9.3 Hz, 1H, H-3), 4.79 (d, J = 10.8 Hz, 1H), 4.70 (d, J = 12.1 Hz, 
1H), 4.61 (d, J = 10.8 Hz, 1H), 4.52 (d, J = 12.1 Hz, 1H), 4.48 (m, 1H, H-5), 4.27 (m, 1H, 
H-2),; 4.19 (t, J = 9.5 Hz, 1H, H-4), 2.07 (s, 3H, CH3); 13C NMR (CDCl3, 100 MHz) δ 
170.9, 165.7, 137.6, 137.5, 134.0, 133.5, 132.0, 130.1,; 130.0, 129.9, 128.7, 128.6, 128.5, 
18.2, 128.2, 128.0, 127.9, 127.8, 85.6, 75.2, 74.7, 73.8, 73.7, 72.6, 70.9, 63.6, 21.1; 
ESI/APCI Calcd for C35H34O7SNa ([M+Na]+) m/z 621.1923; measured m/z 621.1926. 
Phenyl 3,6-di-O-acetyl-2,4-di-O-benzyl-1-thio-α-D-mannopyranoside (37).106 
1H NMR (CDCl3, 400 MHz) δ  7.49 (m, 2H), 7.2 – 7.4 (m, 13H), 5.56 (d, J = 1.9 Hz, 1H, 
H-1) 5.23 (dd, J = 3.3, 9.3 Hz, 1H, H -3), 4.74 (d, J = 11.2Hz, 1H), 4.69 (d, J = 12.2 Hz, 
1H), 4.60 (d, J = 11.2 Hz, 1H), 4.51 ( d, J = 12.2 Hz, 1H), 4.4 (m, 1H, H-5), 4.3 (m, 2H), 
4.14 ( dd, J = 2.0, 3.2 Hz, 1H, H-2), 4.00 (t, J = 9.4 Hz, 1H, H-4), 2.05 (s, 3H, CH3), 2.01 
(s, 3H, CH3); 13C NMR (CDCl3, 100 MHz) δ  170.9, 170.2, 137.9, 137.7, 133.9, 132.0, ( 
2 carbons), 129.2, ( 2 carbons), 128.7, ( 2 carbons), 128.6 ( 2 carbons), 128.2, 128.17, 
128.07 ( 2 carbons), 127.9 ( 2 carbons), 127.8, 85.3, 77.4, 77.1, 75.2, 74.0, 73.7, 72.5, 
70.8, 63.5, 21.2, 21.1.   
Phenyl 2,6-di-O-acetyl-3,4-di-O-benzyl-1-thio-α-D-mannopyranoside (38). 1H 
NMR (CDCl3, 400 MHz) δ  7.2 – 7.5 (m, 15H), 5.62 (dd, J = 1.6, 3.1 Hz, 1H, H-2), 5.50 
(d, J = 1.4 Hz, 1H, H-1), 4.96 (d, J = 10.7 Hz, 1H), 4.75 (d, J = 11.0 Hz, 1H), 4.6 – 6.7 
(m, 2H), 4.3 – 4.5 (m, 3H, H-5, H-6, H-6′), 4.0 (m, 1H, H-3), 3.81 (t, J = 9.4 Hz, 1H, H-
4), 2.17 (s, 3H, CH3), 2.04 (s, 3H, CH3); 13C NMR (CDCl3, 75 MHz) δ 170.9, 170.4, 
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138.1, 137.6, 133.4, 132.2 (2 carbons), 129.3 (3 carbons), 128.7 (2 carbons), 128.7 (2 
carbons), 128.5, 128.4 (2 carbons), 128.3 (2 carbons), 128.2, 128.1 (2 carbons), 86.3, 
78.6, 75.5, 74.5, 72.1, 70.9, 70.2, 63.5, 21.2, 21.0; ESI/APCI Calcd for C30H32O7NaS 
([M+Na]+) m/z 559.1766; measured m/z 559.1768. 
Acetyl 6-O-acetyl-2,3,4-tri-O-benzyl-α-D-mannopyranoside (42).107 1H NMR 
(CDCl3, 300 MHz) δ 7.4 - 7.2 (m, 15H), 6.18 (d, J = 2.1 Hz, 1H, H-1), 4.95 (d, J =  10.6 
Hz, 1H), 4.77 (d, J = 12.4 Hz, 1H), 4.72 (d, J = 12.4Hz, 1H), 4.6 (m, 3H), 4.3 (m, 2H, H-
6, H-6'), 4.0 – 3.8 (m, 2H, H-2, H-5), 3.73 (t, J = 2.5Hz, 5.2 Hz, 1H), 2.06 (s, 3H, CH3), 
2.03 (s, 3H, CH3); 13C NMR (CDCl3, 75 MHz) δ 170.9, 168.9, 138.0 (2 carbons), 137.8, 
128.6 (2 carbons), 128.52 (2 carbons), 128.50 (2 carbons), 128.3 (2 carbons), 128.0 (3 
carbons), 127.9, (2 carbons), 127.8 (2 carbons), 91.6, 79.2, 75.5, 73.9, 73.2, 72.4 (2 
carbons), 72.1, 63.2, 21.1, 20.9. 
Acetyl 2,3,4,6-tetra-O-benzyl-α-D-mannopyranoside (43).135 1H NMR (CDCl3, 
300 MHz) δ 7.4 - 7.1 (m, 20H), 6.23 (d, J = 2.1 Hz, 1H, H-1) 4.90 (d, J = 10, 6 Hz, 1H), 
4.80 (d, J = 12.4 Hz, 1H), 4.73 (d, J = 12.4 Hz, 1H), 4.67 (d, J = 12.1 Hz, 1H) 4.59 (d, J 
= 11.7 Hz, 1H), 4.57 (d, J = 12.0 Hz, 1H), 4.56 (d, J = 12.0 Hz, 1H), 4.55 (d, J = 10.6 Hz, 
1H), 4.54 (d, J = 12.1 Hz, 1H), 4.09 (t, J = 9.6 Hz, H-4), 3.9 - 3.7 (m, 5H), 2.02 (s, 3H, 
CH3); 13C NMR (CDCl3, 75 MHz) δ 169.1, 138.3, (2 carbons), 138.2, 137.9, 128.5 (6 
carbons), 128.4 (2 carbons), 128.16 (2 carbons), 128.11 (2 carbons), 127.9 (2 carbons), 
127.8 (4 carbons), 127.6, 91.9, 79.2, 75.4, 74.5, 74.3, 73.6, 73.4, 72.5, 72.2, 69.0, 21.1. 
Acetyl 3,6-di-O-acetyl-2,4-tri-O-benzyl-α-D-mannopyranoside (44).136 1H 
NMR (CDCl3, 400 MHz) δ 7.4 – 7.3 (m, 10H), 6.19 (d, J = 2.1 Hz, 1H, H-1), 5.22 (dd, J 
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= 3.3, 9.0 Hz, 1H, H-3), 4.73 (d, J = 12.1, 1H), 4.71 (d, J = 11.2 Hz, 1H), 4.60 (d, J = 
11.2 Hz, 1H), 4.57 (d, J = 12.1 Hz, 1H), 4.34 (dd, J = 2.2, H-6), 4.31 (dd, J = 4.4 Hz, H-
6’), 4.00 (t, J = 9.2 Hz, 1H, H-4), 3.95 (m, 1H, H-5), 3.87(dd, J = 2.3, 3.3 Hz, H-2), 2.12 
(s, 3H, CH3), 2.08 (s, 3H, CH3), 1.99 (s, 3H, CH3) ; 13C NMR (CDCl3, 100 MHz) δ 170.9, 
170.3, 169.1, 137.8, 137.6, 128.7, 128.6 (2 carbons), 128.2 (2 carbons), 128.1 (2 
carbons), 128.0 (2 carbons), 91.4, 77.4, 75.2, 74.6, 73.4, 72.9 (2 carbons), 72.3, 63.2, 
21.2, 21.1, 21.0. 
Acetyl 4,6-di-O-acetyl-2,3-tri-O-benzyl-α-D-mannopyranoside (45). 1H NMR 
(CDCl3, 300 MHz) δ 7.2 – 7.4 (m, 10H), 6.18 (d, J = 1.7 Hz, 1H), 5.50 (t, J = 9.9 Hz, 1H, 
H-4), 4.73 (s, 2H), 4.55 (d, J = 12.0 Hz, 1H), 4.44 (d, J = 12.0 Hz, 1H), 4.22 (dd, J = 5.1, 
12.4 Hz, 1H, H-6), 4.12 (dd, J = 2.4, 12.4 hz, 1H, H-6′) 3.92 (m, 1H, H-5), 3.7 – 3.8 (m, 
2H), 2.07 (s, 3H, CH3), 2.06 (s, 3H, CH3), 2.03 (s, 3H, CH3);  13C NMR (CDCl3, 75 
MHz) δ 171.1, 169.8, 168.9, 137.9, 137.8, 128.62, 128.60, 128.2, 128.0, 127.7, 91.9, 
76.2, 73.0, 72.8, 72.0, 71.6, 67.6, 62.8, 21.2, 21.1, 21.0; ESI/APCI Calcd for C26H30O9Na 
([M+Na]+) m/z 509.1788; measured m/z 509.1781. 
Methyl 2-O-benzyl-4,6-benzylidene-α-D-mannopyranoside (47).108 1H NMR 
(CDCl3, 400 MHz) δ 7.5 (m, 2H), 7.3 (m, 8H), 5.59 (s, 1H, H-1′), 4.78 (d, J = 11.7 Hz, 
1H), 4.76 (s, 1H, H-1), 4.70 (d, J = 11.7 Hz, 1H), 4.28 (dd, J = 3.9, 9.3 Hz, 1H), 4.08 ( 
dd, J = 3.6, 6.2 Hz, 1H), 3.92 (t, J = 9.1 Hz, 1H), 3.7 – 3.8 (m, 3H), 3.38 (s, 3H, OMe), 
2.20 (s, 1H, OH); 13C NMR (CDCl3, 100 MHz) δ 137.8, 137.5, 129.3, 128.8 (2 carbons), 
128.5 (2 carbons), 128.3, 128.2 (2 carbons), 126.5 (2 carbons), 102.4, 99.6, 79.7, 78.7, 
77.4, 73.9, 69.0, 68.9, 63.5, 55.2. 
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Methyl 3-O-acetyl-2-O-benzyl-4,6-benzylidene-α-D-mannopyranoside (49).137 
1H NMR (CDCl3, 400 MHz) δ 7.47 (m, 2H), 7.35 (m, 8H), 5.59 (s, 1H), 5.28 (dd, J = 3.4, 
10.5 Hz, 1H, H-3), 4.74 (d, J = 1.6 Hz, 1H, H-1), 4.68 (d, J = 11.9 Hz, 1H), 4.62 (d, J = 
11.9 Hz, 1H), 4.3 (m, 1H), 4.2 (m, 1H), 3.98 (dd, J = 1.6, 3.4 Hz, 1H), 3.89 (m, 2H), 3.39 
(s, 3H, OMe), 2.04 (s, 3H, CH3). 
Methyl 2,4-di-O-benzyl-α-D-mannopyranoside (50).138 1H NMR (CDCl3, 400 
MHz) δ 7.3 – 7.6 (m, 10 H); 4.90 (d, J = 11.0 Hz,1H), 4.75 (d, J = 1.4 Hz, 1H, H-1),  4.72 
(d, J = 11.7 Hz, 1H), 4.66 (d, J = 11.0 Hz, 1H), 4.59 (d, J = 11.7 Hz, 1H), 3.98 (m, 1H, 
H-5), 3.86 (dd, J = 2.7, 11.7 Hz, 1H, H-6), 3.77(dd, J = 4.1, 11.7 Hz, 1H), 3.72(dd, J = 
1.5, 3.8 Hz, 1H, H-3); 3.67 (t, J = 9.6 Hz, 1H, H-4), 3.63 (dd, J = 2.4, 3.8 Hz, 1H, H-2); 
3.33 (s, 3H, OMe). 
Methyl 2-O-acetyl-3-O-benzyl-4,6-benzylidene-α-D-mannopyranoside (52).139 
1H NMR (CDCl3, 400 MHz) δ7.5 (m, 2H), 7.2 – 7.4 (m, 8H), 5.64 (s, 1H, H-1′), 5.41 (dd, 
J = 1.5, 3.2 Hz, 1H, H-2), 4.69 (m, 3H), 4.29 (m, 1H), 4.06 (m, 1H), 4.02 (m, 1H), 3.8 
(m, 2H), 3.38 (s, 3H, OMe), 2.17 (s, 3H, CH3); 13C NMR (CDCl3, 100 MHz) δ 170.4, 
138.2, 137.7, 129.1, 128.6 (2 carbons), 128.4 (2 carbons), 127.9 (3 carbons), 126.3 (2 
carbons), 101.8, 100.0, 78.5, 74.0, 72.3, 69.8, 68.9, 63.9, 55.3, 21.2.  
Methyl 3,6-di-O-acetyl-2,4-di-O-benzyl-α-D-mannopyranoside (53). 1H NMR 
(CDCl3, 400 MHz) δ 7.3 (m, 10H), 5.24 (dd, J = 3.3, 9.2 Hz, 1H, H-3), 4.74 (d, J = 1.8 
Hz, 1H, H-1), 4.70 (d, J = 11.2 Hz, 1H), 4.67 (d, J = 12.2 Hz, 1H), 4.58 (d, J = 11.2 Hz, 
1H), 4.57 (d, J = 12.2 Hz, 1H), 4.35 (m, 2H), 3.92 (t, J = 9.4 Hz, 1H, H-4), 3.88 (dd, J = 
2.1, 3.2 Hz, 1H, H-2), 3.85 (m, 1H, H-5), 3.38 (s, 3H, OCH3), 2.08 (s, 3H, CH3), 1.98 (s, 
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3H, CH3); 13C NMR (CDCl3, 100 MHz) δ 171.0, 170.3, 138.1, (2 carbons), 128.65 (2 
carbons), 128.61, 128.6 (2 carbons), 128.0 (2 carbons), 127.9 (3 carbons), 98.9, 77.3, 
76.0, 74.9, 74.1, 73.6, 73.1, 69.9, 63.6, 55.1, 21.2, 21.0; ESI/APCI Calcd for C25H34O8 
([M+NH4]+) m/z 476.2350. 
Methyl 2,6-di-O-acetyl-3,4-di-O-benzyl-α-D-mannopyranoside (54).140 1H 
NMR (CDCl3, 300 MHz) δ 7.2 - 7.3 (m, 10H), 5.3 (dd, J = 1.7, 3.4 Hz, 1H, H-2), 4.90 (d, 
J = 10.6 Hz, 1H), 4.70 (d, J = 1.7 Hz, 1H, H-1), 4.69 (d, J = 10.9 Hz, 1H), 4.54 (d, J = 
10.6 Hz, 1H), 4.52 (d, J = 10.9 Hz, 1H), 4.33 (m, 2H), 3.98 (dd, J = 3.4, 8.9 Hz, 1H, H-
3), 3.82 (m, 1H, H-5), 3.73( t, J = 9.6 Hz, 1H, H-4), 3.35 (s, 3H, OMe), 2.15 (s, 3H), 2.05 
(s, 3H). 
6'-Azidohexyl 6-O-acetyl-2,3,4-tri-O-benzyl-α-D-mannopyranoside (55). 1H 
NMR (CDCl3, 300 MHz) δ 7.3 – 7.6 (m, 30H), 5.0 - 4.9 (m, 3H), 4.88 (d, J = 1.7 Hz, 
1H), 4.80 (d, J = 12.4 Hz, 1H), 4.74 (d, J = 12.4 Hz, 1H), 4.6 - 4.7 (m, 4H), 4.57 (d, J = 
11.7 Hz, 1H), 4.48 (d, J = 11.7 Hz, 1H), 4.4 (m, 1H), 4.3 – 4.4 (m, 3H), 3.9 – 4.0 (m, 
6H), 3.8 – 3.9 (m, 3H), 3.6 (m, 1H), 3.4 – 3.6 (m, 3H), 3.27 (t, J = 6.9 Hz, 4H), 2.09 (s, 
3H, CH3), 2.07 (s, 3H, CH3), 1.6 (m, 8H), 1.3 (m, 8H); 13C NMR (CDCl3, 75 MHz) δ 
171.05 (β), 171.0 (α), 138.8, 138.5 (2 carbons), 138.4 (2 carbons), 138.29 (2 carbons), 
138.28, 137.16, 128.6 (3 carbons), 128.5 (4 carbons), 128.47 (3 carbons), 128.33 (2 
carbons), 128.28, 128.23, 127.9 (2 carbons), 127.89 (3 carbons), 127.79 (5 carbons), 
127.78 (2 carbons), 127.6, 101.9 (β), 98.0 (α), 82.4, 80.3, 75.3, 74.8, 74.7, 74.68, 73.9, 
73.8, 73.6, 72.7, 72.2, 71.5, 70.2, 69.9, 67.7, 63.9, 63.7, 51.4, 29.6, 29.4, 28.9, 28.87, 
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26.6, 25.9, 25.83, 21.06, 21.04; ESI/APCI Calcd for C35H43N3O7Na ([M+Na]+) m/z 
640.2999; measured m/z 640.2998. 
6'-Azidohexyl 2,3,4-tri-O-benzyl-α-D-mannopyranoside (56). 1H NMR 
(CDCl3, 300 MHz) δ 7.3 – 7.5 (m, 15H), 4.98 (d, J = 12.4 Hz, (β)), 4.96 (d, J = 10.9 Hz, 
(β)), 4.95 (d, J = 10.7 Hz, 1H), 4.87 (d, J = 12.5 Hz, (β)), 4.8 (m, 2H), 4.6 – 4.72 (m, 4H), 
4.55 (d, J = 12.0 Hz, (β)), 4.48 (d, J = 12.0 Hz, (β)), 3.9 – 4.0 (m, 4H), 3.7 – 3.83 (m, 3 
H), 3.6 (m, 2H), 3.2 – 3.4 (m, 3H), 2.04 (s, 1H, OH), 1.5 (m, 4H), 1.3 (m, 4H); 13C NMR 
(CDCl3, 75 MHz) δ 138.7, 138.6, 138.4 (2 carbons), 138.3, 138.2, 128.55 (2 carbons), 
128.5 (3 carbons), 128.2 (2 carbons), 127.9 (3 carbons), 127.8, 127.7 (2 carbons), 127.6, 
101.8 (β), 98.3, 82.4 (β), 80.4, 75.9 (β), 75.4, 75.1, 75.0, 74.1 (β), 73.9 (β), 73.0, 72.3, 
72.2, 71.6 (β), 70.0 (β), 67.5, 62.5, 51.5, 29.6 (β), 29.3, 28.9 (β), 28.8, 26.6, 25.8; 
ESI/APCI Calcd for C33H41N3O6Na ([M+Na]+) m/z 598.2893; measured m/z 598.2907.  
6'-Azidohexyl 3,6-di-O-acetyl-2,4-di-O-benzyl-α-D-mannopyranoside (57). 1H 
NMR (CDCl3, 400 MHz) δ 7.3 (m, 10H), 5.25 (dd, J = 3.3, 9.1 Hz, 1H, H-3), 4.82 (s, 1H, 
H-1), 4.70 (d, J = 11.2 Hz, 1H), 4.66 (d, J = 12.3 Hz, 1H), 4.60 (s, 1H), 4.58 (d, J = 11.1 
Hz, 1H), 4.3 (m, 2H, H-6, H-6'), 3.9 (t, J = 9.6 Hz, 1H, H-4), 3.9 (m, 2H, H-2, H-5), 3.7 
(m, 1H), 3.4 (m, 1H), 3.27 (t, J = 6.9 Hz, 2H), 2.08 (s, 3H, CH3), 2.00 (s, 3H, CH3), 1.6 
(m, 4H), 1.4 (m, 4H); 13C NMR (CDCl3, 100 MHz) δ 171.0, 170.3, 138.1, 138.0, 128.7 (2 
carbons), 128.6 (2 carbons), 128.1 (2 carbons), 128.0 (2 carbons), 127.9 (2 carbons), 
97.9, 76.2, 75.0, 74.1, 73.6, 73.1, 69.9, 68.0, 63.6, 57.6, 29.4, 28.9, 26.7, 26.6, 21.3, 21.1; 
ESI/APCI Calcd for C30H39N3O8Na ([M+Na]+) m/z 592.2635; measured m/z 592.2629. 
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6'-Azidohexyl 2,4-di-O-benzyl-α-D-mannopyranoside (58). 1H NMR (CDCl3, 
300 MHz) δ 7.3 – 7.4 (m, 10H), 4.90 (d, J = 11.0 Hz, 1H), 4.83 (d, J = 1.4 Hz, 1H, H-1), 
4.73 (d, J = 11.7 Hz, 1H), 4.66 (d, J = 11.7 Hz, 1H), 4.60 (d, J = 11.0 Hz, 1H), 4.0 (m, 
1H), 3.8 (m, 2H), 3.72 (dd, J = 1.4, 3.8 Hz, 1H, H-2), 3.6 – 3.7 (m, 3H), 3.3 (m, 1H), 3.25 
(t, J = 6.9 Hz, 2H), 2.34 (d, J = 9.3 Hz, 1H, OH), 2.05 (s, broad, 1H, OH), 1.56 (m, 4H), 
1.35 (m, 4H); 13C NMR (CDCl3, 75 MHz) δ 138.4, 137.8, 128.7 (2 carbons), 128.6 (2 
carbons), 128.2 (3 carbons), 127.9 (3 carbons), 97.1, 78.6, 76.6, 75.1, 73.2, 71.9, 71.4, 
67.6, 62.4, 51.4, 29.3, 28.8, 26.6, 25.8; ESI/APCI Calcd for C26H35N3O6Na ([M+Na]+) 
m/z 508.2424; measured m/z 508.2438. 
6'-Azidohexyl 2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranoside (59). 1H 
NMR (CDCl3, 270 MHz) δ 7.1 – 7.5 (m, 15H), 5.37 (dd, J = 3.0, 1.6 Hz, 1H), 4.87 (d, J = 
12.2 Hz, 1H), 4.84 (d, J = 1.6 Hz, 1H), 4.72 (d, J = 11.2 Hz, 1H), 4.69 (d, J = 12.2 Hz, 
1H), 4.55 (d, J = 10.7 Hz, 1H), 4.52 (d, J = 11.2 Hz, 1H), 4.48 (d, J = 10.7 Hz, 1H), 4.00 
(dd, J = 8.9, 3.0 Hz, 1H), 3.89 (dd, J = 9.2, 9.2 Hz, 1H), 3.6 – 3.8 (m, 2H), 3.52 (dd, J = 
6.8, 6.8 Hz, 1H), 3.43 (dd, J = 6.8, 6.3 Hz, 1H), 3.40 (dd, J = 6.8, 6.3 Hz, 1H), 3.25 (t, J = 
6.8 Hz, 2H), 2.16 (s, 3H), 1.5 – 1.6 (m, 4H), 1.3 – 1.4 (m, 4H); 13C NMR (CDCl3, 68 
MHz) δ 170.6, 138.6, 138.49, 138.22, 128.7, 128.58 (2 carbons), 128.53 (3 carbons), 
128.25 (2 carbons), 128.14 (2 carbons), 127.96 (2 carbons), 127.93, 127.85, 127.78, 97.9, 
78.4, 75.3, 74.5, 73.5, 71.9, 71.5, 69.03, 68.97, 67.8, 51.5, 29.3, 28.8, 26.6, 25.8, 21.2; 
HRFAB Calcd for C35H43N3O7Na ([M+Na]+) m/z 640.2999; measured m/z 640.2987. 
6'-Azidohexyl 3,4,6-tri-O-benzyl-α-D-mannopyranoside (60). 1H NMR 
(CDCl3, 400 MHz) δ 7.1 – 7.3 (m, 15H), 4.90 (d, J = 1.5 Hz, 1H, H-1), 4.82 (d, J = 10.7 
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Hz, 1H), 4.72 (d, J = 11.6 Hz, 1H), 4.69 (d, J = 11.6 Hz, 1H), 4.65 (d, J = 12.1 Hz, 1H), 
4.55 (d, J = 12.1 Hz, 1H), 4.50 (d, J = 10.7 hz, 1H), 4.04 (m, 1H), 3.87 (m, 2H), 3.65 – 
3.8 (m, 4H), 3.41 (m, 1H), 3.25 (t, J = 6.9 hz, 2H), 1.58 (m, 4H), 1.36 (m, 4H); 13C NMR 
(CDCl3, 100 MHz) δ 138.4 (2 carbons), 138.1, 128.7 (2 carbons), 128.6 (2 carbons), 
128.5 (3 carbons), 128.2 (3 carbons), 128.12, 128.06 (4 carbons), 128.04 (2 carbons), 
127.8, 127.7, 99.3, 80.5, 77.4 (3 carbons), 75.4, 74.5, 73.6, 72.2, 71.2, 69.1, 68.6, 
67.751.6, 29.5, 28.9, 26.7, 25.9, ESI/APCI Calcd for C33H41N3O6Na ([M+Na]+) m/z 
598.2884; measured m/z 598.2893.  
6'-Azidohexyl-3-O-acetyl-2-O-benzyl-4,6-O-benzylidene-α-D-manno-
pyranoside (61). 1H NMR (CDCl3, 400 MHz) δ 7.4 – 7.5 (m, 2H), 7.3 – 7.4 (m, 8H), 
5.59 (s, 1H, H-1'), 5.31 (dd, J = 3.4, 10.4 Hz, 1H, H-3), 4.81 (s, 1H, H-1), 4.68 (d, J = 
11.9 Hz, 1H), 4.64 (d, J = 11.9 Hz, 1H), 4.26 (d, J = 5.6 Hz, 1H), 4.2 (m, 1H, H-5), 3.96 
(s, 1H), 3.9 (m, 2H), 3.7 (m, 1H), 3.4 (m, 1H), 3.29 (t, J = 6.8 Hz, 2H), 2.05 (s, 3H, CH3), 
1.6 (m, 4H), 1.4 (m, 4H); 13C NMR (CDCl3, 100 MHz) δ 170.4, 137.8, 137.5, 129.2, 
128.7 (2 carbons), 128.4 (2 carbons), 128.2 (2 carbons), 126.4 (2 carbons), 101.9, 99.0, 
77.4, 76.6, 76.5, 73.9, 70.8, 69.0, 68.0, 64.2, 51.6, 29.4, 28.9, 26.7, 25.9, 21.3; HRFAB 
Calcd for C28H35N3O7Na ([M+Na]+) m/z 548.2373; measured m/z 548.2371. 
6'-Azidohexyl-2,3-di-O-acetyl-4,6-O-benzylidene-α-D-mannopyranoside (62). 
1H NMR (CDCl3, 300 MHz) δ 7.4 – 7.5 (m, 2H), 7.3 – 7.4 (m, 3H), 5.58 (s, 1H), 5.40 
(dd, J = 3.6, 9.6 Hz, 1H, H-3), 5.33 (dd, J = 1.7, 3.6 Hz, 1H, H-2), 4.75 (d, J = 1.3 Hz, 
1H, H-1), 4.27 (dd, J = 4.1, 9.9 Hz, 1H), 4.03 (t, J = 9.3 Hz, 1H), 3.9 (m, 1H, H-5), 3.85 
(t, J = 9.9 Hz, 1H), 3.7 (m, 1H), 3.4 (m, 1H), 3.28 (t, J = 6.9 Hz, 2H), 2.17 (s, 3H, CH3), 
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2.02 (s, 3H, CH3), 1.6 (m, 4H), 1.4 (m, 4H); 13C NMR (CDCl3, 75 MHz) δ 170.0, 169.9, 
137.2, 129.2, 128.4 (2 carbons), 126.2 (2 carbons), 101.9, 98.7, 77.3, 76.3, 70.3, 68.8, 
68.2, 63.9, 51.5, 29.3, 28.8, 26.6, 25.8, 21.0, 20.9; HRFAB Calcd for C23H31N3O8Na 
([M+Na]+) m/z 500.2009; measured m/z 500.2008. 
6'-Azidohexyl-2,3-di-O-benzyl-4,6-O-benzylidene-α-D-mannopyranoside (63). 
1H NMR (CDCl3, 300 MHz) δ 7.5 - 7.6 (m, 4H), 7.2 – 7.5 (m, 26H), 5.68 (s, 1H), 5.66 (s, 
1H), 5.03 (d, J = 12.4 Hz, 1H), 4.8 – 5.0 (m, 3H), 4.82 (d, J = 1.4 Hz, 1H, H-1), 4.79 (s, 
1H), 4.6 – 4.7 (m, 4H), 4.47 (s, 1H), 4.2 - 4.4 (m, 3H), 4.10 (t, J = 6.9 Hz, 1H), 3.9 – 4.1 
(m, 3H), 3.8 – 3.9 (m, 3H), 3.6 (m, 1H), 3.5 (m, 1H), 3.4 (m, 1H), 3.3 (m, 4H), 1.6 (m, 
8H), 1.4 (m, 8H); 13C NMR (CDCl3, 75 MHz δ 138.9, 138.6, 138.5, 138.3, 137.85, 
137.83, 128.9, 128.8, 128.51 (3 carbons), 128.50 (3 carbons), 128.42 (4 carbons), 128.3, 
(5 carbons), 128.29 (2 carbons), 128.2 (3 carbons), 127.9 (2 carbons), 127.7, 127.6 (3 
carbons), 127.2 (3 carbons), 126.2 (2 carbons), 102.4, 101.5, 99.5, 79.4, 78.8, 78.1, 76.7 
(2 carbons), 75.9, 74.8, 73.7, 73.3, 72.5, 70.1, 69.0, 68.7, 67.7 (2 carbons), 64.3, 51.5 (2 
carbons), 29.7, 29.3, 28.9 (2 carbons), 26.6 (2 carbons), 25.8; HRFAB Calcd for 
C33H39N3O6Na ([M+Na]+) m/z 596.2737; measured m/z 596.2731. 
6'-Azidohexyl-2,6-di-O-acetyl-3,4-di-O-benzyl-α-D-mannopyranoside (64). 1H 
NMR (CDCl3, 300 MHz) δ 7.2 – 7.4 (m, 10H), 5.35 (dd, J = 1.7, 3.4 Hz, 1H, H-2), 4.90 
(d, J = 10.7 Hz, 1H), 4.78 (d, J = 1.4 Hz, 1H, H-1), 4.71 (d, J = 11.0 Hz, 1H), 4.54 (d, J = 
10.7 Hz, 1H), 4.52 (d, J = 11.0 Hz, 1H), 4.32 (m, 2H), 4.00 (dd, J = 3.4, 8.9 Hz, 1H, H-
3), 3.8 – 3.9 (m, 2H), 3.74 (t, J = 9.3 Hz, 1H, H-4), 3.65 (m, 1H), 3.4 (m, 1H), 3.26 (t, J = 
6.9 Hz, 2H), 2.15 (s, 3H, CH3), 2.06 (s, 3H, CH3), 1.6 (m, 4H), 1.35 (m, 4H); 13C NMR 
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(CDCl3, 75 MHz δ 171.0, 170.6, 138.1, 137.9, 128.7 (2 carbons), 128.6 (2 carbons), 
128.34 (2 carbons), 128.32 (2 carbons), 128.1, 128.0, 97.9, 78.4, 75.5, 74.3, 73.6, 71.9, 
69.8, 68.8, 68.1, 63.6, 51.6, 29.4, 28.9, 26.7, 25.9, 21.3, 21.1; ESI/APCI Calcd for 
C30H39N3O8Na ([M+Na]+) m/z 592.2635; measured m/z 592.2615.  
6′-Azidohexyl 2-O-acetyl-3-O-benzyl-4,6-benzylidene-α-D-mannopyranoside 
(65). 1H NMR (CDCl3, 300 MHz) δ 7.5 (m, 2H), 7.4 - 7.2 (m, 8H), 5.65 (s, 1H), 5.39 (dd, 
J = 1.6, 3.3Hz, 1H, H-2), 4.78 (s, 1H, H-2), 4.72 (d, J = 12.0Hz, 1H,), 4.68 (d, J = 12.0 
HZ, 1H), 4.3 (m, 1H), 4.1 - 4.0 (m, 2H), 3.9 - 3.8 (m, 2H), 3.7 (m, 1H), 3.4 (m, 1H), 3.3 
(m, 2H), 2.18 (s, 3H, CH3), 1.60 (m, 4H), 1.39 (m, 4H); 13C NMR (CDCl3, 75 MHz) δ 
170.4, 138.1, 137.5, 129.0, 128.4, 128.3, 127.7, 126.1, 101.6, 98.9, 78.5, 77.3, 74.0, 72.3, 
69.9, 68.8, 68.0, 63.9, 51.4, 29.3, 28.8, 26.6, 25.8, 21.1; ESI/APCI Calcd for 
C28H37N3O7Na ([M+Na]+) m/z 548.2356; measured m/z 548.2373. 
6'-Azidohexyl-4,6-di-O-acetyl-2,3-di-O-benzyl-α-D-mannopyranoside (66). 1H 
NMR (CDCl3, 300 MHz) δ7.25 – 7.4 (m, 10H), 5.41 (t, J = 9.6 Hz, 1H, H-4), 4.83 (d, J = 
1.7 Hz, 1H, H-1), 4.77 (d, J = 12.4 Hz, 1H), 4.67 (d, J = 12.4 Hz, 1H), 4.59 (d, J = 12.4 
Hz, 1H), 4.48 (d, J = 12.4 Hz, 1H), 4.21 (dd, J = 5.5, 12.0 Hz, 1H), 4.11 (dd, J = 2.7, 12.0 
Hz, 1H), 3.8 (m, 2H), 3.63 (m, 1H), 3.37 (m, 1H), 3.26 (t, J = 6.9 Hz, 2H), 2.07 (s, 3H, 
CH3), 2.01 (s, 3H, CH3), 1.57 (m, 4H), 1.35 (m, 4H); 13C NMR (CDCl3, 100 MHz) δ 
171.1, 169.9, 138.4 (2 carbons), 128.55 (2 carbons), 128.52 (2 carbons), 128.0 (2 
carbons), 127.8 (2 carbons), 127.6 (2 carbons), 98.5, 77.4 (2 carbons), 74.4, 73.0, 72.1, 
69.3, 68.4, 67.9, 63.3, 51.5, 29.4, 28.9, 26.7, 25.9, 21.1, 21.0; ESI/APCI Calcd for 
C30H39N3O8Na ([M+Na]+) m/z 592.2635; measured m/z 592.2638.  
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6′-Azidohexyl-3-O-benzoyl-2-O-benzyl-4,6-benzylidene-α-D-mannopyra-
noside (67). 1H NMR (CDCl3, 400 MHz) δ 8.1 (m, 2H, ), 7.5 ( m, 1H, ), 7.4 - 7.2 (m, 
12H ), 5.65 (s, 1H, H-1'), 5.62 (1H, H-3), 4.87 (s, 1H, H-1), 4.67 (s, 2H), 4.3 - 4.2 (m, 
2H), 4.1 (m, 1H), 3.9 - 3.8 (m, 2H), 3.79 (m, 1H), 3.4 (m, 1H); 3.3 (t, J = 6.9 Hz, 2H), 1.6 
(m, 4H), 1.4 (m, 4H); 13C NMR (CDCl3, 100 MHz) δ 166.1, 137.8, 137.6, 134.7, 133.6, 
133.3, 130.2, 130.1, 129.9, 129.1, 128.8, 128.7, 128.6, 128.4, 128.3, 128.1, 127.9, 126.3, 
101.9, 99, 76.7, 76.3, 74.0, 71.5, 69.1, 67.9, 64.3, 51.6, 29.5, 29.0, 26.7, 26.0; ESI/APCI 
Calcd for C33H41N4O7 ([M+NH4+]+) m/z 605.2975; measured m/z 605.2959. 
Phenyl 2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-3,4,6-tri-O-
benzyl-1-thio-α-D-mannopyranoside (68). 1H NMR (CDCl3, 400 MHz) δ 7.4 (m, 2H), 
7.1 – 7.4 (m, 33H), 5.67 (d, J = 1.6 Hz, 1H, H-1), 5.54 (dd, J = 1.8, 3.1 Hz, 1H, H-2'), 
5.09 (d, J = 1.5 Hz, 1H, H-1'), 4.91 (d, J = 10.8 Hz, 1H), 4.84 (d, J = 10.9 Hz, 1H), 4.75 
(d, J = 11.7 Hz, 1H), 4.71 (d, J = 11.7 Hz, 1H), 4.68 (d, J = 10.8 Hz, 1H), 4.62 (d, J = 
11.0 Hz, 1H), 4.56 (d, J = 12.3 Hz, 1H), 4.49 (d, J = 12.6 Hz, 2H), 4.4 (m, 2H), 4.3 (m, 
1H), 4.25 (t, J = 2.1 Hz, 1H), 3.9 – 4.0 (m, 5H), 3.8 – 3.9 (m, 2H), 3.7 – 3.8 (m, 2H), 3.60 
(dd, J = 1.7, 10.6 Hz, 1H), 2.15 (s, 3H, CH3); 13C NMR (CDCl3, 100 MHz) δ 170.4, 
138.7, 138.6 (2 carbons), 138.4, 138.3, 138.2, 134.4, 131.9 (2 carbons), 129.2 (2 
carbons), 128.7 (2 carbons), 128.6 (2 carbons), 128.55 (6 carbons), 128.50 (4 carbons), 
128.4 (4 carbons), 128.3 (2 carbons), 128.2 (2 carbons), 128.0 (2 carbons), 127.9 (4 
carbons), 127.8 (2 carbons), 127.7 (3 carbons), 127.6 (2 carbons), 99.9, 87.4, 80.2, 78.3, 
77.0, 75.4, 75.3, 75.0, 74.6, 73.4 (2 carbons), 73.1, 72.4, 72.2, 72.1, 69.4, 69.0, 68.9, 
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21.3; ESI/APCI Calcd for C62H64O11SNa ([M+Na]+) m/z 1039.4067; measured m/z 
1039.4082. 
Phenyl 2-O-(6-O-acetyl-2,3,4-tri-O-benzyl-α-D-mannopyranosyl)-3,4,6-tri-O-
benzyl-1-thio-α-D-mannopyranoside (69). 1H NMR (CDCl3, 400 MHz) δ 7.4 (m, 2H), 
7.2 (m, 33H), 5.60 (d, J = 1.5 Hz, 1H), 5.16 (d, J = 1.7 Hz, 1H), 4.90 (d, J = 10.7 Hz, 
1H), 4.88 (d, J = 10.5 Hz, 1H), 4.72 (d, J = 11.2 Hz, 1H), 4.6 (m, 2H), 4.5 (m, 4H), 4.4 
(m, 3H), 4.3 (m, 4H), 3.8 (m, 7H), 3.7 (m, 1H), 1.85 (s, 3H, CH3). 13C NMR (CDCl3, 100 
MHz) δ 171.2, 138.7, 138.6, 138.5, 138.4, 138.3, 138.1, 134.4, 131.5, 129.3, 129.0, 
128.8, 128.6, 128.6, 128.5, 128.5, 128.3, 128.1, 127.9, 127.8, 127.7, 127.6, 99.9, 87.4, 
80.4, 79.8, 78.6, 76.5, 75.4, 75.3, 75.2, 75.0, 74.9, 74.5, 74.0, 73.5, 73.0, 72.8, 72.5, 71.0, 
69.4, 63.9, 20.8; ESI/APCI Calcd for C62H64O11SNa ([M+Na]+) m/z 1034.4513; 
measured m/z 1034.4496. 
2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-3,4,6-tri-O-benzyl-
α-D-mannopyranoside (70). 1H NMR (CDCl3, 400 MHz) δ 7.4 - 7.1 (m, 38H), 5.56 (dd, 
J = 3.1, 1.9 Hz, 1H, H-2'), 5.26 (s, 1H, H-1'), 5.10 (s, 1H, H-1), 4.86 (d, J = 10.9 Hz, 2H), 
4.7 - 4.6 (m, 5H), 4.6 - 4.5 (m, 6H), 4.47 (d, J = 10.9 Hz, 1H), 4.45 (d, J = 10.9 Hz, 1H), 
4.0 (m, 1H), 4.0 - 3.9 (m, 4H), 3.9 (m, 1H), 3.8 - 3.7 (m, 2H), 3.7 (m, 1H), 3.7 - 3.6 (m, 
2H), 2.69 (s, 1H, OH), 2.14 (s, 3H, CH3); 13C NMR (CDCl3, 100 MHz) δ 170.3, 138.6, 
138.5, (2 C), 138.4, 138.2, 128.7, 128.6, 128.4, 128.3, 128.1, 128.0, 127.9, 127.8, 127.7, 
127.6, 99.7, 93.6, 79.3, 78.9, 78.3, 75.3, 75.3, 73.1, 74.9, 74.5, 74.3, 73.6, (2 C), 72.3, 
72.1, 72.0, 71.9, 69.8, 69.1 (2 C), 68.9, 21.4; ESI/APCI Calcd for C56H64NO12 
([M+NH4]+) m/z 942.4429; measured m/z 942.4447. 
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Acetyl 2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-3,4,6-tri-O-
benzyl-α-D-mannopyranoside (71). 1H NMR (CDCl3, 300 MHz) δ 7.2 – 7.4 (m, 30H), 
6.12 (d, J = 2.1 Hz, 1H, H-1), 5.54 (s, 1H, H-2′), 5.14 (d, J = 1.4 Hz, 1H, H-1′), 4.87 (d, J 
= 10.7 Hz, 1H), 4.82 (d, J = 10.7 Hz, 1H), 4.6 – 4.73 (m, 5H), 4.5 – 4.6 (m, 5H), 4.46 (d, 
J = 12.0 Hz, 1H), 4.45 (d, J = 10.7 Hz, 1H), 4.38 (d, J = 10.9 Hz, 1H), 3.8 – 4.0 (m, 6H), 
3.6 – 3.8 (m, 4H), 2.13 (s, 3H, CH3), 2.01 (s, 3H, CH3); 13C NMR (CDCl3, 75 MHz) δ 
170.3, 168.7, 138.5, 138.33, 138.32, 138.2, 138.1 (2 carbons), 128.54 (2 carbons), 128.50 
(2 carbons), 128.4 (3 carbons), 128.3 (3 carbons), 128.23 ( 2 carbons), 128.21 (2 
carbons), 127.9, 127.8 (3 carbons), 127.7, 127.68 (2 carbons), 127.6 (3 carbons), 99.5, 
92.8, 79.0, 78.3, 77.3, 75.4, 75.2, 74.4, 74.2, 74.1, 73.52 (2 carbons), 73.0, 72.3, 72.1, 
68.9, 68.7, 68.5, 21.2. 21.0; ESI/APCI Calcd for C58H62O13Na ([M+Na]+) m/z 989.4088; 
measured m/z 989.4104. 
Phenyl 2-O-(2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl)-3,4,6-tri-O-benzyl-
1-thio-α-D-mannopyranoside (72). 1H NMR (CDCl3, 400 MHz) δ 7.5 (m, 2H), 7.2 – 7.4 
(m, 18H), 5.59 (s, 1H, H-1), 5.45 (dd, J = 1.6, 3.4 Hz, 1H, H-2′), 5.41 (dd, J = 3.4, 9.7 
Hz, 1H, H-3′), 5.24 (t, J = 9.7 Hz, 1H, H-4′), 4.98 (d, J = 0.6 Hz, 1H, H-1′), 4.88 (d, J = 
10.9 Hz, 1H), 4.77 (d, J = 11.8 Hz, 1H), 4.66 (d, J = 11.8 Hz, 1H), 4.64 (d, J = 12.1 Hz, 
1H), 4.56 (d, J = 11.1 Hz, 1H), 4.52 (d, J = 12.1 Hz, 1H), 4.33 (m, 1H, H-5′), 4.1 – 4.2 
(m, 4H), 3.9 – 4.0 (m, 2H), 3.90 (dd, J = 2.6, 9.2 Hz, 1H), 3.7 – 3.8 (m, 2H), 2.14 (s, 3H, 
CH3), 2.02 (s, 3H, CH3), 1.98 (s, 3H, CH3), 1.87 (s, 3H, CH3); 13C NMR (CDCl3, 75 
MHz) δ 170.9, 170.05, 170.0, 169.9, 138.5, 138.4, 138.2, 134.0, 132.1 (2 carbons), 129.3 
(2 carbons), 128.7 (2 carbons), 128.6 (2 carbons), 128.5 (2 carbons), 128.3 (2 carbons), 
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128.0, 127.9 (6 carbons), 127.6, 99.6, 87.2, 80.0, 78.3, 75.5, 75.1, 73.3, 72.9, 72.7, 69.7, 
69.3, 69.2 (2 carbons), 66.3, 62.7, 21.1, 20.9, 20.8, 20.6; ESI/APCI Calcd for 
C47H52O14SNa ([M+Na]+) m/z 895.2975; measured m/z 895.2992. 
Methyl-2-O-(2,3,4,6-tetra-O-benzyl-α-D-mannopyranosyl)-3-O-benzyl-4,6-
benzylidene-α-D-mannopyranoside (73). 1H NMR (CDCl3, 400 MHz) δ 7.2 - 7.6 (m, 
30H), 5.63 (s, 1H, H-1'), 5.24 (s,1H, H-1"), 4.91 (d, J = 10.7 Hz, 1H), 4.79 (d, J = 11.9 
Hz, 1H), 4.77 (s, 1H, H-1), 4.7 - 4.5 (m, 13H), 4.2 (m, 1H), 4.1 (m, 1H), 3.9 (m, 9H), 3.8 
- 3.7 (m, 7H), 3.2 (m, 3H, OMe); 13C NMR (CDCl3, 75 MHz) δ 138.6, 138.5, 138.4 (2 
carbons), 137.7, 128.5, 128.4, 128.4, 128.3, 128.2, 127.8, 127.8, 127.6, 127.5, 126.2, 
101.5, 101.0, 100.3, 79.6, 79.3, 77.3, 75.9, 75.3, 75.2, 75.0, 73.4, 73.3, 72.4, 72.1, 69.6, 
69.0, 63.7, 54; ESI/APCI Calcd for C55H58O11Na ([M+Na]+) m/z 917.3877; measured 
m/z 917.3853. 
Methyl 2,3,4-tri O-benzyl-α-D-mannopyranoside (76).111 1H NMR (CDCl3, 400 
MHz) δ 7.3 – 7.4 (m, 15H), 4.96 (d, J = 10.9 Hz, 1H), 4.80 (d, J = 12.0 Hz, 1H), 4.67 – 
4.73 (m, 5H), 3.98 (t, J = 9.4 Hz, 1H), 3.92 (dd, J = 2.9, 9.4 Hz, 1H, H-3), 3.85 (m, 1H), 
3.81 (m, 2H), 3.65 (m, 1H, H-5), 3.32 (s, 3H, OCH3), 2.01 (s, 1H, OH). 
Methyl 2,3,4-tri-O-benzyl-6-O-(2,3,4-tri-O-benzyl-α-D-mannopyranosyl)-α-
D-mannopyranoside (77). 1H NMR (CDCl3, 300 MHz) δ 7.2 - 7.4 (m, 30H), 5.06 (d, J = 
1.3 Hz, 1H), 4.95 (d, J = 10.7 Hz, 1H), 4.91 (d, J = 10.7 Hz, 1H), 4.7 (m, 4H), 4.6 - 4.7 
(m, 5H), 4.54 (d, J = 12.0 Hz, 1H), 4.49 (d, J = 11.0 Hz, 1H), 3.8 – 4.0 (m, 7H), 3.8 (m, 
1H), 3.8 - 3.6 (m, 4H), 3.25 (s, 3H, OMe), 1.92 (s, 1H, OH); 13C NMR (CDCl3, 75 MHz) 
δ 138.7 (2 carbons), 138.6, 138.5, 138.4, 138.3, 128.5 (4 carbons), 128.4 (5 carbons), 
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128.4 (2 carbons), 128.1 (2 carbons), 127.9 (2 carbons), 127.9 (2 carbons), 127.84, 
127.80 (3 carbons), 127.7 (4 carbons), 127.6 (2 carbons), 99.0, 98.3, 80.3, 79.4, 75.2, 
75.1, 75.0, 74.8, 74.7, 74.6, 72.9, 72.8, 72.3, 72.2, 71.7, 71.4, 66.2 (2 carbons), 62.4 (2 
carbons), 54.8; ESI/APCI Calcd for C55H60O11Na ([M+Na]+) m/z 919.4033; measured 
m/z 919.4054. 
6′-Azidohexyl-2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-
3,4,6-tri-O-benzyl-α-D-mannopyranoside (78). 1H NMR (CDCl3, 300 MHz) δ  7.1 – 
7.4 ( m, 30H), 5.56 ( dd, J = 1.0, 3.1 Hz, 1H, H-2'), 5.10 ( d, J = 1.4 Hz, 1H), 4.86 ( d, J = 
10.3 Hz, 3H), 4.7 ( m, 5H), 4.5 – 4.6 (m, 3H), 4.50 ( d, J = 11.7 Hz, 1H), 4.47 ( d, J = 
10.7 Hz, 1H), 4.42 ( d, J =11.0 Hz, 1H), 4.0 (m, 3H), 3.7 -3.9 ( m, 8H), 3.6 ( m, 1H ), 
3.29 ( m, 1H), 3.23 ( t, J = 6.9 Hz, 2H), 2.13 ( s, 3H, CH3), 1.53 ( m, 4H), 1.31 (m, 4H); 
13C NMR (CDCl3, 75 MHz) δ  170.3, 138.6, 138.55, 138.50, 138.46, 138.3, 138.1, 128.5, 
128.4, 128.3, 128.2, 127.9, 127.8, 127.7, 127.62, 127.60, 99.7, 98.8, 79.8, 78.4, 75.3, 
75.2, 75.0, 74.8, 74.5, 73.5, 73.4, 72.1, 72.0, 71.9, 69.4, 69.2, 68.8, 67.6, 51.5, 29.4, 28.8, 
26.6, 25.8, 21.3; ESI/APCI Calcd for C62H71N3O12Na ([M+Na]+) m/z 1072.4935; 
measured m/z 1072.4923. 
6′-azidohexyl-2-O-(3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-3,4,6-tri-O-
benzyl-α-D-mannopyranoside (79). 1H NMR (CDCl3, 270 MHz) δ 7.1 – 7.4 (m, 30H), 
5.17 (s, 1H, H-1′), 4.93 (s, 1H), 4.87 (d, J = 10.6 Hz, 1H), 4.84 (d, J = 10.9 hz, 1H), 4.5 – 
4.8 (m, 10H), 4.15 (s, 1H), 3.7 – 4.05 (m, 10H), 3.6 (m, 1H), 3.5 (m, 1H), 3.3 (m, 1H), 
3.2 (t, J = 6.9 Hz, 2H), 2.34 (s, 1H, OH), 1.55 (m, 4H), 1.32 (m, 4H); 13C NMR (CDCl3, 
68 MHz) δ 138.7, 138.6, 138.5, 138.4, 138.1, 128.6 (4 carbons), 128.5 (2 carbons), 128.4 
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(6 carbons), 128.1 (2 carbons), 127.9 (6 carbons), 127.8 (5 carbons), 127.7, 127.6, 127.55 
(2 carbons), 127.5, 101.2, 98.9, 80.1, 79.9, 75.3, 75.1 (2 carbons), 74.9, 74.6, 73.5, 73.4, 
72.3, 72.2, 72.0, 71.7, 69.5, 69.4, 68.6, 67.6, 51.5, 29.4, 28.8, 26.6, 25.8; ESI/APCI Calcd 
for C60H69N3O11Na ([M+Na]+) m/z 1030.4824; measured m/z 1030.4826. 
6′-Azidohexyl -4,6-benzylidene-α-D-mannopyranoside (80). 1H NMR (CDCl3, 
300 MHz) δ  7.5 ( m, 2H), 7.3 – 7.4 ( m, 3H), 5.57 ( s, 1H), 4.84 ( d, J = 1.1 Hz, 1H, H-
1), 4.27 ( dd, J = 1.5, 4.0 Hz, 1H), 4.08 ( dd, J = 3.4, 9.4 Hz, 1H), 4.02 ( m, 1H), 3.9 ( m, 
1H, H-5), 3.8 ( m, 2H) 3.7 (m, 1H), 3.4 ( m, 1H), 3.28 ( t, J = 6.9 Hz, 2H), 2.80 (s, 2H, 
0H) 1.6 ( m, 4H), 1.4 ( m, 4H); 13C NMR (CDCl3, 75 MHz) δ  137.4, 129.5, 128.6 ( 2 
carbons), 126.5 ( 2 carbons), 102.4, 100.4, 79.2, 71.2, 69.1, 68.9, 68.0, 63.3, 51.6, 29.5, 
28.9, 26.7, 25.9; ESI/APCI Calcd for C19H27N3O7Na ([M+Na]+) m/z 416.1797; measured 
m/z 416.1785. 
6'-Azidohexyl 3-O-pivaloyl-4,6-O-benzylidene-α-D-mannopyranoside (81). 1H 
NMR (CDCl3, 300 MHz) δ 7.3 – 7.5 (m, 5H), 5.57 (s, 1H), 5.34 (dd, J = 3.4, 9.9 Hz, 1H, 
H-3), 4.84 (d, J = 1.4 Hz, 1H, H-1), 4.29 (dd, J = 3.4, 8.9 Hz, 1H, H-6), 4.0 – 4.1 (m, 
2H), 3.8 – 3.9 (m, 2H), 3.7 (m, 1H), 3.4 (m, 1H), 3.28 (t, J = 6.9 Hz, 2H), 2.07 (d, 1H, 
OH), 1.6 (m 4H), 1.4 (m 4H), 1.23 (s, 9H, 3 CH3); 13C NMR (CDCl3, 75 MHz) δ 177.4, 
137.3, 128.9, 128.5 (2 carbons), 125.9 (2 carbons), 100.45, 100.41, 76.4, 70.5, 70.2, 68.9, 
67.9, 63.8, 51.5, 39.1, 29.3, 28.8, 27.2 (3 carbons), 26.6, 25.8; ESI/APCI Calcd for 
C24H35N3O7Na ([M+Na]+) m/z 478.2553; measured m/z 478.2566. 
6'-Azidohexyl 2-O-pivaloyl-4,6-O-benzylidene-α-D-mannopyranoside (82). 1H 
NMR (CDCl3, 300 MHz) δ 7.5 (m, 2H), 7.3 – 7.4 (m, 3H), 5.61 (s, 1H), 5.17 (dd, J = 1.4, 
104 
 
3.8 Hz, 1H, H-2), 4.73 (d, J = 1.3 Hz, 1H, H-1), 4.1 – 4.3 (m, 2H), 3.8 (m, 2H), 3.7 (m, 
1H), 3.4 (m, 1H), 3.27 (t, J = 6.9 Hz, 2H), 2.18 (d, J = 4.5 Hz, 1H, OH), 1.6 (m, 4H), 1.4 
(m, 4H), 1.27 (s, 9H, 3 CH3); 13C NMR (CDCl3, 75 MHz) δ 178.1, 137.2, 129.3, 128.4 (2 
carbons), 126.3 (2 carbons), 102.3, 98.6, 79.6, 72.0, 68.9, 68.1, 67.6, 63.5, 51.4, 39.2, 
29.3, 28.8, 27.3 (3 carbons), 26.6, 25.8; ESI/APCI Calcd for C24H35N3O7Na ([M+Na]+) 
m/z 500.2373; measured m/z 500.2380.   
6'-Azidohexyl 3-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-2-O-
pivaloyl-4,6-O-benzylidene-α-D-mannopyranoside (83). 1H NMR (CDCl3, 300 MHz) δ  
7.1 – 7.5 (m, 20H), 5.63 (s, 1H), 5.48 (dd, J = 1.7, 2.7 Hz, 1H), 5.25 (d, J = 1.7 Hz, 1H), 
5.15 ( dd, J = 1.4, 3.4 Hz, 1H), 4.84 (d, J = 11.4 Hz, 1H), 4.71 ( d, J = 1.4 Hz, 1H), 4.70 ( 
d, J = 12.0 Hz, 1H), 4.65 ( d, J = 11.4 Hz, 1H), 4.47 ( d, J = 11.0 Hz, 1H), 4.46 ( d, J = 
12.4 Hz, 1H), 4.42 ( d, J = 11.4 Hz, 1H), 4.3 ( m, 1H), 3.25 ( t, J = 6.9 Hz, 2H), 2.09 ( s, 
3H, CH3), 1.57 ( m, 4H), 1.36 ( m, 4H), 1.22 (s, 9H, 3CH3); 13C NMR (CDCl3, 75 MHz) 
δ  170.5, 170.3, 138.8, 138.4, 138.0, 137.2, 128.9, 128.4 ( 2 carbons), 128.3 ( 2 carbons), 
128.2 ( 3carbons), 127.9 ( 2 carbons), 127.8 ( 2 carbons), 127.7, 127.6 ( 2 carbons) 127.4, 
126.0, 101.4, 99.2, 98.5, 79.3, 78.2, 77.3, 74.8, 74.1, 73.4, 71.9, 71.8, 71.7, 71.6, 68.9, 
68.6, 68.5, 68.06, 63.6, 51.4, 39.0, 29.3, 28.8, 27.2 ( 3 carbons), 26.6, 25.7, 21.1; 
ESI/APCI Calcd for C53H65N3O13Na ([M+Na]+) m/z 974.4415; measured m/z 974.4433. 
6'-Azidohexyl 3-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-4-O-
benzyl-2-O-pivaloyl-α-D-mannopyranoside (84). 1H NMR (CDCl3, 300 MHz) δ  7.1 – 
7.4 (m, 20H), 5.36 (dd, J = 1.7, 3.1 Hz, 1H), 5.16 (d, J = 1.7 Hz, 1H), 5.06 (dd, J = 1.0, 
3.1 Hz 1H), 4.86 ( d, J = 11.7 Hz, 1H), 4.75 (d, J = 10.3 Hz, 1H), 4.69 (s, 1H), 4.62 (d, J 
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= 11.4 Hz, 1H), 4.55 (d, J = 11.0 Hz, 1H), 4.48 (d, J = 11.7 Hz, 1H), 4.43 (d, J = 12.4 
1H), 4.55 (d, J = 11.0 Hz, 1H), 4.48 (d, J = 11.7 Hz, 1H) 4.43 (d, J = 12.4 Hz, 1H), 4.17 
(dd, J = 3.1, 9.6 Hz, 1H), 3.96 (t, J = 9.6 Hz, 1H), 3.5-3.9 (m, 10H), 3.34 (m, 1H) 3.24 (t, 
J = 6.9 Hz, 2H), 2.12 (s, 3H, CH3), 1.55 (m, 4H), 1.33 (m, 4H), 1.19 (s, 9H, 3CH3); 
ESI/APCI Calcd for C53H67N3O13Na ([M+Na]+) m/z 976.4572; measured m/z 976.4584.  
Benzyl 2,3,4,6-tetra-O-acetyl-α-D-mannopyranoside (85). 1H NMR (CDCl3, 
400 MHz) δ 7.4 (m, 5H), 5.38 (dd, J = 3.2, 10.0 Hz, 1H), 5.3 (m, 2H), 4.88 (s, 1H, H-1), 
4.70 (d, J = 11.8 Hz, 1H), 4.56 (d, J = 11.8 Hz, 1H), 4.26 (dd, J =  5.0, 12.2 Hz, 1H), 4.1 
- 3.9 (m, 2H), 2.12 (s, 3H, CH3), 2.09 (s, 3H, CH3), 2.02 (s, 3H, CH3), 1.97 (s, 3H, CH3); 
13C NMR (CDCl3, 75 MHz) δ 170.6, 170.0, 169.9, 169.8, 136.3, 128.9, 128.6, 128.3, 
128.2, 96.8, 69.8, 69.6, 69.2, 68.7, 66.2, 62.4, 20.9, 20.8, 20.7 (2 carbons); ESI/APCI 
Calcd for C21H26O10Na ([M+Na]+) m/z 461.1424; measured m/z 461.1429. 
Benzyl 2,3,4-tri-O-benzyl-α-D-mannopyranoside (87).114 1H NMR (CDCl3, 400 
MHz) δ 7.5 - 7.4 (m, 20H), 5.04 (d, J = 10.8 Hz, 1H) 5.01 (d, J = 1.6 Hz, 1H, H-1), 4.85 
(d, J = 12.3 Hz, 1H),  4.8 - 4.7 (m, 5H), 4.51 (d, J = 11.9 Hz, 1H), 4.2 - 4.1 (m, 2H), 3.9 - 
3.8 (m, 3H), 3.8 (m, 1H, H-5), 2.37 (t, J = 2.4 Hz, 1H, OH); 13C NMR (CDCl3, 100 MHz) 
δ 138.8, 138.7, 138.5, 137.5, 128.7, 128.7, 128.4, 128.2, 128.1, 128.0, 128.0, 127.9, 
127.8, 97.8, 80.5, 75.6, 75.2, 75.1, 73.2, 72.8, 72.6, 69.4, 62.6. 
Benzyl 6-O-(6-O-acetyl-2,3,4-tri-O-benzyl-α-D-mannopyranosyl)-2,3,4-tri-O-
benzyl-α-D-mannopyranoside (88). 1H NMR (CDCl3, 300 MHz) δ 7.2 - 7.4 (m, 35H), 
5.13, (s, 1H, H-1), 4.97 (d, J = 10.6 HZ, 1H), 4.94 (d, J = 11.0 Hz, 1H), 4.90 (d, J = 1.7 
Hz, 1H, H-1'), 4.4 - 4.7 (m, 11H), 4.41 (d, J = 12.0 HZ, 1H), 4.2 – 4.4 (m, 2H), 3.8 - 3.9 
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(m, 6H), 3.84 (m, 2H), 3.7 - 3.8 (m, 2H) 2.03 (s, 3H, CH3); 13C NMR (CDCl3, 75 MHz) δ 
171.1, 138.7, 138.5 (3 carbons), 138.29, 138.24, 137.2, 128.56, 128.53 (8 carbons), 
128.3, 128.2, 128.0 (4 carbons), 127.9 (4 carbons), 127.85, 127.80 (3 carbons), 127.7, 
127.65 (2 carbons), 127.6, 98.1, 97.0, 80.4, 79.5, 75.2 (2 carbons), 74.9, 74.7 (2 carbons), 
74.4, 72.9, 72.5, 72.3, 72.0, 71.6, 70.2, 68.9, 66.3, 63.6, 21.0; ESI/APCI Calcd for 
C63H66O12Na ([M+Na]+) m/z 1037.4452; measured m/z 1037.4445. 
Benzyl 2,3,4-tri-O-benzyl-6-O-(2,3,4-tri-O-benzyl-α-D-mannopyranosyl)-α-D-
mannopyranoside (89). 1H NMR (CDCl3, 300 MHz) δ 7.2 - 7.4 (m, 35H), 5.10 (d, J = 
1.4 Hz, 1H), 5.00 (d, J = 11.0 Hz, 1H), 4.92 (d, J = 1.7 Hz, 1H, H-1), 4.6 - 4.8 (m, 9H ), 
4.61 (d, J = 12.0 Hz, 1H), 4.55 (d, J = 12.0 Hz, 1H), 4.53 (d, J = 14.0 Hz, 1H), 4.43 (d, J 
= 11.7 Hz, 1H), 3.7 – 4.0 (m, 12H) 1.98 (s, 1H, OH); 13C NMR (CDCl3, 75 MHz) δ 
138.72, 138.70, 138.5 (2 carbons), 138.4, 138.2, 137.2, 128.6, 128.5 (10 carbons), 128.4 
(2 carbons), 128.1, 128.0 (5 carbons), 127.9 (2 carbons), 127.8 (2 carbons), 127.7 (3 
carbons), 127.6 (2 carbons), 98.4, 97.1, 80.4, 79.5, 75.3, 75.1, 74.90, 74.86, 74.7, 72.9, 
72.8, 72.3 (2 carbons), 71.9, 71.7, 69.0, 66.3, 62.4; ESI/APCI Calcd for C61H64O11Na 
([M+Na]+) m/z 995.4346; measured m/z 995.4340. 
Benzyl 6-O-(6-O-(6-O-acetyl-2,3,4-tri-O-benzyl-α-D-mannopyranosyl)-2,3,4-
tri-O-benzyl-α-D-mannopyranosyl)-2,3,4-tri-O-benzyl-α-D-mannopyranoside (90). 
1H NMR (CDCl3, 400 MHz) δ 7.2 - 7.4 (m, 65H), 5.15 (s, 1H), 5.07 (s, 1H), 4.8 - 5.0 (m, 
4H), 4.4 - 4.7 (m, 20H), 4.23 (m, 1H), 3.8 - 4.0 (m, 10H), 3.7 (m, 2H), 3.6 (m, 1H), 2.01 
(s, 3H, CH3), 1.99 (s, 3H, CH3); 13C NMR (CDCl3, 75 MHz) δ 171.0 (2 carbons), 138.8 
(2 carbons), 138.6 (2 carbons),, 138.5 (3 carbons),, 138.3, 138.2 (3 carbons), 137.2, 128.5 
 
107 
 
(2 carbons), 128.4 (8 carbons),, 128.31 (2 carbons), 128.30 (2 carbons), 128.1, 127.9 (8 
carbons), 127.82 (2 carbons), 127.8 (2 carbons), 127.7 (3 carbons), 127.66 (3 carbons), 
127.60, 102.4 (β), 98.3 (α), 98.1 (2 carbons, α/β), 97.0 (2 carbons, α/β), 81.9, 80.4, 79.6 
(2 carbons), 79.3, 77.9, 77.3 (4 carbons), 75.2 (5 carbons), 74.8 (2 carbons), 74.7 (3 
carbons), 74.5, 74.3 (2 carbons), 72.9, 72.8, 72.3, 72.2, 71.9, 71.8, 71.6, 71.3, 71.2, 70.1, 
68.9 (2 carbons), 66.2, 65.9, 63.3, 20.9; ESI/APCI Calcd for C90H98NO17 ([M+NH4]+)  
m/z 1464.6835; measured m/z 1464.6818. 
Benzyl-2,3,4-tri-O-benzyl-6-O-(6-O-(2,3,4-tri-O-benzyl-α-D-mannopyra-
nosyl)-2,3,4-tri-O-benzyl-α-D-mannopyranosyl)-α-D-mannopyranoside (91). 1H 
NMR (CDCl3, 400 MHz) δ 7.2 - 7.4 (m, 50H), 5.10 (d, J = 1.0 Hz, 1H), 5.08 (s, 1H), 4.94 
(d, J = 11.0 Hz, 1H), 4.93 (d, J = 10.9 Hz, 1H), 4.90 (d, J = 1.6 Hz, 1H), 4.6 (m, 11H), 
4.6 (m, 2H), 4.5 (m, 4H), 4.42 (d, J = 11.9 Hz, 1H), 3.9 (m, 10H), 3.8 (m, 2H), 3.6 (m, 
7H); 13C NMR (CDCl3, 75 MHz) δ 138.8 (2 carbons), 138.7, 138.6, 138.5 (2 carbons), 
138.4, 138.3, 138.2, 137.2, 128.5 (2 carbons), 128.45 (6 carbons), 128.40 (4 carbons), 
128.3 (4 carbons), 128.1 (2 carbons), 127.95 (4 carbons), 127.92 (4 carbons), 127.82 (2 
carbons), 127.78 (2 carbons), 127.71 (4 carbons), 127.64 (4 carbons), 127.58 (2 carbons), 
127.54 (2 carbons), 98.4, 98.3, 97.1, 80.4, 79.6, 79.4, 77.3 (2 carbons), 75.2 (5 carbons), 
75.1 (3 carbons), 74.8 (2 carbons), 74.7 (2 carbons), 74. 67, 74.4, 72.9, 72.8, 72.7, 72.3 (4 
carbons), 71.9, 71.7, 71.7, 71.6 (2 carbons), 71.5 (2 carbons); ESI/APCI Calcd for 
C88H92O16Na ([M+Na]+) m/z 1427.6283; measured m/z 1427.6259. 
6-O-(6-O-(α-D-mannopyranosyl)-α-D-mannopyranosyl)-D-mannopyranose 
(92). 1H NMR (D2O, 400 MHz) δ 5.06 (s, 1H), 4.8 (m, 3H), 4.71 (s, 1H), 3.8 (m, 11H), 
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3.5 - 3.7 (m, 16H); 13C NMR (D2O, 75 MHz) δ 102.2 (β), 102.1, 101.9, 96.8, 96.4 (β), 
84.3, 76.7 (β), 75.8 (β), 75.3 (2 carbons), 73.7 (β), 73.3 (3 carbons), 73.1 (4 carbons), 
72.5 (2 carbons), 72.4 , 69.3 (2 carbons), 69.2 (2 carbons), 69.1 (2 carbons), 69.0 (β), 
68.3 (β), 68.2 (2 carbons), 63.5; ESI/APCI Calcd for C18H32O16Na ([M+Na]+) m/z 
527.1588; measured m/z 527.1581 
Methyl 6-O-(6-O-acetyl-2,3,4-tri-O-benzyl-α-D-mannopyranosyl)-2,3,4-tri-O-
benzyl-α-D-mannopyranoside (93). 1H NMR (CDCl3, 300 MHz) δ 7.2 – 7.4 (m, 30H), 
5.10 (s, 1H), 4.92 (d, J = 10.9 Hz, 1H), 4.90 (d, J = 10.9 Hz, 1H), 4.4 – 4.7 (m, 11H), 4.2 
(m, 2H), 3.86 -3.94 (m, 6H), 3.8 (m, 2H), 3.7 (m, 2H), 3.24 (s, 3H, OMe), 1.99 (s, 3H, 
CH3); 13C NMR (CDCl3, 75 MHz) δ 171.04, 138.6, 138.5 (2 carbons), 138.47, 138.3, 
138.27, 128.5 (5 carbons), 128.4 (4 carbons), 128.3 (2 carbons), 128.1 (2 carbons), 127.9 
(3 carbons), 127.8, 127.7 (4 carbons), 127.68 (2 carbons), 127.64 (2 carbons), 127.56, 
99.02, 98.04, 80.4 (2 carbons), 79.3, 77.3, 75.1 (2 carbons), 74.8, 74.7, 74.6, 74.4, 72.9, 
72.4, 72.2, 71.5 (4 carbons), 70.2, 66.2, 63.6, 54.8, 20.9; ESI/APCI Calcd for 
C57H62O12Na ([M+Na]+) m/z 961.4139; measured m/z 961.4135. 
Methyl 6-O-(6-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-2,3,4-
tri-O-benzyl-α-D-mannopyranosyl)-2,3,4-tri-O-benzyl-α-D-mannopyranoside (94). 
1H NMR (CDCl3, 400 MHz) δ 7.4 - 7.10 (m, 45H), 5.51 (dd, J = 2.7, 4.8 Hz, 1H, H-2"), 
5.10 (s, 1H, H-1"), 4.96 (s, 1H, H-1'), 4.95 (d, J = 10.9 Hz, 1H), 4.90 (d, J = 10.6 Hz, 
1H), 4.83 (d, J = 10.9 Hz, 1H), 4.6 - 4.7 (m, 13H), 4.3 - 4.5 (m, 8H), 3.8 - 3.9 (m, 14H), 
3.5 - 3.7 (m, 8H), 3.23 (s, 3H, OMe), 2.15 (s, 3H, CH3); 13C NMR (CDCl3, 100 MHz) δ 
170.3, 138.97, 138.91, 138.8, 138.7, 138.54, 138.50, 138.47, 138.1, 128.6 (6 carbons), 
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128.48 (5 carbons), 128.41 (4 carbons), 128.1 (2 carbons), 128.08 (2 carbons), 128.00 (3 
carbons), 127.9 (4 carbons), 127.87 (4 carbons), 127.85 (4 carbons), 127.81 (4 carbons), 
127.7 (2 carbons), 127.67 (4 carbons), 127.60, 127.5, 99.1, 98.3, 98.1, 80.5, 79.5, 77.9, 
75.2 (2 carbons), 75.1, 75.02, 74.9, 74.7, 74.6, 74.3, 73.5, 73.04, 72.6, 72.3, 71.7, 71.6, 
71.5 (2 carbons), 71.3, 68.9, 68.6, 66.7, 66.2, 21.4; ESI/APCI Calcd for C84H94NO17 
([M+NH4]+) m/z 1388.6522; measured m/z 1388.6500. 
Methyl-2,3,4-tri-O-benzyl-6-O-(6-O-(3,4,6-tri-O-benzyl-α-D-mannopyra-
nosyl)-2,3,4-tri-O-benzyl-α-D-mannopyranosyl)-α-D-mannopyranoside (95). 1H 
NMR (CDCl3, 400 MHz) δ 7.1 - 7.4 (m, 45H), 5.1 (m, 2H, H-1', H-1"), 4.9 (m, 3H), 4.8 
(m, 2H), 4.4 - 4.7 (m, 27H), 4.1 (m, 1H), 3.8 - 3.9 (m, 17H), 3.6 - 3.7 (m, 11H), 3.3 (m, 
3H, OMe); 13C NMR (CDCl3, 100 MHz) δ 138.93, 138.88, 138.78, 138.71, 138.6, 
138.56, 138.51, 138.4, 138.1, 128.66 (3 carbons), 128.60 (5 carbons), 128.54 (4 carbons), 
128.50 (5 carbons), 128.45 (3 carbons), 128.15 (2 carbons), 128.11 (5 carbons), 128.08 (5 
carbons), 127.9 (2 carbons), 127.86 (3 carbons), 127.81 (5 carbons), 127.7 (2 carbons), 
127.6, 99.9, 99.2, 98.1, 80.5, 79.8, 79.4, 77.4, 75.2 (3 carbons), 74.9, 74.7, 74.6, 74.4, 
73.6, 73.1, 72.7, 72.3, 71.7 (2 carbons), 71.6 (2 carbons), 71.3, 69.0, 68.1, 66.3, 66.1, 
54.9; ESI/APCI Calcd for C82H92O16N ([M+NH4]+) m/z 1346.6416; measured m/z 
1346.6383. 
Methyl-2,3,4-tri-O-benzyl-6-O-(6-O-(3,4,6-tri-O-benzyl-β-D-mannopyra-
nosyl)-2,3,4-tri-O-benzyl-α-D-mannopyranosyl)-α-D-mannopyranoside (epi-95). 1H 
NMR (CDCl3, 400 MHz) δ 7.5 (m, 2H), 7.2 - 7.4 (m, 41H), 7.1 (m, 2H), 5.31 (s, 1H), 
5.07 (s, 1H), 4.99 (d, J = 12.2 Hz, 1H), 4.9 (d, J = 11.0 Hz, 1H), 4.89 (d, J = 11.4 Hz, 
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1H), 4.8 (m, 2H), 4.6 – 4.7 (m, 4H) 4.68 (m, 4H), 4.4 - 4.6 (m, 13H), 4.1 - 4.2 (m, 3H), 
3.9 - 3.7 (m, 14H), 3.7 (m, 1H), 3.6 (m, 2H), 3.5 (m, 1H), 3.3 (m, 1H), 3.2 (m, 3H, OMe); 
13C NMR (CDCl3, 75 MHz) δ 138.9, 138.7, 138.6 (2 carbons), 138.5, 138.4, 138.2 (2 
carbons), 138.0, 128.7 (2 carbons), 128.5 (2 carbons), 128.4 (8 carbons), 128.34 (2 
carbons), 128.31 (2 carbons), 128.2 (2 carbons), 128.1 (2 carbons), 128.0 (2 carbons), 
127.9 (2 carbons), 127.8 (4 carbons), 127.7 (4 carbons), 127.6 (4 carbons), 127.5, 
(2carbons), 102.2, 100.3, 98.9, 82.2, 80.4, 79.4, 77.9, 77.3 (2 carbons), 75.3, 75.1, 75.0 (3 
carbons), 74.8, 74.4 (2 carbons), 74.3, 73.8, 73.4 (3 carbons), 72.7, 72.0, 71.4 2 (carbons) 
71.3 (2 carbons), 69.0, 68.9, 67.8, 66.8, 54.7; ESI/APCI Calcd for C82H92O16N 
([M+NH4]+) m/z 1346.6416; measured m/z 1346.6401. 
Methyl-6-O-(6-O-(α-D-mannopyranosyl)-α-D-mannopyranosyl)-α-D-manno-
pyranoside (96). 1H NMR (D2O, 400 MHz) δ 4.80 (s, 1H), 4.78 (s, 1H), 4.70 (s, 2H), 
4.64 (s, 1H), 3.8 (m, 7H), 3.7 (m, 6H), 3.6 (m, 10H), 3.29 (s, 3H, OMe), 3.23 (d, J = 2.2 
Hz, 1H), 2.90 (s, 1H), 2.74 (s, 1H); 13C NMR (D2O, 100 MHz) δ 101.2, 99.6, 99.4, 72.9, 
70.9 (2 carbons), 70.8, 70.7 (2 carbons), 70.1 (3 carbons), 66.9, 66.7, 66.6, 65.7, 65.6, 
61.1, 54.9; ESI/APCI Calcd for C19H34O16Na ([M+Na]+)  m/z 541.1745; measured m/z 
541.1736. 
Methyl 2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-3,4,6-tri-O-
benzyl-α-D-mannopyranoside (97). 1H NMR (CDCl3, 300 MHz) δ 7.1 - 7.5 (m, 30H), 
5.53 (dd, J = 3.1, 1.8 Hz, 1H), 5.07 (d, J = 1.8 Hz, 1H), 4.84 (d, J = 10.9 Hz, 1H), 4.83 
(d, J = 10.9 Hz, 1H), 4.76 (d, J = 2.0 Hz, 1H), 4.6 - 4.7 (m, 4H), 4.4 - 4.6 (m, 5H), 4.39 
(d, J = 10.9 Hz, 1H), 3.7 - 4.0 (m, 11H), 3.24 (s, 3H), 2.10 (m, 3H); 13C NMR (CDCl3, 75 
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MHz) δ 170.2, 138.61, 138.58, 138.55, 138.46, 138.29, 138.09, 128.48 (3 carbons), 
128.40 (5 carbons), 128.28 (2 carbons), 128.15 (2 carbons), 127.97 (3 carbons0, 127.8, 
127.68 (3 carbons), 127.61 (3 carbons), 127.5 (3 carbons), 99.8, 99.6, 79.8, 78.2, 77.3, 
75.2 (2 carbons), 74.7 (3 carbons), 74.4, 73.5 (2 carbons), 73.4 (2 carbons), 72.1 (2 
carbons), 72.0 (2 carbons), 71.9 (2 carbons), 71.7 (2 carbons), 54.8, 21.2; HRFAB Calcd 
for C57H62O12Na ([M+Na]+) m/z 961.4133; measured m/z 961.4148. 
Methyl 3,4,6-tri-O-benzyl-2-O-(3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-α-
D-mannopyranoside (98). 1H NMR (CDCl3, 300 MHz) δ 7.4 (m, 30H), 5.16 (s, 1H, H-
1'), 4.8 – 4.9 (m, 3H), 4.7 (m, 1H), 4.6 – 4.7 (m, 4H), 4.5 – 4.6 (m, 5H), 4.1 (m, 1H), 4.0 
(m, 1H), 3.7 – 4.0 (m, 11H), 3.25 (s, 3H, O Me), 2.44 (d, J = 1.7 Hz, 1H, OH); 13C NMR 
(CDCl3, 75 MHz) δ 138.7, 138.6, 138.5, 138.4, 138.3, 138.1, 128.6 (3 carbons), 128.4 (7 
carbons), 127.99 (5 carbons), 127.96 (6 carbons), 127.8 (3 carbons), 127.7 (2 carbons), 
127.6, 127.56 (2 carbons), 127.50, 101.2, 99.9, 80.1, 79.9, 75.2, 75.1, 74.9, 74.8, 74.5, 
73.5, 73.4, 72.3, 72.2, 71.8, 71.7, 69.4, 69.3, 68.6, 54.8; ESI/APCI Calcd for 
C55H60O11Na ([M+Na]+) m/z 919.4033; measured m/z 919.4030. 
Methyl 2-O-(2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-3,4,6-
tri-O-benzyl-α-D-mannopyranosyl)-3,4,6-tri-O-benzyl-α-D-mannopyranoside (99). 
1H NMR (CDCl3, 300 MHz) δ 7.1 -7.4 (m, 45H), 5.52 (d, J = 2.1 Hz, 1H), 5.18 (s, 1H), 
5.04 (d, J = 1.7 Hz, 1H), 4.8 (m, 4H), 4.6 – 4.7 (m, 3H), 4.61 (m, 1H), 4.5 (m, 4H), 4.5 
(m, 2H), 4.4 - 4.5 (m, 3H), 4.30 (d, J = 12.0 Hz, 1H), 4.1 (m, 1H), 3.8 – 4.0 (m, 6H), 3.6 
– 3.8 (m, 10H), 3.51 (d, J = 10.3 Hz, 1H), 3.22 (s, 3H, OMe), 2.12 (s, 3H, CH3); 13C 
NMR (CDCl3, 100 MHz) δ 170.1, 138.65 (2 carbons), 137.54 (3 carbons), 138.4 (2 
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carbons), 138.25, 138.1, 128.5 (8 carbons), 128.4 (3 carbons), 128.36 (3 carbons), 128.2 
(3 carbons),128.10 (3 carbons), 127.97 (3 carbons), 127.96 (3 carbons), 127.90 (3 
carbons), 127.88 (3 carbons), 127.7 (5 carbons), 127.68 (4 carbons), 127.5 (3 carbons), 
100.8, 99.9, 99.8, 79.9, 78.3 (2 carbons), 77.4 (4 carbons), 75.3 (2 carbons), 75.2, 74.95, 
74.94, 73.56 (3 carbons), 72.3, 72.29, 72.25, 72.1 (2 carbons), 71.8, 69.5 (2 carbons), 
68.9 (2 carbons), 54.8, 21.4; ESI/APCI Calcd for C84H94NO17 ([M+NH4]+) m/z 
1388.6522; measured m/z 1388.6519. 
Methyl-3,4,6-tri-O-benzyl-2-O-(2-O-(3,4,6-tri-O-benzyl-α-D-mannopyra-
nosyl)-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-α-D-mannopyranoside (100). 1H 
NMR (CDCl3, 400 MHz) δ 7.2 - 7.4 (m, 45H), 5.25 (d, J = 1.6 Hz, 1H), 5.15 (d, J = 1.5 
Hz, 1H), 4.8 (m, 4H), 4.70 (d, J = 12.1 Hz, 1H), 4.68 (d, J = 12.3 Hz, 1H), 4.6 (m, 4H), 
4.5 (m, 6H), 4.49 (d, J = 10.7 Hz, 1H), 4.47 (d, J = 11.6 Hz, 1H), 4.36 (d, J = 12.2 Hz, 
1H), 4.14 (s, 2H), 4.00 (t, J = 2.4 Hz, 1H), 3.9 (m, 5H), 3.8 (m, 2H), 3.8 (m, 4H), 3.7 (m, 
2H), 3.6 (m, 1H), 3.6 (m, 1H), 3.25 (s, 3H, OMe), 2.46 (s, 1H, OH); 13C NMR (CDCl3, 
100 MHz) δ 138.8 (2 carbons), 138.7 (3 carbons), 138.6, 138.5, 138.4, 138.3, 128.7 (4 
carbons), 128.6 (2 carbons), 128.5 (8 carbons), 128.1 (8 carbons), 128.0 (5 carbons), 
127.9 (2 carbons), 127.81 (2 carbons), 127.8 (2 carbons), 127.7 (5 carbons), 127.6 (2 
carbons), 101.2, 101.0, 99.9, 80.2, 79.6 (2 carbons), 77.5, 75.3, 75.2 (3 carbons), 75.2 (3 
carbons), 74.9, 74.5, 73.55 (2 carbons), 73.50 (3 carbons), 72.54, 72.5, 72.3, 71.9, 71.8, 
71.7, 69.8, 69.6, 69.1, 68.7, 54.7; ESI/APCI Calcd for C82H92NO16 ([M+NH4]+) m/z 
1346.6391; measured m/z 1346.6397. 
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Methyl-2-O-(2-O-(α-D-mannopyranosyl)-α-D-mannopyranosyl)-α-D-manno-
pyranoside (101). 1H NMR (D2O, 400 MHz) δ 5.15 (d, J = 1.0 Hz, 1H), 4.90 (d, J = 1.4 
Hz, 1H), 4.85 (d, J = 1.0 Hz, 1H), 4.68 (s, 2H), 3.93 (s, 1H), 3.92 (s, 1H), 3.4 – 3.8 (m, 
22H), 3.26 (s, 3H, OMe); 13C NMR (D2O, 100 MHz) δ 102.4, 100.8, 99.4, 78.9, 78.7, 
73.4 (2 carbons), 72.7, 70.5, 70.3, 70.1 (2 carbons), 67.2, 67.1, 66.9, 61.3, 61.2, 61.1, 
55.0; ESI/APCI Calcd for C19H34O16Na ([M+Na]+) m/z 541.1745; measured m/z 
541.1733. 
Benzyl-2-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranoside (102).115 1H NMR 
(CDCl3, 400 MHz) δ 7.6 - 7.3 (m, 18H), 7.3 (m, 2H), 5.51 (s, 1H, H-2), 5.03 (s, 1H, H-1), 
4.94 (d, J = 10.7 Hz, 1H), 4.78 (d, J = 11.4 Hz, 2H), 4.77 (d, J = 12.1 Hz, 1H), 4.6 - 4.5 
(m, 4H), 4.11 (dd, J = 3.1, 8.8 Hz, 1H, H-2), 4.0 - 3.9 (m, 3H), 3.78 (broad, 1H), 2.21 (s, 
3H, CH3); 13C NMR (CDCl3, 100 MHz) δ 170.6, 138.7, 138.5, 138.3, 137.2, 128.7, 
128.6, 128.6, 128.3, 128.2, 128.2, 128.0, 128.9, 127.9, 127.8, 97.4, 78.6, 75.5, 74.7, 73.7, 
72.1, 71.9, 69.6, 69.2, 69.1. 
Benzyl-3,4,6-tri-O-benzyl-α-D-mannopyranoside (103).115 1H NMR (CDCl3, 
400 MHz) δ 7.4 - 7.2 (m, 18H), 7.2 – 7.1 (m, 2H), 5.03 (d, J = 1.4 Hz, 1H, H-1), 4.86 (d, 
J = 10.8 Hz, 1H),  4.75 (d, J = 11.8 Hz, 1H), 4.71 (s, 2H), 4.69 (d, J = 11.2 Hz, 1H), 4.58 
(d, J = 12.2 Hz, 1H),   4.54 (d, J = 10.8 Hz, 1H), 4.52 (d, J = 11.8 Hz, 1H), 4.11 (dd, J = 
2.5, 4.4 Hz, 1H), 3.97 (m, 1H), 3.9 (m, 2H), 3.79 (dd, J = 3.9, 10.6 Hz,  1H), 3.74 (dd, J = 
1.2, 10.9 Hz, 1H), 2.50 (d, J = 2.5 Hz, 1H, OH); 13C NMR (CDCl3, 75 MHz) δ 138.4, 
138.0, 137.3, 128.6, 128.5, 128.5, 128.4, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7, 98.5, 
80.4, 75.3, 74.4, 73.6, 72.1, 71.4, 69.2, 69.0, 68.5. 
114 
 
Benzyl 2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-3,4,6-tri-O-
benzyl-α-D-mannopyranoside (104). 1H NMR (CDCl3, 400 MHz) δ 7.1 - 7.4 (m, 35H) , 
5.59 (d, J = 0.9 Hz, 1H, H-2), 5.11 (s, broad, 1H, H-1'), 5.00 (d, J = 0.9 Hz, 1H, H-1), 
4.90 (d, J = 10.7 Hz, 1H), 4.88 (d, J = 10.8 Hz, 1H), 4.6 - 4.7 (m, 6H), 4.5 – 4.6 (m, 2H), 
4.3 -4.5 (m, 4H), 4.08 (broad, 1H), 3.9 – 4.0 (m, 2H), 3.7 - 3.9 (m, 7H), 3.59 (d, J = 10.1 
Hz, 1H), 2.16 (s, 3H, CH3); 13C NMR (CDCl3, 100 MHz) δ 170.4, 138.75, 138.71, 138.6 
(2 carbons), 138.4, 138.2, 137.5, 128.6 (4 carbons), 128.55 (5 carbons), 128.5 (4 
carbons), 128.41 (2 carbons), 128.3 (2 carbons), 128.1 (2 carbons), 128.06 (2 carbons), 
128.02 (3 carbons), 127.9 (2 carbons), 127.8, 127.76 (4 carbons), 127.71 (2 carbons), 
127.6, 99.9, 98.2, 79.9, 78.4, 75.4, 75.3, 75.1, 74.9, 74.5, 73.6, 73.5, 72.3,  72.2, 72.0, 
69.4, 69.2, 69.0, 68.9 (2 carbons), 21.4; ESI/APCI Calcd for C63H70NO12 ([M+NH4]+) 
m/z 1032.4898; measured m/z 1032.4892. 
Benzyl 3,4,6-tri-O-benzyl-2-O-(3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-α-D-
mannopyranoside (105). 1H NMR (CDCl3, 300 MHz) δ 7.1 - 7.4 (m, 35H), 5.16 (s, 1H), 
5.02 (s, 1H), 4.8 - 4.9 (m, 2H), 4.6 – 4.7 (m, 4H), 4.6 (m, 1H), 4.4 – 4.6 (m, 6H), 4.36 (d, 
J = 12.0 Hz, 1H), 4.15 (s, 1H), 4.09 (s, 1H), 3.9 (m, 1H), 3.7 – 3.9 (m, 6H), 3.6 – 3.7 (m, 
2H), 3.58 (d, J = 10.7 Hz, 1H), 2.42 (d, J = 2.1 Hz, 1H, OH); 13C NMR (CDCl3, 75 MHz) 
δ 138.7, 138.5 (2 carbons), 138.3 (2 carbons), 138.1, 137.4, 128.7, 128.6 (3 carbons), 
128.5 (5 carbons), 128.4 (5 carbons), 128.1, 128.09 (3 carbons), 127.9, 127.86 (3 
carbons), 127.82 (3 carbons), 127.7 (4 carbons), 127.6 (2 carbons), 127.5, 101, 98.3, 
80.1, 79.8, 75.3, 75.07, 75.0, 74.9, 74.4 (2 carbons), 73.5, 73.4, 72.4, 72.3, 72.2, 71.6, 
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69.4, 69.1 (2 carbons), 69.0, 68.6 (2 carbons); ESI/APCI Calcd for C61H64O11N 
([M+NH4]+) m/z 995.4346; measured m/z 995.4354. 
Benzyl 2-O-(2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-3,4,6-
tri-O-benzyl-α-D-mannopyranosyl)-3,4,6-tri-O-benzyl-α-D-mannopyranoside (106). 
1H NMR (CDCl3, 400 MHz) δ 7.1 - 7.4 (m, 50H), 5.55 (dd, J = 1.8, 3.2 Hz, 1H, H-2"), 
5.19 (d, J = 1.6 Hz, 1H, H-1"), 5.06 (d, J = 1.6 Hz, H-1'), 5.02 (d, J = 1.7 Hz, 1H, H-1), 
4.8 - 4.9 (m, 3H), 4.71 (d, J = 11.6 Hz, 2H), 4.5 - 4.7 (m, 9H), 4.5 (m, 1H), 4.41 (d, J = 
10.9 Hz, 1H), 4.33 (d, J =11.7 Hz, 1H), 4.30 (d, J =12.0 Hz, 1H), 4.1 (m, 1H), 4.03 (m, 
2H), 3.8 - 3.9 (m, 6H), 3.7 - 3.8 (m, 5H), 3.6 - 3.7 (m, 5H), 3.52 (d, J = 10.5 Hz, 1H), 
2.14 (s, 3H, CH3); 13C NMR (CDCl3, 100 MHz) δ 170.3, 138.8 (2 carbons), 138.7 (2 
carbons), 138.6 (2 carbons), 138.5, 138.4, 138.2, 137.6, 128.6 (3 carbons), 128.5 (6 
carbons), 128.4 (3 carbons), 128.4 (2 carbons), 128.2 (4 carbons), 128.0 (4 carbons), 
127.9 (4 carbons), 127.8 (3 carbons), 127.7 (5 carbons), 127.7 (6 carbons), 100.9, 99.6, 
98.4, 79.7 (2 carbons), 79.5, 78.4 (2 carbons), 77.5 (3 carbons), 75.3 (4 carbons), 75.2 (2 
carbons), 75.1, 74.9, 74.4, 73.5, (5 carbons) 72.3, (2 carbons), 72.2, 72.1, (3 carbons), 
69.5 (2 carbons), 69.3, 68.9 (3 carbons), 21.9;  ESI/APCI Calcd for C90H98NO17 
([M+NH4]+) m/z 1464.6835; measured m/z 1464.6838. 
Benzyl-3,4,6-tri-O-benzyl-2-O-(2-O-(3,4,6-tri-O-benzyl-α-D-mannopyra-
nosyl)-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-α-D-mannopyranoside (107). 1H 
NMR (CDCl3, 300 MHz) δ 7.1 - 7.4 (m, 50H), 5.21 (d, J = 1.7 Hz, 1H, H-1"), 5.13 (d, J 
= 1.4 Hz, 1H, H-1'), 5.03 (d, J = 1.7 Hz, 1H, H-1), 4.82 (d, J =11.0 Hz, 1H), 4.80 (d, J = 
10.7 Hz, 1H), 4.7 - 4.4 (m, 16H ), 4.34 (d, J = 11.7 Hz, 1H), 4.31 (d, J = 12.0 Hz, 1H), 
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4.12 (s, 2H), 4.02 (s, 1H), 3.8 - 3.9 (m, 7H ), 3.5 - 3.8 (m, 8H), 2.36 (d, J = 2.4 Hz, 1H, 
OH); 13C NMR (CDCl3, 75 MHz) δ 138.7 (2 carbons), 138.6 (2 carbons), 138.5, 138.4 (2 
carbons), 138.3, 138.1, 137.5, 128.55 (3 carbons), 128.5 (2 carbons), 128.4 (9 carbons), 
128.1 (2 carbons), 127.9 (8 carbons), 127.86 (3 carbons), 127.79 (4 carbons), 127.72 (5 
carbons), 127.6 (5 carbons), 127.5 (2 carbons), 101.1, 101.0, 98.3, 80.1, 79.5, 77.3 (2 
carbons), 75.4, 75.2 (2 carbons), 75.1, 75.0, 74.9 (2 carbons), 74.4, 73.4 (2 carbons), 73.3 
(3 carbons), 72.4 (2 carbons), 72.3, 72.2 (2 carbons), 72.1, 71.96, 71.67, 69.5, 69.4, 69.16 
(2 carbons), 69.03, 68.63 (2 carbons); ESI/APCI Calcd for C88H96NO16 ([M+NH4]+) m/z 
1422.6729; measured m/z 1422.6729. 
2-O-(2-O-(α-D-mannopyranosyl)-α-D-mannopyranosyl)-D-mannopyranose 
(108). 1H NMR (D2O, 400 MHz) δ 5.26 (s, 1H), 5.19 (s, 1H), 4.93 (s, 2H), 3.5 – 4.0 (m, 
28H); 13C NMR (D2O, 100 MHz) δ 102.4, 100.7, 92.6, 79.5, 78.7, 73.4 (2 carbons), 72.6, 
70.5, 70.1 (3 carbons), 67.2 (2 carbons), 66.9, 61.2 (2 carbons), 61.1; ESI/APCI Calcd for 
ESI/APCI Calcd for C18H32O16Na ([M+Na]+) m/z 527.1588; measured m/z 527.1577. 
Methyl 3-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-2-O-benzyl-
4,6-O-benzylidene-α-D-mannopyranoside (109). 1H NMR (CDCl3, 400 MHz) δ 7.2 - 
7.5 ( m, 25H), 5.64 (s, 2H, H-1', H-2), 5.33 (s, 1H, H-1), 4.90 (d, J = 10.8 Hz, 2H), 4.74 
(d, J = 12.2 Hz), 4.72 (s, 1H, H-1), 4.6 - 4.7 (m, 5H), 4.4 - 4.5 (m, 4H),  4.2 - 4.3 (m, 4H), 
4.00 (dd, J = 3.2, 12.1 Hz, 2H), 3.6 - 3.9 (m, 9H ), 3.31 (s, 3H, OMe). 2.11 (s, 3H, CH3); 
13C NMR (CDCl3, 100 MHz) δ 170.2, 138.8, 138.6, 138.1, 138.0, 137.6, 128.9, 128.7, 
128.5, 128.4 (3 carbons), 128.30 (2 carbons), 128.28 (2 carbons), 128.0 (4 carbons), 
127.9 (4 carbons), 127.7 (2 carbons), 126.2 (2 carbons), 101.4, 100.5, 99.0, 79.3, 78.1, 
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77.4 (4 carbons), 75.2, 74.5, 73.8, 73.6, 73.4, 72.4, 71.7, 68.9, 68.4, 64.1, 60.6, 55.0, 
21.2; ESI/APCI Calcd for C50H54O12Na ([M+Na]+) m/z 869.3513; measured m/z 
869.3507. 
Methyl-3-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-2,4-di-O-
benzyl-α-D-mannopyranoside (110). The starting material, methyl 3-O-(2-O-acetyl-
3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-2-O-benzyl-4,6-O-benzylidene-α-D-
mannopyranoside (0.72 g, 0.85 mmol) and cupper triflate (0.03 g, 0.085 mmol) were 
dissolved in  10 mL dichloromethane and borane tetrahydrofuran complex (1.0 mL) was 
added and the mixture was stirred for 2 hr at room temperature. When complete, reaction 
was quenched with methanol, filtered off precipitate, concentrated and purified resulting 
residue. Product (0.71 g) was obtained in 98 % yield. 1H NMR (CDCl3, 400 MHz) δ 7.2 - 
7.4 ( m, 25H), 5.52 (d, J = 1.7 Hz, 1H, H-2), 5.23 (s, 1H, H-1), 4.90 (d, J = 11.2 Hz, 1H), 
4.81 (d, J = 10.9 Hz, 1H), 4.6 - 4.7 (m, 8H), 4.4 - 4.5 (m, 4H), 4.1 - 4.2 (m, 3H), 3.6 – 4.0 
(m); 3.28 (s, 3H, OMe), 2.11 (s, 3H, CH3); 13C NMR (CDCl3, 100 MHz) δ 170.3, 138.8, 
138.5, 138.3, 138.1, 138.0, 128.7 (5 carbons), 128.6 (2 carbons), 128.4 (5 carbons), 128.3 
(2 carbons), 128.2 (3 carbons), 128.0, 127.9 (2 carbons), 127.88 (4 carbons), 127.74 (2 
carbons), 127.71, 99.8, 98.9, 78.26, 78.1, 77.4, 75.4, 75.2, 75.14, 74.6, 73.7, 72.7, 72.4, 
72.3, 71.9, 69.4, 68.9, 62.3, 55.04, 21.2; ESI/APCI Calcd for C50H56O12Na ([M+Na]+) 
m/z 871.3664; measured m/z 871.3650. 
Methyl 3-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-6-O-(3,6-di-
O-acetyl-2,4-di-O-benzyl-α-D-mannopyranosyl)-2,4-di-O-benzyl-α-D-mannopyra-
noside (111). The acceptor, methyl 3-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D-
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mannopyranosyl)-2,4-di-O-benzyl-α-D-mannopyranoside (0.70 g, 0.836 mmol) and 
donor,  phenyl 3,4-di-O-acetyl-2,4-O-dibenzyl-1-thio-α-D-mannopyranoside (0.50 g, 
0.92 mmol) were dissolved in 8 mL dichloromethane.  NIS (0.226 g, 1.00 mmol) and 
TMSOTf (22.71 µL, 0.125 mmol) were added and the mixture was sonicated for 10 min. 
TLC showed reaction is complete. The reaction mixture was quenched by adding sodium 
thiosulfate and sodium bicarbonate solid and letting it stir for some hours or until solution 
turn yellow. The solid residue was filtered off and washed with excess ethyl acetate, then 
the filtrate was concentrated, and purified in a chromatography column. The product 
(1.05 g) was obtained in 98% yield. 1H NMR (CDCl3, 400 MHz) δ 7.1 - 7.3 (m, 35H), 
5.51 (s, 1H, H-2"), 5.31 (s, 1H, H-1"), 5.21 (s, 1H, H-3"'), 5.11 (d, J = 1.8 Hz, 1H, H-1"), 
4.88 (d, J = 10.9 Hz, 1H), 4.83 (d, J = 11.1 Hz, 1H), 4.5 - 4.7 (m, 9H), 4.4 - 4.5 (m, 3H), 
4.39 (d, J = 12.2 Hz, 1H), 4.1 (m, 1H), 3.6 – 4.0 (m, 15H), 3.25 (s, 3H, OMe), 2.08 (s, 
3H, CH3), 2.05 (s, 3H, CH3), 1.98 (s, 3H, CH3); 13C NMR (CDCl3, 75 MHz) δ 170.9, 
170.1 (2 carbons), 138.7, 138.4, 138.3, 138.2, 138.1, 138.07, 137.9, 128.5 (7 carbons), 
128.4 (2 carbons), 128.3 (6 carbons), 127.9 (4 carbons), 127.8 (3 carbons), 127.7 (2 
carbons), 127.65 (3 carbons), 127.6 (3 carbons), 99.8, 98.6, 97.7, 78.1 (2 carbons), 77.9, 
77.3 (6 carbons), 76.3, 75.2 (2 carbons), 74.9, 74.8, 74.4, 73.8, 73.5, 73.3, 72.7, 72.6, 
72.3, 71.9 (2 carbons), 69.8, 69.2, 68.8, 63.4, 54.8, 21.2, 21.1, 20.9; ESI/APCI Calcd for 
C74H82O19Na ([M+Na]+) m/z 1297.5348; measured m/z 1297.5328. 
Methyl-6-O-(2,4-di-O-benzyl-α-D-mannopyranosyl)-3-O-(3,4,6-tri-O-benzyl-
α-D-mannopyranosyl)-2,4-di-O-benzyl-α-D-mannopyranoside (112). 1H NMR 
(CDCl3, 400 MHz) δ 7.2 - 7.4 (m, 35H), 5,26 (s, 1H), 5.15 (s, 1H), 4.94 (d, J = 11.1 Hz, 
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1H), 4.86 (d, J = 11.1 Hz, 1H), 4.77 (d, J = 11.0 Hz, 1H), 4.5 - 4.7 (m, 11H), 4.42 (d, J = 
11.8 Hz, 1H), 4.1 (m, 1H), 3.6 – 4.0 (m, 18H), 3.27 (s, 3H, OMe), 2.39 (s, 1H, OH), 2.33 
(d, J = 9.4 Hz, 1H, OH); 13C NMR (CDCl3, 100 MHz) δ 138.7, 138.6, 138.5, 138.4, 
138.2, 138.0 (2 carbons), 128.7 (5 carbons), 128. 6 (4 carbons), 128.4 (4 carbons), 128.1 
(2 carbons), 128.0 (2 carbons), 127.97 (3 carbons), 127.9 (4 carbons), 127.79 (4 carbons), 
127.76 (3 carbons), 127.6 (2 carbons), 127.56, 101.5, 98.7, 97.5, 80.2, 78.9, 77.7, 76.7, 
75.2 (4 carbons), 75.0, 74.6, 73.7 (2 carbons), 72.9, 72.7, 72.3, 72.2, 71.9 (2 carbons), 
71.6, 69.5, 68.9, 66.2, 62.4, 55.0; ESI/APCI Calcd for C68H76O16Na ([M+Na]+) m/z 
1171.5031; measured m/z 1171.5005. 
Methyl 3-O-(2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-3,4,6-
tri-O-benzyl-α-D-mannopyranosyl)-6-O-(3,6-di-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-
D-mannopyranosyl)-2,4-di-O-benzyl-α-D-mannopyranosyl)-2,4-di-O-benzyl-α-D-
mannopyranoside (113). 1H NMR (CDCl3, 300 MHz) δ 7.4 – 7.1 (m, 80H), 5.51 (s, 
broad, 3H), 5.21 (s, 2H), 5.01 (s, 1H), 4.98 (s, 1H), 4.96 (s, 1H),  4.7 – 4.9 (m, 5H), 4.72 
(d, J = 11.3 Hz, 2H), 4.3 – 4.7 (m, 28H), 4.30 (d, J = 12.0 Hz, 2H), 4.25 (d, J = 12.0 Hz, 
1H), 4.0 – 4.2 (m, 3H), 3.4 – 4.0 (m, 28H), 3.35 (d, J = 10.3 Hz, 1H), 3.17 (s, 3H, OMe), 
2.14 (s, 3H, CH3), 2.10 (s, 3H, CH3), 2.06 (s, 3H, CH3); 13C NMR (CDCl3, 75 MHz) δ 
170.3, 170.2 (2 carbons), 138.8 (2 carbons), 138.7, 138.6 (2 carbons), 138.5 (2 carbons), 
138.3 (4 carbons), 138.18 (2 carbons), 138.16, 137.96, 137.89, 128.6 (2 carbons), 128.47 
(8 carbons), 128.40 (8 carbons), 128.3 (6 carbons), 128.29 (10 carbons), 128.16 (3 
carbons), 127.89 (8 carbons), 127.86 (6 carbons), 127.78 (3 carbons), 127.67 (4 carbons), 
127.56 (4 carbons), 127.55 (5 carbons), 127.48 (4 carbons), 127.29 (2 carbons), 101.2, 
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99.8, 99.5, 98.4, 98.1, 97.0, 79.8, 78.3 (2 carbons), 78.2 (2 carbons), 77.8 (2 carbons), 
77.3 (3 carbons), 75.09 (2 carbons), 74.98 (3 carbons), 74.8 (2 carbons), 74.76, 74.74, 
74.16 (4 carbons), 73.46 (2 carbons), 73.44 (3 carbons), 73.25 (2 carbons), 72.8, 72.25 (4 
carbons), 72.12 (3 carbons), 71.92 (2 carbons), 72.90 (2 carbons), 71.63 (2carbons), 71.5, 
71.3 (2 carbons), 71.0, 68.8 (3 carbons), 68.4 (2 carbons), 54.8, 21.26 (2 carbons), 21.2; 
ESI/APCI Calcd for C155H170O34N ([M+NH4]+) m/z 2589.1599; measured m/z 
2589.1604. 
Methyl-3-O-(2-O-(3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-3,4,6-tri-O-
benzyl-α-D-mannopyranosyl)-6-O-(3,6-di-O-(3,4,6-tri-O-benzyl-α-D-mannopyra-
nosyl)-2,4-di-O-benzyl-α-D-mannopyranosyl)-2,4-di-O-benzyl-α-D-
mannopyranoside (114). 1H NMR (CDCl3, 300 MHz) δ 7.1 – 7.4 (m, 80H), 5.25 (s, 2H), 
5.20 (s, 1H), 5.09 (s, 1H), 5.05 (s, 1H), 4.82 (s, 1H), 4.8 (m, 6H), 4.4 – 4.7 (m, 35H), 4.34 
(d, J = 11.7 Hz, 1H), 4.31 (d, J = 12.4 Hz, 1H), 4.1 (m, 4H), 4.05 (m, 2H), 3.4 – 4.0 (m, 
40H), 3.18 (s, 3H, OCH3), 2.34 (s, broad, 3H, OH); ESI/APCI Calccd for C149H160O31Na 
([M+Na]+) m/z 2468.0836; measured m/z 2468.0746. 
6'-Azidohexyl 2,3,4,6-tetra-O-acetyl-α-D-mannopyranoside (115).78 1H NMR 
(CDCl3, 400 MHz) δ 5.37 (dd, J = 3.4, 9.9 Hz, 1H, H-3), 5.28 (t, J = 9.9 Hz, 1H, H-4), 
5.24 (dd, J = 1.4, 3.4 Hz, 1H, H-2), 4.80 (d, J = 1.4 Hz, 1H, H-1), 4.29 (dd, J = 5.4, 12.2 
Hz, 1H, H-6), 4.10 (dd, J = 2.3, 12.2 Hz, 1H, H-6′), 3.98 (m, 1H, H-5), 3.68 (m, 1H), 3.45 
(m, 1H), 3.28 (t, J = 6.9 Hz, 2H), 2.16 (s, 3H), 2.11 (s, 3H), 2.05 (s, 3H), 2.00 (s, 3H), 
1.62 (m, 4H), 1.40 ( m, 4H); 13C NMR (CDCl3, 100 MHz) δ 170.8, 170.3, 170.1, 169.9, 
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97.8, 69.9, 69.3, 68.7, 68.5, 66.5, 62.7, 51.5, 29.3, 28.9, 25.9, 25.5, 21.1, 20.9, 20.8 (3 
carbons). 
6'-Azidohexyl 2-O-benzyl-4,6-O-benzylidene-α-D-mannopyranoside (117). 
The starting material, 6′-azidohexyl-4,6-O-benzylidene-α-D-mannopyranoside (1.35 g, 
3.43 mmol) was dissolved in 15 mL dichloromethane and tetrabutylammonium hydrogen 
sulfate (0.35 g, 1.03 mmol) was added followed by benzyl bromide (0.45 ml, 3.77 mmol) 
and 1N NaOH (6 mL). The mixture was refluxed for 15 hr, and then it was diluted with 
dichloromethane, and washed with water, and brine. The mixture was then dried over 
Na2SO4, filtered, concentrated and purification gave product (0.71 g) in 58% yield. A 
byproduct 118 was also obtained and some starting material was left. 1H NMR (CDCl3, 
300 MHz) δ 7.5 - 7.6 (m, 2H), 7.3 - 7.4 ( m, 8H ), 5.59 (s, 1H, H-1’), 4.84 (d, J = 1.2 Hz, 
H-1, 1H,), 4.76 (d, J = 11.8 Hz, 1H), 4.72 (d, J = 11.8 Hz, 1H), 4.26 (dd, J = 3.7, 9.1 Hz, 
H-6, 1H), 4.10 (m, 1H, H-5), 3.93 (t, J = 9.0 Hz, H-4, 1H), 3.8 - 3.7 (m, 3H), 3.6 (m, 1H), 
3.3 (m, 1H), 3.28 (t, J = 6.9 Hz. 2H), 2.38 (d, 1H, OH), 1.61 (m, 4H), 1.39 (m, 4H); 13C 
NMR (CDCl3, 100 MHz) δ 137.9, 137.5, 129.3, 128.8 (2 carbons), 128.5 (2 carbons), 
128.3, 128.2 (2 carbons), 126.4 (2 carbons), 102.3, 98.5, 79.8, 78.9, 73.9, 69.0, 68.9, 
67.9, 63.7, 51.6,  29.4,  28.9,  26.7,  25.9; ESI/APCI Calcd for C26H33N3O6Na ([M+Na]+) 
m/z 506.2267; measured m/z 506.2281. 
6'-Azidohexyl 3-O-benzyl-4,6-O-benzylidene-α-D-mannopyranoside (118). 
Please refer to compound 117. 1H NMR (CDCl3, 400 MHz) δ 7.5 (m, 2H), 7.4 - 7.3 (m, 
8H) 5.64 (s, 1H, H-1'), 4.90 (d, J = 11.9 Hz, 1H), 4.88 (s, 1H, H-1), 4.74 (d, J = 11.8 Hz, 
1H), 4.28 (m, 1H), 4.11 (t, J = 9.2 Hz, 1H, H-4), 4.07 (dd, J = 1.7, 3.2 Hz, 1H, H-2), 3.94 
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(dd, J = 3.4, 9.6 Hz, 1H, H-3), 3.8 (m, 2H), 3.7 (m, 1H), 3.4 (m, 1H), 3.28 (t, J = 6.9 Hz, 
2H), 2.67 (s, 1H, OH), 1.6 (m, 4H), 1.4 (m, 4H); 13C NMR (CDCl3, 100 MHz) δ 138.3, 
137.7, 129.1, 128.7, 128.4, 128.1, 127.9, 126.4, 126.2, 101.7, 100.1, 76.1, 75.9, 73.3, 
70.3, 69.1, 67.9, 63.5, 51.6, 29.5, 28.9, 26.7, 25.9; ESI/APCI Calcd for C26H33N3O6Na 
([M+Na]+) m/z 506.2267; measured m/z 506.2273. 
6'-Azidohexyl 3-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-2-O-
benzyl-4,6-O-benzylidene-α-D-mannopyranoside (119). 1H NMR (CDCl3, 400 MHz) δ 
7.4 - 7.6 ( m, 3H, ), 7.1 - 7.3 (m, 22H), 5.65 (s, 1H), 5.63 (d, J = 1.9 Hz, 1H), 5.34 (s, 
1H), 4.90 (d, J = 10.9 Hz, 2H), 4.77 (s, 2H), 4.73 (d, J = 5.4 Hz, 1H), 4.6 (m, 3H), 4.4 - 
4.5 (m, 4H), 4.2 (m, 2H), 4.0 (m, 1H), 3.7 - 3.9 (m, 3H), 3,5 - 3.6 (m, 2H), 3.3 (m, 1H), 
3.24 (t, J = 6.9 Hz, 2H), 2.11 (s, 3H, CH3), 1.5 (m, 4H), 1.4 (m, 4H); 13C NMR (CDCl3, 
100 MHz) δ 170.2, 138.8, 138.5, 138.1 (2 carbons), 137.6, 128.9, 128.7 (2 carbons), 
128.6 (3 carbons), 128.5 (4 carbons), 128.4 (3 carbons), 128.3 (2 carbons), 128.3 (3 
carbons), 128.0 (4 carbons), 127.9 (3 carbons), 127.7 (2 carbons), 126.2 (2 carbons), 
101.4, 99.4, 99.1, 79.3, 78.1, 77.8 (2 carbons), 77.4 (2 carbons), 75.2, 74.4, 73.8, 73.7, 
73.5 (2 carbons), 72.4, 71.7, 69.1, 68.9, 68.4, 67.8, 64.3, 51.6, 29.4, 28.9, 26.7, 25.9, 
21.2; ESI/APCI Calcd for C55H67N4O12 ([M+NH4]+) m/z 975.4755; measured m/z 
975.4774     
6'-Azidohexyl 3-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-2,4-
di-O-benzyl -α-D-mannopyranoside (120). 1H NMR (CDCl3, 400 MHz) δ 7.2 - 7.4 ( m, 
25H), 5.50 (s, 1H, H-2'), 5.22 (s, 1H, H-1'), 4.90 (d, J = 10.9 Hz, 1H), 4.81 (d, J = 10.9 
Hz, 1H), 4.75 (s, 1H, H-1), 4.6 – 4.7 (m, 5H), 4.4 - 4.5 (m, 3H), 4.15 (dd, J = 2.8, 9.4 Hz, 
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1H), 3.9 – 4.0 (m, 3H), 3.6 – 3.9 (m, 10H), 3.3 (m, 1H), 3.24 (t, J = 6.9 Hz, 2H), 2.11 (s, 
3H, CH3), 1.53 (m, 4H), 1.32 (m, 4H). 13C NMR (CDCl3, 100 MHz) δ 170.3, 138.8, 
138.4, 138.3, 138.1, 137.9, 128.7 (2 carbons), 128.6 (2 carbons), 128.6 (2 carbons), 128.4 
(4 carbons), 128.3 (2 carbons), 128.29 (2 carbons), 128.1, 127.98 (2 carbons), 127.90 (2 
carbons), 127.8 (2 carbons), 127.74, 127.71 (2 carbons), 99.9, 97.7, 78.9, 78.1, 77.9, 77.4, 
75.5,  75.2, 75.1, 74.6, 73.6, 72.6, 72.4 (2 carbons), 72.0, 69.3, 69.0, 67.8, 62.3, 51.6, 
29.5, 28.9, 26.7, 25.9, 21.1; ESI/APCI Calcd for C55H65N3O12Na ([M+Na]+) m/z 
982.4466;  measured m/z 982.4453. 
6′-Azidohexyl- 3-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-2-O-
benzyl-α-D-mannopyranoside (121). 1H NMR (CDCl3, 300 MHz) δ 7.1 – 7.4 (m, 20H), 
5.42 (s, broad, 2H, H -1', H-2'), 4.87 (d, J = 11.4 Hz, 1H), 4.76 (d, J = 1.4 Hz, 1H, H – 1), 
4.70 (d, J = 11.0 Hz, 1H), 4.5 – 4.6 (m, 4H), 4.48 (d, J = 12.0Hz, 1H), 4.46 (d, J = 
11.0Hz, 1H), 3.9 -4.1 ( m, 4H), 3.5 -3.9 (m, 10H), 3.3 (m, 1H), 3.25 (t, J = 6.9 Hz, 2H), 
3.16 (s, 1H, OH) 2.09 (s, 3H, CH3), 1.54 (m, 4H), 1.33 (m, 4H); 13C NMR (CDCl3, 75 
MHz) δ  170.5, 138.5, 137.9 (2 carbons), 137.9, 128.5 (2 carbons), 128.4, 128.37, 128.2, 
127.9, 127.8 (2 carbons), 127.71, 127.70, 98.3, 97.5, 78.8, 78.4, 77.9, 74.9, 74.6, 73.6, 
72.6, 72.3, 71.9, 71.7, 69.5, 69.1, 67.6, 67.0, 62.9, 51.5, 29.3, 28.8, 26.6, 25.8, 21.1; 
ESI/APCI Calcd for C48H59N3O12Na ([M+Na]+) m/z 892.3996; measured m/z 892.4001. 
6′-Azidohexyl-6-O-(6-O-acetyl-3-O-benzoyl-2,4-di-O-benzyl-α-D-mannopyra-
nosyl)-3-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-2,4-di-O-benzyl-α-
D-mannopyranoside (122). 1H NMR (CDCl3, 400 MHz) δ 8.1 (m, 2H), 7.6 (m, 1H), 7.5 
– 7.1 (m, 37H), 5.59 (dd, J = 2.7, 9.2 Hz, 1H, H-3), 5.52 (s, 1H, H-2), 5.24 (s, 1H, H-1), 
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5.16 (s, 1H, H-1), 4.87 (d, J = 11.0 Hz, 2H), 4.8 – 4.3 (m, 15H), 4.1 – 3.6 (m, 15H), 3.3 
(m, 1H), 3.21 (t, J = 6.9 Hz, 2H), 2.1 (s, 3H, CH3), 2.06 (s, 3H, CH3), 1.5 (m, 4H), 1.3 
(m, 4H); 13C NMR (CDCl3, 100 MHz) δ 171.1, 170.3, 165.6, 138.9, 138.5, 138.4, 138.2, 
137.9, 133.3, 132.7, 130.3, 129.9, 128.7, 128.4, 128.4, 128.2, 128.1, 128.0, 127.9, 127.9, 
127.8, 127.7, 127.6, 99.9, 98.0, 97.4, 78.9, 78.2, 77.9, 76.6, 75.7, 75.4, 75.3, 75.1, 74.6, 
73.6, 73.5, 73.3, 72.9, 72.6, 72.4, 72.2, 72.1, 70.0, 69.3, 69.1, 67.7, 66.0, 63.5, 51.6, 29.5, 
28.9, 26.7, 25.9, 21.2, 21.1; ESI/APCI Calcd for C84H97N4O19 ([M+Na]+) m/z 1465.6747; 
measured m/z 1465.6711.   
6′-Azidohexyl-6-O-(2,4-di-O-benzyl-α-D-mannopyranosyl)-3-O-(3,4,6-tri-O-
benzyl-α-D-mannopyranosyl)-2,4-di-O-benzyl-α-D-mannopyranoside (123). 1H NMR 
(CDCl3, 400 MHz) δ 7.6 – 7.4 (m, 35H), 5.49 (s, 1H), 5.38 (s, 1H), 5.16 (d, J = 11.1 Hz, 
1H), 5.07 (d, J = 11.1 Hz, 1H), 4.9 (m, 2H), 4.8 (m, 8H), 4.74 (d, J = 11.1 Hz, 1H), 4.71 
(d, J = 12.2 Hz, 1H), 4.62 (d, J = 11.7 Hz, 1H), 4.39 (dd, J = 2.8, 9.5 Hz, 1H), 4.3 (m, 
2H), 4.1 (m, 8H), 3.9 ( m, 7H), 3.8 (m, 1H), 3.5 (m, 1H), 3.45 ( t, J = 6.9 Hz, 2H), 2.60 (s 
1H, OH), 2.54 (d, J = 9.4 Hz, 1H, OH), 2.18 (s, 1H, OH), 1.7 (m, 4H), 1.5 (m, 4H). 13C 
NMR (CDCl3, 75 MHz) δ 138.6, 138.5, 138.4, 138.3, 138.1, 137.9 (2 carbons), 128.75 (2 
carbons), 128.71 (4 carbons), 128.6 (4 carbons), 128.4 (2 carbons), 128.2 (2 carbons), 
128.1 (2 carbons), 128.0 (2 carbons), 127.9 (2 carbons), 127.88 (4 carbons), 127.82, 
127.7 (3 carbons), 101.5, 97.5, 97.4, 80.1, 78.9, 77.8, 77.4, 76.7, 75.3, 75.2 (2 carbons), 
75.0, 74.5, 73.5 72.8, 72.6, 72.3 (2 carbons), 72.2, 72.1, 72.0, 71.6, 71.5, 69.3, 68.9, 67.7, 
66.1, 62.3, 51.4, 29.3, 28.8, 26.6, 25.8; ESI/APCI Calcd for C73H85N3O16Na ([M+Na]+) 
m/z 1282.5828; measured m/z 1282.5790. 
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6′-Azidohexyl 3-O-(2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-
3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-6-O-(3,6-di-O-(2-O-acetyl-3,4,6-tri-O-
benzyl-α-D-mannopyranosyl)-2,4-di-O-benzyl-α-D-mannopyranosyl)-2,4-di-O-
benzyl-α-D-mannopyranoside (124). 1H NMR (CDCl3, 300 MHz) δ 7.1 – 7.4 (m, 80H), 
5.53 (m, 3H), 5.27 (s, 2H), 5.09 (d, J = 1.7 Hz, 1H), 5.04 (s, 1H), 5.00 (d, J = 1.7 Hz, 
1H), 4.8 – 4.92 (m, 6H), 4.78 (d, J = 9.6 Hz, 1H), 4.5 – 4.73 (m, 18H), 4.4 – 4.5 (m, 
10H), 4.2 – 4.33 (m, 2H), 3.7 – 4.2 (m, 25H), 3.5 – 3.7 (m, 15H), 3.33 (d, J = 9.9 Hz, 
1H), 3.24 (m, 1H), 3.16 (t, J = 6.9 Hz, 2H), 2.15 (s, 3H, CH3), 2.12 (s, 3H, CH3), 2.08 (s, 
3H, CH3), 1.4 (m, 4H), 1.25 (m, 4H);  13C NMR (CDCl3, 75 MHz) δ 170.3, 170.2 (2 
carbons), 138.8, 138.77, 138.71, 138.6, 138.57, 138.52, 138.45 (2 carbons), 138.40, 138.3 
(3 carbons), 138.2 (2 carbons), 138.1, 137.9, 137.89, 128.7, 128.5 (4 carbons), 128.4 (8 
carbons), 128.3 (10 carbons), 128.2, 127.9 (6 carbons), 127.7 (2 carbons), 127.6 (2 
carbons), 127.56 ( 2 carbons), 127.51, 127.45 92 carbons), 127.40, 127.2, 101.3, 99.8, 
99.4, 98.4, 97.0 (2 carbons), 80.1, 80.0, 78.3, 78.2 (2 carbons), 77.8, 77.4, 75.2, 75.1, 
74.9 (2 carbons), 74.7 (2 carbons), 74.1 (3 carbons), 73.4 (4 carbons), 73.2, 72.2 (2 
carbons), 72.17, 72.1 (2 carbons), 71.98, 71.92, 71.7, 71.3, 71.0, 69.7, 68.9 (3 carbons), 
68.7 (4 carbons), 68.4 (2 carbons),  68.3, 67.6, 66.2, 65.9, 51.4, 29.3, 28.8, 26.6, 25.8, 
21.3 (2 carbons), 21.1; ESI/APCI Calcd for C160H175N3O34Na ([M+Na]+) m/z 2705.1949; 
measured m/z 2705.1872. 
6′-Azidohexyl 3-O-(2-O-(3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-3,4,6-tri-
O-benzyl-α-D-mannopyranosyl)-6-O-(3,6-di-O-(3,4,6-tri-O-benzyl-α-D-mannopyra-
nosyl)-2,4-di-O-benzyl-α-D-mannopyranosyl)-2,4-di-O-benzyl-α-D-
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mannopyranoside (125). 1H NMR (CDCl3, 300 MHz) δ 7.2 – 7.4 (m, 80H), 5.30 (s, 1H), 
5.22 (s, 1H), 5.16 9 (s, 2H), 4.99 9s, 1H), 4.8 – 4.9 (m, 6H), 4.4 – 4.8 (m, 30H), 4.38 (d, J 
= 11.7 Hz, 1H), 4.36 (d, J = 12.4 Hz, 1H), 4.1 – 4.2 (m, 6H), 3.5 – 4.1 (m, 35H), 3.44 (m, 
1H), 3.28 (m, 1H), 3.17 (t, J = 6.9 Hz, 2H), 2.34 (s, broad, 3H, OH), 1.5 (m, 4H), 1.28 
(m, 4H);  13C NMR (CDCl3, 75 MHz) δ 138.8, 138.7, 138.6 (24 carbons), 138.5 (2 
carbons), 138.4, 138.37 (4 carbons), 138.2 (2 carbons), 138.1, 138.0 (2 carbons), 128.7, 
128.6, 128.5, 128.4, 128.3, 128.1, 128.0, 127.8, 127.7, 127.6, 127.5, 101.7, 101.3, 101.0, 
99.8, 97.0, 96.9, 80.2, 80.0, 79.7, 78.0, 77.9, 77.4, 75.2 (2 carbons), 75.1 (4 carbons), 
74.9 (3 carbons), 74.3 ( 2carbons), 74.2, 73.6, 73.5 (2 carbons), 73.4, 73.2, 72.7, 72.37, 
72.30, 72.2 (2 carbons), 72.0 (5 carbons), 71.7 (3 carbons), 71.5 (2 carbons), 71.3, 69.7, 
69.2, 68.9 (2 carbons), 68.8 (2 carbons), 68.6 (2 carbons), 68.5, 68.0 (2 carbons), 67.6, 
66.0, 65.7, 51.4, 29.3 28.8, 26.6, 25.8; ESI/APCI Calcd for C154H169N3O31Na ([M+Na]+) 
m/z 2579.1632; measured m/z 2579.1593. 
6′-Azidohexyl 2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside (129). 1H NMR 
(CDCl3, 300 MHz) δ 5.47 (t, J = 9.6 Hz, 1H, H-4), 4.97 – 5.3 (m, 3H), 4.84 (dd, J = 3.8, 
10.3 Hz, 1H), 4.46 (d, J = 6.8 hz, 1H), 4.0 – 4.3 (m, 4H), 3.87 9m, 1H), 3.68 (m, 2H), 
3.43 (m, 2H), 3.27 (t, J = 6.9 Hz, 4H)2.0 – 2.2 (m, 20H), 1.69 9m, 6H), 1.38 (m, 6H); 
ESI/APCI Calcd for C20H35N4O10 ([M+NH4]+) m/z 491.2353; measured m/z 491.2345. 
6′-Azidohexyl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside (130).78 1H NMR 
(CDCl3, 300 MHz) δ 5.0 – 5.5 (m, 4H), 5.00 (dd, J = 3.4, 10.3 Hz, 1H), 4.44 (d, J = 7.9 
Hz, 1H), 4.1 (m, 4H), 3.89 (m, 2H), 3.67 (m, 1H), 3.43 (m, 2H), 3.26 (t, J = 6.9 Hz, 4H),  
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2.14 (s, 6H, 2 CH3), 2.06 (s, 3H, CH3), 2.04 (s, 6H, 2 CH3), 1.98 (6H, 2 CH3), 1.60 (m, 
4H0, 1.38 (m, 4H). 
6′-Azidohexyl 2,3,4-tri-O-acetyl-β-D-xylopyranoside (131). 1H NMR (CDCl3, 
400 MHz) δ 5.49 (t, J = 9.7 Hz, 1H), 5.16 (t, J = 9.8 Hz), 5.00 (d, J = 3.5 Hz, 1H), 4.95 
(m, 3H), 4.80 (dd, J = 3.6, 10.2 Hz, 1H), 4.46 (d, J = 6.8 Hz), 3.79 (dd, J = 5.9, 10.8 Hz, 
2H), 3.70 (m, 2H), 3.61 (t, J = 2.9 Hz, 2H), 3.4 (m, 2H), 3.27 (t, J = 6.9 Hz, 4H), 2.07 (s, 
3H, CH3), 2.06 (s, 3H, CH3), 2.05 (s, 3H), 2.04 (s, 3H, CH3), 1.60 (m, 4H), 1.4 (m, 4H); 
ESI/APCI Calcd for C17H31N4O8 ([M+NH4]+) m/z 419.2141; measured m/z 419.2139. 
6′-Azidohexyl 2,3,4-tri-O-acetyl-α-L-rhamnopyranoside (132).78 1H NMR 
(CDCl3, 400 MHz) δ 5.30 (d, J = 3.5, 10.0 Hz, 1H), 5.22 (dd, J = 1.7, 3.4 Hz, 1H), 5.07 
(t, J = 9.9 Hz, 1H), 4.70 (d, J = 1.6 Hz, 1H), 3.8 (m, 1H), 3.67 (m, 1H), 3.4 (m, 1H), 3.28 
(t, J = 6.9 Hz, 2H), 2.15 (s, 3H, CH3), 2.05 (s, 3H, CH3), 1.99 (s, 3H, CH3), 1.6 (m, 4H), 
1.4 (m, 4H), 1.22 (d, J = 6.3 Hz, 3H, CH3); 13C NMR (CDCl3, 100 MHz) δ 170.4, 170.2 
(2 carbons), 97.7, 71.4, 70.2, 69.4, 68.2, 66.5, 51.6, 29.4, 28.9, 25.9, 21.1, 20.9, 20.9, 
17.6. 
6′-Azidohexyl 2,3,4-tri-O-acetyl-α-L-fucopyranoside (133). 1H NMR (CDCl3, 
400 MHz) δ 5.58 (dd, J = 3.4, 9.7 Hz, 1H), 5.32 (dd, J = 1.1, 3.3 Hz, 1H), 5.15 (dd, J = 
3.7, 10.7 Hz, 1H), 5.08 (d, J = 3.7 Hz, 1H), 4.18 (m, 1H), 3.64 (m, 1H), 3.4 (m, 1H), 3.23 
(t, J = 6.9 Hz, 2H), 2.20 (s, 3H), 2.14 (s, 3H), 2.02 (s, 3H), 1.6 (m, 4H), 1.4 (m, 4H), 1.16 
(d, J = 5.7 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 170.9, 170.7, 170.3, 96.3, 71.4, 68.6, 
68.3, 64.5, 51.6, 29.9, 29.4, 29.0, 26.7, 25.9, 21.0, 20.9, 20.8, 16.1; ESI/APCI Calcd for 
C18H33N4O8 ([M+Na]+) m/z 433.2298; measured m/z 433.2313.  
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6′-Azidohexyl 2,3,4-tri-O-acetyl-β-L-fucopyranoside (134).78 1H NMR (CDCl3, 
400 MHz) δ 5.23 (d, J = 3.4 Hz, 1H), 5.20 (dd, J = 7.9, 10.4 Hz, 1H), 5.02 (dd, J = 3.4, 
6.9 Hz, 1H), 4.40 (d, J = 7.9 Hz, 1H), 3.9 (m, 1H), 3.77 (m, 1H), 3.45 (m, 1H), 3.26 (t, J 
= 6.9 Hz, 2H), 2.16 (s, 3H, CH3), 2.08 (s, 3H, CH3), 2.00 (s, 3H, CH3), 1.61 (m, 4H), 1.38 
(m, 4H), 1.25 (d, J = 6.4 Hz, 3H, CH3). 
6′-Azidohexyl 2,3,4-tri-O-acetyl-β-D-maltopyranoside (135). 1H NMR (CDCl3, 
400 MHz) δ 5.48 (m, 1H), 5.3 (m, 3H), 5.2 (m, 2H), 5.1 (m, 4H), 4.9 (m, 5H), 4.85 (m, 
1H), 4.78 (m, 1H), 4.46 (m, 4H), 4.0 – 4.2 (m, 6H), 3.89 (m, 1H), 3.65 (m, 1H), 3.38 (t, J 
= 6.9 Hz, 2H), 3.26 (t, J = 6.9 Hz, 2H), 1.97 – 2.2 (m), 1.6 (m, 8H), 1.4 (m, 8H); 
ESI/APCI Calcd for C32H51N4O18 ([M+NH4]+) m/z 779.3198; measured m/z 779.3206. 
6′-Azidohexyl 2-O-(2-O-(6-O-acetyl-2,3,4-tri-O-benzyl-α-D-mannopyranosyl)-
3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-3,4,6-tri-O-benzyl-α-D-mannopyranoside 
(136). 1H NMR (CDCl3, 300 MHz) δ 7.2 – 7.4 (m, 45H), 5.17 (s, 1H), 5.15(d, J = 1.7 Hz, 
1H), 4.8 – 4.9 (m, 3H), 4.5 – 4.7 (m, 15H), 4.23 (s, 2H), 4.12 (s, 1H), 3.86 – 4.0 (m, 7H), 
3.65 – 3.84 (m, 9H), 3.5 (m, 1H), 3.27 (m, 1H), 3.22 (t, J = 6.9 Hz, 2H), 1.7 (s, 3H, 
CH3), 1.55 (m, 4H), 1.31 (m, 4H); 13C NMR (CDCl3, 75 MHz) δ 171.0, 138.8, 138.7, 
138.6 (2 carbons), 138.57 (2 carbons), 138.5 (2 carbons), 138.4, 128.7 (2 carbons), 128.6 
(5 carbons), 128.5 (5 carbons), 128.4 (4 carbons), 128.3 (2 carbons), 128.2 (3 carbons), 
128.1 (5 carbons), 128.0 (4 carbons), 127.95 (5 carbons), 127.90 (5 carbons), 127.7 (5 
carbons), 100.9, 99.4, 98.9, 79.8, 75.5, 75.4 (3 carbons), 75.2 (2 carbons), 75. (2 
carbons), 74.9, 74.6, 73.5 (4 carbons), 72.7, 72.5 (2 carbons), 72.3, 72.29 (2 carbons), 
129 
 
72.0, 70.8, 69.5, 67.7, 51.6, 29.5, 28.9, 26.7, 25.9, 21.1; ESI/APCI Calcd for 
C89H99N3O17Na ([M+Na]+) m/z 1504.6872; measured m/z 1504.6895. 
6′-Azidohexyl 6-O-(2,6-di-O-acetyl-3,4-di-O-benzyl-α-D-mannopyranosyl)-2-
O-(2,6-di-O-acetyl-3,4-di-O-benzyl-α-D-mannopyranosyl)-3,4-di-O-benzyl-α-D-
mannopyranoside (137). 1H NMR (CDCl3, 400 MHz) δ 7.2 – 7.4 (m, 30H), 5.59 (s, 1H), 
5.43 (s, 1H), 5.08 (s, 1H), 4.9 (m, 4H), 4.7 (m, 5H), 4.45 – 4.6 (m, 5H), 4.3 (m, 4H), 3.9 – 
4.1 (m, 5H), 3.7 (m, 5H), 3.63 (m, 2H), 3.37 (m, 1H), 3.25 (t, J = 6.9 Hz, 2H), 2.13 (s, 
6H), 2.05 (s, 3H, CH3), 2.02 (s, 3H, CH3), 1.57 (m, 4H), 1.35 (m, 4H); 13C NMR (CDCl3, 
100 MHz) δ 170.9 (2 carbons), 170.2, 170.17, 138.3 (2 carbons), 138.26, 138.2, 138.0, 
137.8, 128.6 (5 carbons), 128.4 (5 carbons), 128.3 (3 carbons), 128.2 (3 carbons), 128.1 
(5 carbons), 128.0 (5 carbons), 127.9 (2 carbons), 127.7 (2 carbons), 99.7, 98.7, 97.6, 
80.1, 78.3, 78.2, 75.3 (5 carbons), 74.9, 74.8, 74.2, 74.1,72.3, 72.1, 71.8, 70.4, 69.9, 68.6, 
68.4, 67.7, 66.8, 51.5, 29.5, 28.9, 26.8, 26.1, 21.2 (2 carbons), 21.0 (2 carbons); 
ESI/APCI Calcd for C74H87N3O20Na([M+Na]+) m/z 1360.5781; measured m/z 
1360.5790. 
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